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Overview of gestational diabetes mellitus 
  
Chapter 1 
 2 
1.1. Metabolic disease in pregnancy  
Diabetes mellitus is chronic metabolic disease characterised by hyperglycaemia, 
which in Type 2 diabetes mellitus (T2D) is due to combination of insulin resistance 
and beta-cell dysfunction. There is an escalating epidemic of T2D across the world 
with 380 million people affected in 2013, which is expected to increase to 470 million 
by 2035 (International Diabetes Federation 2013). The age of diagnosis of T2D is also 
coming down with more children and young adults being diagnosed with it, which 
runs in parallel with the increase in childhood obesity (Rocchini 2002). Studies from 
the Pima Indian group and a Japanese population show a 6-fold and 2-fold increase in 
the incidence of T2D in children in the last 20-40 years (Fagot-Campagna et al. 2001; 
Urakami et al. 2005). 
 
Pregnancy is a period of physiological insulin resistance due to placental secretion of 
diabetogenic hormones such as progesterone, growth hormone and corticotrophin-
releasing hormone which ensure an adequate supply of nutrients to the fetus. It is 
estimated that insulin resistance increases by 50-60% in the latter half of pregnancy 
(Catalano and Hauguel-De Mouzon 2011) and clinically recognisable diabetes 
develops when the maternal pancreas is unable to secrete enough insulin to cope with 
this. Nearly 50% of people in the world with T2D remain undiagnosed (International 
Diabetes Federation 2013) and therefore pregnancy provides a crucial window of 
opportunity to identify women at risk and intervention can be provided during 
pregnancy as well as postnatally.  
 
Gestational diabetes mellitus (GDM) is described as glucose intolerance first 
recognised in pregnancy. Similar to T2D, GDM is also increasing at an alarming rate, 
attributed partly to increasing maternal age and body weight (Ferrara et al. 2004; 
Hedderson et al. 2010). The current estimate is around 4% of all pregnancies 
(Metzger et al. 2005) though this could increase to as much as 18% if the new 
International Association of the Diabetes and Pregnancy Study Groups (IADPSG) 
guidelines are implemented (Moses 2010).  
 
 
 
 3 
1.2. Diagnosis of GDM 
There is no internationally accepted method of screening for GDM with disparities in 
whom to screen, gestation of screening, dose and duration of glucose tolerance test 
(GTT), and the cut-off levels used. In the UK, the National Institute for Health and 
Care Excellence (NICE) recommends a 75g 2-hour GTT to be done at 24-28 weeks 
pregnancy in mother with risk factors (i.e. prepregnancy BMI >30kg/m2, previous 
macrosomic baby, previous GDM, 1st-degree relative with diabetes and ethnic 
minority groups) (National Institute for Health and Care Excellence 2008). The WHO 
criteria (fasting plasma glucose ≥ 7.0 and/or 2-hour post-prandial glucose ≥ 
7.8mmol/l) is suggested by NICE for the diagnosis of GDM (World Health 
Organisation 1999), although many Trusts in the UK use the modified WHO criteria 
with fasting glucose ≥ 6.0mmol/l (Nanda et al. 2011), for which there is no direct 
evidence. There is a strong case for revising these cut-offs based on data from the 
large international Hyperglycaemia in Pregnancy and Adverse Outcomes study which 
showed that the risk of adverse neonatal outcomes (neonatal hypoglycaemia, cord C-
peptide >90th centile, C-section rate and birthweight >90th centile) was linear 
according to maternal plasma glucose level at GTT with no threshold (The HAPO 
Study Cooperative Research Group 2008). Cut-off values of fasting glucose ≥ 5.1, 1-
hour ≥ 10 and 2-hour ≥ 8.5 mmol/l on a 75g GTT were therefore recommended based 
on a 1.75 relative risk for these outcomes and has been adopted by Scotland and USA 
(American Diabetes Association 2013; Scottish Intercollegiate Guidelines Network 
2010). While this data is compelling, the benefits of treating at these cut-offs is not 
known due to lack of evidence from intervention studies. 
 
1.3. Adverse maternal outcomes of GDM 
Mothers with a diagnosis of GDM are more likely to have complications during the 
pregnancy with higher risk of polyhydramnios (Farooq et al. 2007), hypertension and 
vaginal candidiasis (Odar et al. 2004), pre-eclampsia (Yogev et al. 2010) and primary 
caesarean section (The HAPO Study Cooperative Research Group 2008).  
 
Women who develop GDM are at have a relative risk of 7.43 of developing T2D, 
with the higher risk being seen as early as 5 years after pregnancy (Bellamy et al. 
2009). Another systematic review concluded that the 3 most significant factors which 
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predict the conversion to T2D in these women were suboptimal body anthropometry, 
poor glycaemic control during pregnancy (use of insulin was associated with a 
hazards ratio 3.5 for future T2D in Lee et al) (A. J. Lee et al. 2007), and diagnosis of 
GDM prior to 24 weeks gestation (Baptiste-Roberts et al. 2009).  
 
Additionally, these women are at higher risk of cardiovascular morbidity with the 
largest study showing significantly higher adjusted odds ratio of around 2.5 for simple 
cardiovascular events and hospitalisations at 10-20 years post-pregnancy (Kessous et 
al. 2013).  
 
1.4. Offspring outcomes of GDM 
1.4.1.  Perinatal outcomes 
Fetal macrosomia (defined as birthweight > 4-4.5kg) and large for gestational age 
(LGA) (defined as birthweight >2 SD greater than mean or >90th centile after 
controlling for age and sex) are 2 of the most common and serious outcomes of GDM 
in pregnancy (Suhonen et al. 2008). Babies born to GDM mothers are 4 - 7 times 
likely to be macrosomic (Ostlund et al. 2003; Suhonen et al. 2008).   
 
Other perinatal complications which are also associated with hyperglycaemia include 
shoulder dystocia and birth injuries, neonatal hypoglycaemia and respiratory distress 
syndrome (The HAPO Study Cooperative Research Group 2008). The complications 
are at least in part related to glycaemic control because it was found in a meta-
analysis that specific treatment of GDM significantly reduced shoulder dystocia, large 
for gestational age babies and macrosomia by about 60% compared to usual care, 
although it must be noted that the diagnostic targets for GDM and threshold of 
treatment varied in the studies (Horvath et al. 2010). 
 
Apart from body weight per se, it is the distribution of fat in fetuses of mothers with 
GDM that is concerning because it has been shown that these babies are born with 
greater skinfold thickness and fat mass, which are markers of fetal adiposity, even 
when the birthweight is appropriate for gestational age, sex and ethnicity (Catalano et 
al. 2003; Catalano and Hauguel-De Mouzon 2011). Aside from glucose, an 
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oversupply of nutrients such as triglycerides and free fatty acids may also drive fetal 
weight gain in these babies (Catalano and Hauguel-De Mouzon 2011). 
 
1.4.2.  Transgenerational effect 
In the long-term, children born to GDM mothers are at increased risk of becoming 
overweight before puberty, developing central obesity and metabolic syndrome in 
adolescence and having pre-diabetes or T2D in young adulthood (Damm et al. 2016; 
Gillman et al. 2003). 
 
Several questionnaire-based studies which have looked into the parental history of 
diabetic probands found that the individuals were 2 to 4 times more likely to have a 
mother affected with diabetes than father (Alcolado and Alcolado 1991; Bo et al. 
2000). While mitochondrial deoxyribonucleic acid (DNA) mutations in genes that 
control insulin secretion from the beta-cell are inherited exclusively from a mother, 
this is likely to only account for a small proportion of the risk of the transmission of 
T2D (Alcolado et al. 2002).  
 
The focus therefore shifts to the role of the offspring’s exposure to a diabetic 
intrauterine environment, which increases their risk of diabetes and obesity above that 
which can be attributable to genetic factors (Portha et al. 2011). This was 
demonstrated in the Pima Indian cohort study where the children who were born to 
mothers who developed T2D before the pregnancy had a 3.7 higher odds of 
developing T2D and a mean body mass index (BMI) 2.6kg/m2 higher than their 
siblings who were born before their mother developed T2D (Dabelea et al. 2000).  
 
It has been shown that daughters born to mothers diagnosed with GDM in their 
pregnancy had nearly 2-times the odds of obesity and insulin resistance themselves at 
age 15, even after adjustment for birthweight (Egeland and Meltzer 2010). Therefore 
it is not surprising that these female individuals are at higher risk of gestational 
diabetes themselves when they reach childbearing age in their adolescence or early 
adulthood. This sets up a vicious cycle of metabolic disease in young adults, which 
can be passed on from one generation to another.  
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1.4.3.  Outcomes in children born at extremities of birthweight 
It is well known that babies born to mothers with GDM are at high risk of 
macrosomia and obesity later on in life. However, a notion that babies born at low 
birthweight (LBW) are at a similarly at high risk of T2D as larger babies is one that 
has gained acceptance over the last 20 years, in a pattern known as the U-shaped 
curve (Figure 1.1) (Harder et al. 2007). The thinking behind this is known as the 
‘thrifty phenotype hypothesis’ and in short, proposes that poor nutrition in fetal and 
early postnatal life impairs the growth of the beta-cells of the pancreas which 
predisposes an individual to the development of T2D later on (Hales and Barker 
1992).  
 
Figure 1.1 Meta-regression curve of log odds ratios for type 2 diabetes mellitus by birth 
weight in a meta-analysis (1966–2005). (From Harder et al. 2007). 
Several studies from around the world lend support to this theory and the outcome of 
T2D and metabolic syndrome has been demonstrated from as early as age 4 (C.S. 
Yajnik et al. 1995) and pre-puberty (Hofman et al. 1997) in individuals born with a 
low birthweight or ponderal index (weight/length3). A meta-analysis confirmed that 
the odds ratio (OR) for T2D was 0.76 (95% CI 0.70-0.82) for every 1kg increase in 
birthweight, after correcting for current BMI (Whincup et al. 2008). 
 
The hypothesis is that the cross-talk between key organs involved in glucose 
metabolism, namely beta-cells of the pancreas, liver, skeletal muscle and adipocytes, 
may be affected due to nutritional insults in pregnancy (Maloney and Rees 2005). 
. 
 7 
Therefore any alteration to the environment in childhood / adulthood, particularly an 
obesogenic one, can make the individual to the unable to adapt, leading to the 
development of a disease state (Hales and Barker 2001). Therefore birthweight is 
likely to be a surrogate for an extremity of nutritional insult in the intrauterine 
environment which adversely programmes a fetus for postnatal ill-health.  
 
1.5. Established maternal risk factors for GDM 
There is a close association between maternal obesity and GDM. A meta-analysis of 
20 studies found that overweight (BMI 25-29.9 kg/m2), obese (BMI ≥30 kg/m2) and 
morbidly obese (BMI generally ≥40 kg/m2 but variable in some studies) women had 
an 2.1-, 3.6- and 8.6-fold increased risk of GDM compared to lean women (Chu et al. 
2007). It is not just the maternal BMI which is a predictor of GDM – Martin et al 
found in small study that higher visceral adipose tissue depth measured by 
ultrasonography at 12 weeks gestation, was associated with an OR of 17 for GDM 
diagnosis later in the pregnancy (Martin et al. 2009). No association was seen for 
subcutaneous fat measurement suggesting that it is the distribution of the fat rather 
than overall fat mass which is more pathogenic (Martin et al. 2009). 
 
GDM is also related to underlying components of the metabolic syndrome as 
demonstrated by Retnakaran et al who found that these mothers as well as those with 
mild glucose intolerance in pregnancy had odds of over 2 of developing metabolic 
syndrome (as defined by International Diabetes Federation) at 3 months-postpartum 
(Retnakaran et al. 2010a). However, when prepregnancy BMI and weight gain in 
pregnancy were added to the model the risk in the latter group lost significance, 
strengthening the case for the role of obesity.  
 
Being of South Asian origin increases the risk of GDM, even at lower BMI levels 
(Hedderson et al. 2012) but the reasons for this is unclear.  Both a higher fasting 
glucose (Jenum et al. 2012) and higher postprandial glucose levels (Gunton et al. 
2001) are found in this group in different studies. Aside from genetics, other factors 
which could mediate this risk include lower socio-economic status (maternal height, 
which is a surrogate marker for deprivation in-utero or early childhood, is a negative 
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predictor of GDM (Ogonowski and Miazgowski 2010)), distribution of fat (Lear et al. 
2007) or as-yet unidentified factors.  
 
If the well-established risk factors were able to accurately predict the risk of GDM, 
selective screening criteria based on these risk factors should be able to pick-up most 
of the women GDM. However, selective screening strategies consistently perform 
poorer than universal screening, with a diagnostic rate of around 60%, and a very high 
false negative rate of 30-40% (D. A. Scott et al. 2002) suggesting that there are 
additional factors in the background population mediating the risk.  
 
1.6. Novel biomarkers known to be associated with glucose intolerance or 
metabolic disease in pregnancy 
Increased free fatty acids (FFA) and triglycerides are important surrogates of insulin 
resistance and it is possible that these factors are also involved in the adverse 
outcomes both for mothers and their offspring, especially in obese individuals 
(Catalano and Hauguel-De Mouzon 2011). This was confirmed by Brisson et al who 
showed that a combination of high triglycerides and waist circumference at 1st 
trimester had an aOR of 4.7 for future diabetes mellitus (DM) (Brisson et al. 2010). 
Furthermore the risk of high maternal FFA and lipids are also associated with 
increased neonatal weight (Kitajima et al. 2001) and neonatal adiposity (Schaefer-
Graf et al. 2008) in GDM women, independent of glycaemia.  
 
The notion that we need to move away from a ‘glucocentric’ approach when 
discussing GDM and its outcomes is also supported by studies on offspring of 
mothers with GDM. In a follow-up study of children of mothers with diabetes in 
pregnancy, those offspring whose mothers had GDM had a 1.5 times higher risk of 
T2D/pre-diabetes at mean age 23 years compared to both offspring of Type 1 diabetes 
mothers and mothers who had risk factors for GDM but were GTT negative (no-
GDM) (Clausen et al. 2008). This suggests that there are additional factors which 
predispose a woman to developing GDM that also have adverse consequences for 
offspring. The same authors showed that the risk of offspring metabolic syndrome 
(defined as central obesity plus any 2 of high triglycerides, low high density 
lipoprotein (HDL), hypertension or elevated fasting glucose) were 1.5-fold higher in 
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children of mothers with GDM compared to type 1 diabetes or no-GDM in pregnancy 
(Clausen et al. 2009). This implies that additional risk factors either on their own or in 
combination with intrauterine hyperglycaemia confer the higher adverse 
consequences. In another study, the risk of overweight and abdominal obesity in 16 
year old offspring were highest in those had concomitant antenatal exposure to GDM 
and maternal pre-pregnancy overweight but not for maternal GDM alone again 
implying that maternal BMI may be a surrogate for factors contributing to this risk 
(Pirkola et al. 2010).  
 
Several other groups have also attempted to identify various biomarkers associated 
with increased incidence of GDM. Markers of inflammation such as highly-sensitive 
C-reactive protein (CRP) and ferritin have been associated with OR of GDM of 2 -3, 
which is partly mediated by obesity (X. Chen et al. 2006; Wolf et al. 2003). Fat- and 
liver-derived biomarkers such as adiponectin and sex-hormone binding globulin at 
11-14 weeks gestation increased the detection rate of GDM later to nearly 75% 
compared to 62% for maternal factors alone, with the false positive rate set at 20% 
(Georgiou et al. 2008; Nanda et al. 2011). Abnormal carbohydrate metabolism in 
diabetic pregnancies is associated with increased glycosylation of proteins such as 
fibronectin (C. L. Lee et al. 2011). In a study looking at several biomarkers at early 
pregnancy including glycosylated fibronectin, adiponectin, high-sensitivity CRP and 
placental lactogen, fibronectin had the highest sensitivity (81%) and specificity (90%) 
for detection of GDM although the authors did not include maternal characteristics in 
the ROC model (Rasanen et al. 2013). With the advent of metabolomic studies, a 
whole host of new biomarkers associated with GDM are beginning to emerge and we 
await with interest the results from these studies and potential clinical utility of these 
markers (S. Finer et al. 2014).  
 
1.7. Combined screening tool 
The reality is likely to be a combination of factors accounting for the multifactorial 
pathogenesis of GDM. This was studied by Savvidou et al, who used a combination 
of biochemical parameters associated with T2D, namely lipid profile, adiponectin, E-
selectin (an adhesion molecule), gamma-glutamyl transferase, CRP, and tissue 
plasminogen activator (t-PA), at 11-13 weeks gestation as predictors of GDM. They 
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found that the strongest biochemical predictors of GDM were t-PA and low HDL 
which, when combined with the basic model of risk factor screening increased the 
AUC-ROC to 0.86 from 0.82, suggesting a higher pick-up rate whilst reducing false-
positives (Savvidou et al. 2010).  
 
Therefore it can be seen that while the incidence GDM continues to increase and there 
is clear evidence of its long-term consequences for both maternal and offspring 
health, our understanding of its pathogenesis is still incomplete and warrants further 
study. In my thesis, I would like to discuss the role of 2 novel biomarkers which are 
potentially associated with this condition and their clinical implications.     
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Overall aims 
  
Chapter 2 
	 12	
The overall research question of my thesis is to evaluate the contributory role of 2 
novel biomarkers in the diagnosis of gestational diabetes (GDM) and related materno-
fetal outcomes, namely maternal obesity and extremities of fetal birthweight. Of the 
various biomarkers associated with metabolic disease in pregnancy, the 2 which I 
have selected to study in depth are vitamin B12 (B12) and glucagon-like peptide-1 
(GLP-1).  
 
The justification of selecting these 2 biomarkers are that while the micronutrient B12 
is historically known to be essential for normal embryogenesis, its role in non-
communicable diseases, such as metabolic disease and obesity, is gaining more 
attention with emerging studies on epigenetics and intrauterine programming. 
Consequently, its association with metabolic disease in pregnancy warrants further 
evaluation. On the other hand GLP-1, an incretin hormone known to stimulate insulin 
secretion from the pancreas, has been studied in depth in adults with insulin resistance 
and type 2 diabetes but is less well characterised in GDM, which is considered to be a 
‘pre-diabetes’ state. Therefore, these 2 biomarkers may differentially affect the 
pathogenic abnormalities in GDM (insulin resistance and insulin secretion 
respectively), providing insight into our understanding of this condition, which is still 
incomplete.  
 
Additionally, if my research and further studies do prove an association between these 
factors and GDM/metabolic outcomes in pregnancy, there are potential treatment 
options available in the form of B12 supplements and GLP-1 agonists. Of course, 
clinical studies will first need to be carried out to test the safety and efficacy of these 
drugs during pregnancy but it is necessary to prove an association, if not causality, 
prior to any intervention trials.  
 
Prior to investigating the association between low B12 and GDM, my aim is to assess 
B12 status in ‘normal’ pregnancy which will be done in a systematic review and 
meta-analysis of the prevalence of B12 insufficiency in pregnant women across the 
world and its potential impact on low birthweight. This is followed by a retrospective 
observational study to look at the relationship between B12 insufficiency with GDM 
in a local UK population and its effects on extremities of offspring birthweight. I will 
then examine the adequacy of dietary B12 intake in women of child-bearing age with 
	 13	
the goal of discussing strategies to optimise B12 status in the pre-conception/early 
pregnancy period. The objectives of the second part of my thesis are to characterise 
the GLP-1 response during a glucose tolerance test in women who subsequently 
develop GDM compared to controls, and finally to describe the methodology for a 
pilot laboratory project exploring mechanisms by which liraglutide, a GLP-1 agonist, 
can alleviate vascular complications due to hyperglycaemia.  	 	
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Role of vitamin B12 in cellular metabolism, 
embryogenesis and pregnancy  
  
Chapter 3 
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3.1. Biochemistry and absorption of vitamin B12 in the human body 
3.1.1. Vitamin B12 structure and cellular function 
Vitamin B12 (B12), also known as cobalamin, is a micronutrient essential for cellular 
growth, differentiation and development (C. S. Yajnik and Deshmukh 2012). Along 
with folic acid, it is necessary for the synthesis of DNA, RNA, lipids and protein in 
the cellular cytoplasm (Saravanan and Yajnik 2010; A David Smith et al. 2008).  
 
B12 is composed of a central cobalt atom surrounded by the 4 nitrogen atoms of a 
corrin ring. Additionally, it contains a dimethylbenzimidazolyl side group at its lower 
pole and the sixth position of the cobalt atom on its upper pole can be occupied by a 
variety of groups such as OH- (hydroxocobalamin), CH3- (methylcobalamin), 
5’deoxyadenosylcobalamin or CN- (cyanocobalamin, the term B12 commonly refers 
to this form). However in the human body, B12 is required for 2 cellular reactions as 
a necessary cofactor in the form of methylcobalamin (methylCbl, the cofactor of 
methionine synthase) and adenosylcobalamin (adoCbl, the cofactor of 
methylmalonyl-CoA mutase) (Krautler 2012). Commonly used synthetic preparations 
of B12 are cyanocobalamin and hydroxocobalamin. These cellular reactions involving 
B12 are summarised in Figure 3.1 and discussed in more detail below (Figure 3.1) 
(W. Herrmann and Obeid 2012).  
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Related to B12 is another micronutrient, folate, which is a group of related 
compounds based on the folic acid structure and is essential for the one-carbon 
metabolism reactions (see below). It is consumed in the body either as folic acid (used 
in supplements and fortified foods as it is highly bioavailable and easily reduced to 
tetrahydrofolate (THF)) or dietary folate (usually in the polyglutamate form).  
 
B12 enters the cytosol as hydroxocobalamin (OHCbl), which becomes methylated to 
methylCbl after binding to methionine synthase. The first reaction which for which 
B12 and folate are needed as co-factors is the conversion of homocysteine (Hcy) to 
methionine by methionine synthase. This is one of many reactions in the one-carbon 
metabolism cycle, which is so called because a carbon unit is transferred from serine 
or glycine to THF to form 5,10-methyleneTHF (Johansson et al. 2009; Selhub 2002) 
(Figure 3.2).  5,10-methyleneTHF can then be used for the formation of thymidine 
(dTMP, required for DNA), converted to 10-formylTHF (required for synthesis of 
purines, a component of DNA and RNA) or reduced to methyl-THF by the rate 
limiting enzyme methylenetetrahydrofolate reductase (MTHFR) (Selhub 2002). 
Methyl-THF donates its methyl group to Hcy to form methionine by the enzyme 
methionine synthase, which uses B12 as a co-factor. The methionine thus formed 
Figure 3.1 Metabolic pathways enhanced by vitamin B12 or cobalamin (Cbl) (see text for 
details). TC-Cbl: transcobalamin, Hcy: homocysteine, Meth: methionine, SAH: S-
adenosylhomocysteine, SAM: S-adenosylmethionine, methyl-Cbl: methyl cobalamin, Ado-
Cbl: adenosyl cobalamin [adapted from Herrmann and Obeid 2012].    
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becomes converted to S-adenosylmethionine (SAM), a universal donor of methyl 
groups necessary for the formation of DNA, RNA, neurotransmitters, membrane 
phospholipids, proteins and hormones (Johansson et al. 2009; Saravanan and Yajnik 
2010; Selhub 2002). 
 
In the second reaction which occurs in the mitochondria, methylmalonyl-CoA mutase 
(MCM), using adoCbl as a co-factor, produces succinyl-CoA from methylmalonyl-
CoA. Succinyl-CoA is required for the catabolism of fatty acids, cholesterol and 
amino acids via the Krebs cycle (W. Herrmann and Obeid 2012). Any excess 
methylmalonyl-CoA is converted into methylmalonic acid (MMA) so B12 deficiency 
which would inhibit the conversion of methylmalonyl-CoA to succinyl-CoA, can lead 
to elevation of MMA that can be detected in plasma.  
 
Broadly speaking, the cellular level effects of B12 deficiency are 2-fold, in keeping 
with the 2 primary reactions involving B12 as described above (Figure 3.3) 
(Saravanan and Yajnik 2010). These are:- 
Methionine 
synthase 
(polyglutamate) 
(folate monoglutamate) 
Dietary folate (polyglutamyl)  
and folic acid 
Intes nal absorp on 
Figure 3.2 Diagram of the one-carbon metabolism pathway. Labile methyl groups are supplied by dietary serine, choline 
(via betaine), and methionine. One-carbon units are derived from serine through the activity of the vitamin B6 – dependent 
serine hydroxymethyltransferase, which generates 5,10-methyleneTHF. 5,10-MethyleneTHF, in turn, is then reduced to 5-
methylTHF, the predominant form of folate in the circulation, in an irreversible reaction catalyzed by vitamin B2 – 
dependent MTHFR. MS serves as a methyl donor in a reaction converting homocysteine to methionine, in which vitamin 
B12 serves a cofactor. Homocysteine can also be metabolized to cysteine through the sequential action of two vitamin B6 – 
dependent enzymes [i.e., the transsulfuration pathway]. The methionine derivative, S-adenosylmethionine, is the universal 
methyl donor for the methylation of a vast variety of molecules, including DNA.  
5,10-methyleneTHF: 5,10-methylenetetrahydrofolate, 5-methylTHF: 5-methyltetrahydrofolate, MTHFR: 
methylenetetrahydrofolate, MS: methinoine synthase [Adapted from Johansson et al. 2009]    
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1) Deficiency of cytosolic B12: This leads to build up of Hcy in the cell and 
consequently reduction in methionine and SAM. Lack of SAM leads disrupts the 
stability of the genome due to hypomethylation of DNA and myelin sheaths (Fenech 
2001; Saravanan and Yajnik 2010). Additionally, SAM is an inhibitor of MTFHR, an 
irreversible rate-limiting enzyme that converts 5,10-methyleneTHF to 5-methylTHF. 
Reduction in SAM leads to increased MTHFR activity and production of 5-
methylTHF, which gets trapped in that form due to B12 deficiency (known as ‘folate 
trap hypothesis’) (Das and Herbert 1976; Selhub et al. 2008). The resulting deficiency 
of nonmethylated forms of folate affects serine to glycine and deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) conversions, 
causing uracil incorporation into DNA (instead of thymidylate) and increasing risk of 
chromosomal breakage (Blount et al. 1997) (Figure 3.3).  
 
2) Deficiency of mitochondrial B12: In the absence of B12, build-up of methylmalonyl-
CoA and MMA inhibit a key enzyme required for beta-oxidation of fatty acids, 
known as carnitine palmitoyl transferase 1. The resulting increase in non-oxidised 
fatty acids can contribute to lipogenesis and insulin resistance especially if impaired 
glucose metabolism co-exists (Saravanan and Yajnik 2010). 
 
Figure 3.3 Pathways that involve vitamin B12 and the suggested mechanisms of increased adiposity and 
insulin resistance in maternal B12 deficiency (see text for details).  
dTMP: thymidine monophosphate, dUMP: deoxyuridine monophosphate, TS: thymidylate synthase, 
MTHF: methyl tetrahydrofolate, MTHFR: methylene tetrahydrofolate reductase, DHF: dihydrofolate, 
THF: tetrahydrofolate, MS: methionine synthase, SAH: S-adenosylhomocysteine, SAM-e: S-adenosyl 
methionine, R: methyl acceptor, R–: methylated compound, MM-CoA: methylmalonyl-CoA, MCM : 
methylmalonyl-CoA mutase, CPT1: carnitine palmitoyltransferase-1  [From Saravanan and Yajnik 2010]    
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3.1.2. Absorption and dietary sources of B12 
The absorption of B12 by the human body is complex and involves several processes 
in the gastro-intestinal tract. These steps as well as causes of B12 deficiency relating 
to disruption in this absorption process are summarised in Figure 3.4 (Andres et al. 
2004). In summary, dietary B12 is released from food in the stomach by pepsin, 
which functions only in the acidic environment of the stomach. It then binds to R-
protein, a B12-transport protein produced in salivary and gastric parietal cells. A key 
carrier protein for B12 is intrinsic factor (IF) which is also secreted by the gastric 
parietal cells. Since B12 binding to IF is very weak in the acidic environment of the 
stomach, B12 enters the duodenum where it is becomes dissociated from the R-
protein complex due to the action of pancreatic proteases. Then it binds to IF and this 
complex is carried down the small intestine until the terminal ileum where it attaches 
to IF-receptors and is absorbed into the bloodstream by endocytosis. Over 95% of 
dietary B12 is absorbed through the IF-pathway as described above and only small 
fraction (1-2%) is passively absorbed via the surface of the intestinal tract. 
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Figure 3.4 The metabolic pathway of vitamin B12 (cobalamin or Cbl) and corresponding 
causes of deficiency. (1) Dietary intake of vitamin B12 enters the stomach bound to food 
protein (P). (2) In the stomach, the acidic environment (pepsin and hydrochloric acid (HCL)) 
facilitates the cleavage of vitamin B12 that is bound to P, giving the free form of the vitamin. 
The released form of vitamin B12 is immediately passed to a mixture of glycoprotein such as 
R-protein (R), which is primarily produced by the parietal and salivary cells, to protect 
vitamin B12 from chemical denaturation in the stomach. Intrinsic factor (IF) is also secreted 
by parietal cells in the stomach, but its binding to vitamin B12 is weak in the presence of 
gastric and salivary R-protein. (3) Then, vitamin B12 leaves the stomach and enters the 
duodenum bound to R-protein and accompanied by IF and by vitamin B12-R-protein complex 
that have been secreted from the bile. (4) In the mildly alkaline environment of the jejunum, 
pancreatic enzymes degrade both biliary and dietary vitamin B12-R-protien complexes, 
releasing free vitamin B12. IF is resistant to proteolysis and binds to the released vitamin B12 
to facilitate its active absorption in the ileum. (5) The IF-B12 complex is carried down until 
the distal 80 cm of the ileum where it binds to mucosal cell receptors (cubilin), then vitamin 
B12 is bound to transport proteins known as transcobalamin I, II and III (TCI, TCII and 
TCIII). Vitamin B12 is subsequently transported systemically via the portal system. (6) 
Within each cell, the TCII–vitamin B12 complex is taken up by means of endocytosis and 
vitamin B12 is liberated and then converted enzymatically into its two coenzyme forms, 
methylcobalamin and adenosylcobalamin [from Andres et al. 2004]. 
 
After being absorbed in the terminal ileum, B12 is forms a complex with 
transcobalamin II (TC-II, the active extracellular carrier protein) and is distributed to 
the tissues by the TC-II receptor-mediate endocytosis. Although newly absorbed B12 
is associated with TC-II in a complex known as holo-transcobalamin (holo-TC), 75% 
of B12 in plasma is actually bound to haptocorrin (or TC-I) (Shane 2008). TC-II 
levels are 3 to 3 fold higher in plasma than TC-I but the latter is over 90% saturated 
with cobalamin, compared to about 10% for TC-II. The functional significance of 
haptocorrin in the human body is not entirely clear but it is believed to facilitate 
uptake of B12 into the liver, which has receptors for both TC-I and TC-II (Shane 
2008). 
 
B12 is predominantly stored in the liver at concentrations of 2 to 4mg, in the form of 
5’-deoxyadenosylcobalamin (Shane 2008). So, based on a recommended daily 
nutrient intake (RNI) of 2mcg/day (it varies from 1.5mcg/day in the UK to 4.5 
mcg/day in Europe), it would take 3 to 4 years for deficiency to become apparent 
(COMA (Committee on Medical Aspects of Food Policy) 1991; EFSA NDA Panel 
(EFSA Panel on Dietetic Products 2015).  
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B12 can only be synthesised by certain strains of bacteria (not humans or animals) 
and animals obtain this vitamin by consuming food contaminated by these bacteria 
and then incorporating it into their organs. Therefore humans get their B12 by eating 
foods from animal sources that are rich in B12. These include red meat (2-
10mcg/100g, however liver contains up to 95mcg/100g), fish (2-8mcg/100g), eggs 
(2mcg/100g), milk (1.5mcg/100g) and cheese (1.5mcg/100g) (W. Herrmann and 
Obeid 2012; J. M. Scott 1997). The bioavailability of dietary B12 is around 50% on 
average but it varies according to the type and B12 content of food consumed. For 
instance only around 11% is absorbed from liver, which has a high B12 content 
(Allen 2008). The quoted figures are 50% absorption from an intake of 1mcg dose, 
25% from 5mcg and 5% from 25mcg (Adams et al. 1971). However the maximum 
absorption possible from a meal is around 3mcg, due to saturation of the intestinal 
receptors, so any additional absorption is from the 1% which occurs passively through 
the intestines (W. Herrmann and Obeid 2012). Therefore B12 deficient individuals are 
often given very high doses of the crystalline form (around 500mcg/day to meet their 
daily requirements).  
 
3.1.3. Biochemical markers of B12 insufficiency 
The biomarkers used to diagnose B12 insufficiency in human plasma/serum are 
summarised in Table 3.1. These include:- 
1) Total serum cobalamin: this is usually the first line test done when B12 deficiency is 
suspected. However, problems with it are that since around 90% of B12 is bound to 
the inactive haptocorrin, minor changes in the ‘active’ cobalamin will not be reflected 
by total cobalamin measurement. This test has low sensitivity and specificity to detect 
‘true’ cobalamin deficiency especially when the readings are between 150 to 300 
pmol/l (R. Green 1995; W. Herrmann and Obeid 2012).  
2) Holotranscobalamin (holoTC): this is the earliest marker of cobalamin deficiency in 
the blood (Bor et al. 2004) but drugs like the oral contraceptive pill can lower the 
values and renal failure increase it. 
3) Hcy: this is a useful reflection of functional cobalamin insufficiency but elevation 
may also be caused by folate or vitamin B6 deficiencies 
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4) MMA: concentrations above 300nmol/L are the most sensitive and specific marker of 
cobalamin deficiency (W. Herrmann and Obeid 2012). However false positives can 
occur with renal insufficiency and intestinal bacterial overgrowth 
 
 
3.1.4. Causes, symptoms and diagnosis of B12 insufficiency 
The causes of B12 insufficiency in adults are summarised in Table 3.2. Population 
surveys in Western countries quote B12 insufficiency rates to be 3-5% in adults in 
their 3rd to 5th decades but it rises to between 6 – 20% in the over 60’s in the USA and 
around 10% of the over 75’s in the UK, depending on the cut-off levels used (Allen 
2009; Clarke et al. 2004; Pfeiffer et al. 2007). In developing countries, the estimates 
are 40 to 70% of all adults (Allen 2004; Refsum et al. 2001). The main reason for 
high rates of insufficiency in the elderly is malabsorption of food-based B12 due to 
age-related gastric atrophy. Gastric acid is required for the release of B12 from food 
and subsequent binding to R-protein or haptocorrin. However, absorption of synthetic 
vitamins from fortified foods or supplements is not affected because they exist in the 
crystalline form and therefore do not require release in an acidic pH prior to binding 
to IF.  
Table 3.1  Available markers of vitamin B12 deficiency (from Herrmann and Obeid 2012) 
tHcy: total homocysteine, MMA: methylmalonic acid, holoTC: holotranscobalamin, GCMS: gas chromatograph 
mass spectrometer , HPLC: high performance liquid chromatography, LC_MS/MS: liquid chromatography mass 
spectrometry, RIA: radioimmunoassay, ELISA: enzyme-linked immunosorbant assay,  
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A classical finding in B12 or folate insufficiency is megaloblastic anaemia which 
arises due to double-stranded DNA breaks in a rapidly dividing red blood cell. The 
defective DNA synthesis occurs due to decreased uracil to thymidylate conversion (as 
described above) resulting in uracil misincorporation into DNA. Megaloblastosis 
identified as erythrocytes with a large mean corpuscular volume (MCV) (i.e. 
macrocytic). However, this can be a late feature of B12 insufficiency and if there is 
co-existing iron deficiency (which causes microcytosis), the MCV may be normal.  
 
Neurological signs of B12 deficiency include sensory disturbances in the extremities, 
memory loss and dementia and in infants/children can cause significant 
developmental regression and poor intellectual outcomes. The reasons for these 
effects is not entirely clear but are believed to be either due to impaired methylation 
of essential amino acids or neurotransmitters from methionine synthase deficiency 
(Weir et al. 1988) or because of build-up of mitochondrial methylmalonyl CoA and 
propionyl CoA which abnormally accumulate in myelin sheaths causing 
demyelination (Metz 1992).  
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From Figure 3.2, it can be seen that the defective DNA synthesis causing 
megaloblastosis occurs primarily due to deficiency of non-methylated 
tetrahydrofolate. However it also occurs in B12 deficiency due to the folate trap 
hypothesis (i.e. folate is trapped as 5-methylfolate because of inhibition of methionine 
synthase activity). These biochemical mechanisms explain why giving high doses of 
folate can reverse the haematological abnormalities of B12 deficiency but will not 
prevent, or may even exacerbate, the neurological complications.  
 
3.2. Role of B12 in embryogenesis and pregnancy outcomes 
Vitamin B12 and folate vitamins are pivotal in normal embryogenesis and therefore 
there is increasing attention on optimising levels in young women in the 
periconceptional period and pregnancy. The levels of both these micronutrients have 
been associated with pregnancy complications such as neural tube defects (NTD), 
spontaneous abortion (George et al. 2002), pre-eclampsia (Mujawar et al. 2011; 
Sanchez et al. 2001) and preterm birth (Ronnenberg et al. 2002), with the latter two 
conditions mediated in part by elevated Hcy.  
 
NTDs occur when the embryo’s neural tube fails to close by around 28th day after 
conception, causing damage to the underlying neural tissues which is exposed. The 
resulting defects cause much morbidity and mortality to the developing embryo with 
the most severe being anencephaly, a condition which is incompatible with life. In 
spina bifida where the defect is more caudal, several morbidities such as urinary and 
fecal incontinence and paralysis of the lower limbs occur. The precise reason why 
folate (and/or B12 deficiency) causes NTDs is not entirely clear but is believed to be 
related to its interference with cellular proliferation by inhibiting the one-carbon 
metabolism, DNA synthesis and methylation pathways (Crider et al. 2011; Pitkin 
2007). Indeed genetic studies looking at polymorphisms of the MTHFR and other 
candidate genes causing low folate confirmed that its deficiency was indeed causative 
for NTDs (Molloy et al. 2009). Randomised control trials have demonstrated a 70 – 
100% decrease in NTDs following folic acid supplementation (Czeizel and Dudas 
1992; MRC Vitamin Study Research Group 1991). However, the importance of B12 
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in preventing NTDs cannot be overlooked since it can cause functional folate 
deficiency (by ‘folate trap hypothesis’) and is also required for the synthesis of methyl 
donors.  
 
The reason that B12 (along with folate) is so essential to embryogenesis can be 
explained by revisiting its role in the one-carbon metabolism and methylation 
pathways discussed in Section 3.1.1. There are 2 critical periods of DNA methylation 
reprogramming during early fetal development: firstly during germ cell differentiation 
(pre-implantation) when rapid genome wide demethylation occurs to reset the genes 
followed by remethylation to allow parent-specific allele expression at around 12 days 
post-fertilisation (Santos and Dean 2004) (Figure 3.5). The second phase occurs in the 
blastocyst stage (days 5-7 post-fertilisation) when de novo methylation begins. Any 
insults which occur during these periods can result in heritable changes in gene 
expression that are not due to alterations in DNA  (known as epigenetics) (Canovas 
and Ross 2016; Waterland and Jirtle 2004).  
 
 
Aside from DNA methylation, other processes that can lead to epigenetic alterations 
are post-translational modification of histones and noncoding RNAs. Any 
perturbations during these key points of epigenetic remodelling can lead to permanent 
Figure 3.5 Methylation reprogramming during mouse development. The diagram depicts 
methylation levels of various classes of genes during germ cell and embryonic development 
(methylated imprinted genes (black line) and non-imprinted genetic sequences (red, maternal; 
blue, paternal)). Highly methylated primordial germ cells enter the germinal ridge and undergo 
loss and reacquisition of methylation during their expansion phase. Examples of these cells 
(day 11.5, 13.5 and 14.5) stained for alkaline phosphatase, a PGC marker, are pictured above.  
[from Santos and Dean 2004]    
 26 
and inheritable changes to the epigenome, which can make the individual susceptible 
to chronic disease in later life (Figure 3.6) (Ross and Canovas 2016; Warner and 
Ozanne 2010).   
 
 
 
Due to the rapid differentiation of the developing embryo, these DNA methylation 
sequences must be maintained over several cycles of cellular proliferation during the 
in-utero stage necessitating adequate provision of substrate. Several of the methyl 
donors required for normal DNA synthesis and methylation are obtained from the diet 
(e.g. methionine, choline, B12, folic acid, choline) so there is increasing attention 
being given to optimising the nutritional status of women in the peri-conception 
period.  
 
The importance of adequate nutrition during pregnancy, especially a methyl-rich diet, 
has been demonstrated in several animal studies. Maternal calorie restriction leads to 
lower offspring birthweight with reduced pancreatic beta-cell mass, putting the 
offspring at increased risk of glucose intolerance, hyperinsulinaemia, 
hyperleptinaemia and obesity later on (Bertin et al. 2002; Garofano et al. 1997; 
Figure 3.6 Summary of the structural and molecular adaptations made during the intrauterine 
programming of metabolic disease. A schematic representation of how a perturbed intrauterine 
environment, induced by a variety of physiological disturbances in animal models, can elicit changes in the 
structure and function of multiple organs, subsequently leading to the development of features of metabolic 
syndrome [from Warner and Ozanne 2010]    
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Vickers et al. 2000). Similar metabolic outcomes were also observed in lambs born to 
sheep fed a ‘methyl-deficient diet’ during pregnancy, highlighting the key role of the 
intra-uterine environment in determining future metabolic diseases (Sinclair et al. 
2007).  
 
3.3. Next steps 
In the next 3 chapters I will examine, in two systematic reviews, the prevalence of 
vitamin B12 insufficiency in pregnancy across the world and its impact on fetal birth 
weight followed by a retrospective case-control study of scale of the problem in a UK 
population of pregnant women with and without GDM. Finally I will discuss if there 
needs to be a national policy change with respect to dietary reference intake for B12 
by utilising micronutrient intake and biomarker results from the National Dietary 
Nutrition Survey in women of child-bearing age.  
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Prevalence of vitamin B12 insufficiency during 
pregnancy and its effect on offspring birthweight: a 
systematic review and meta-analysis 
  
Chapter 4 
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4.1. Introduction 
In Chapter 3, I have discussed the role that vitamin B12 (B12) plays in normal 
embryogenesis and potential impact of insufficiency during pregnancy.  
 
Low B12 can have an impact on fetal birthweight by influencing placental 
development (Koukoura et al. 2012) but the relationship between B12 and birth 
weight is far from established (Furness et al. 2013; Hogeveen et al. 2010). LBW or 
small for gestational age (SGA) are outcomes of particular interest as they are well-
established surrogate markers for metabolic disorders such as obesity, type 2 diabetes 
and metabolic syndrome in later life in many populations (Hales and Barker 2001; 
Whincup et al. 2008; C.S. Yajnik et al. 1995). Most studies showing the link between 
B12 and LBW are from Indian subcontinent, where rates of both LBW/SGA and B12 
insufficiency are high (Muthayya et al. 2006b; United Nations Children’s Fund and 
World Health Organization 2004; C. S. Yajnik et al. 2008). High prevalence of B12 
insufficiency in India has been attributed to vegetarianism (i.e. no consumption of 
animal products except for dairy) and infrequent meat consumption in omnivores (i.e. 
consumption of small quantities of non-vegetarian food less often than alternate days) 
(Refsum et al. 2001; C. S. Yajnik et al. 2008). However, B12 insufficiency has also 
been found in other countries where vegetarianism is rare such as Brazil and Turkey 
(Ackurt et al. 1995; Guerra-Shinohara et al. 2004). 
 
The aims of this systematic review and meta-analysis are to evaluate the prevalence of 
vitamin B12 (B12) insufficiency in pregnancy across a worldwide population and 
assess whether this is associated with low birthweight (LBW) and/or small for 
gestational age (SGA). 
 
4.2. Methods 
This systematic review comprises of 2 sub-reviews (namely (1) Prevalence of B12 
insufficiency and (2) B12 insufficiency and birthweight (BW)) and in the following 
sections will be divided accordingly where appropriate. 
 
4.2.1. Sources of data 
Published guidelines on reporting systematic reviews and meta-analysis of 
observational studies (MOOSE Guidelines) were followed (Stroup et al. 2000). A 
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comprehensive literature search in 5 bibliographic databases was conducted for the 
‘Prevalence sub-review’: MEDLINE/PUBMED (National Library of Medicine and 
National Institute of Health), EMBASE (The Excerpta Medica database), Global 
health (CABI), CAB (Commonwealth Agricultural Bureau database) and CINAHL 
(The Nursing & Allied Health database). For the ‘Birthweight sub-review’, 4 
databases were used, namely MEDLINE/PUBMED, EMBASE, Global Health and 
Scopus (Elsevier). All databases were searched from inception until December 2014. 
We also examined reference lists of key publications for further articles. Where 
needed, the authors were contacted by email for more complete information. 
 
4.2.2. Search criteria 
For the ‘Prevalence sub-review’, a search strategy based on the following keywords 
and medical subject headings (MeSH) was used: “cobalamin”, “vitamin B12”, 
“vitamin B12 insufficiency”, “vitamin B12 deficiency”, “methylmalonic acid”, 
“holotranscobalamin”, “homocysteine”, “pregnancy”, “pregnant women”. Search 
words were combined using Boolean operators (AND, OR). A similar search string 
was used in all bibliographic databases. Studies conducted on adult pregnant women 
(aged 18-45 years) at any trimester, including delivery, which report prevalence of 
vitamin B12 insufficiency with clearly defined cut-off levels were included. Only 
results from the trimesters where B12 values were available from at least 50 women 
are reported. 
 
The keywords and MeSH used for the ‘Birthweight sub-review’ included: 
“cobalamin”, “vitamin B12 insufficiency”, “vitamin B12 deficiency”, 
“methylmalonic acid”, “holotranscobalamin”, “homocysteine”, “pregnancy outcome”, 
“birth weight”, “intrauterine growth retardation”, “small for gestational age”. An 
identical approach to that described above was used for combining search words.  
 
4.2.3. Eligibility criteria 
Both longitudinal and cross-sectional observational studies, conducted in the 
community or hospital setting on adult pregnant women (aged 18 to 45 years) without 
any major co-morbidities were included. We restricted the search to studies conducted 
on human subjects and published in English language in peer-reviewed journals. If the 
results of a study were reported in more than one publication, the study with the most 
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complete information pertaining to our review’s outcomes was used. If these were 
identical, the one published earlier was included.  The following types of studies were 
excluded: randomised controlled trials where B12 supplementation was given as part 
of the study design, case-control studies and studies done exclusively on mothers with 
co-morbidities (e.g. HIV, post-bariatric surgery). Additionally, we excluded studies 
which were designed specifically to look at pregnancies with neural tube defects, 
intra-uterine growth retardation, early pregnancy loss and anaemia (however, if the 
studies were conducted on ‘normal’ pregnant women with no prior medical history 
and reported rates of anaemia in their results, they were included). For the 
‘Birthweight sub-review’, we included studies which reported vitamin B12 results 
from maternal or cord blood and offspring birth weight. 
 
4.2.4. Data extraction 
Level one screening of initial database search results (titles and abstracts) was 
independently performed by at least two reviewers (NS and NB/SBR) according to 
the inclusion and exclusion criteria. Level two screening was conducted by reviewing 
the full manuscripts of the articles. Two reviewers (NS and SBR) independently 
extracted the study characteristics onto pre-designed forms which included 
information on the study population and methods, vitamin B12 values and birthweight 
outcomes. Any discrepancy in data extraction was resolved by consensus and 
consulting a third reviewer (PS) where necessary. 
   
4.2.5. Data synthesis 
For the ‘Prevalence sub-review’, we analyzed and reported the results of the 
systematic review according to the 3 trimesters of pregnancy, to ensure like-for-like 
comparison. It is well known from longitudinal studies that there is a progressive 
decline of B12 during the course of pregnancy (Cikot et al. 2001; Garcia-Casal et al. 
2005), which reaches a nadir towards the end of the 3rd trimester (Van Sande et al. 
2013).  To assess the impact of geography on the worldwide prevalence of B12 
insufficiency, the broad World Health Organization (WHO) Region classification was 
used (i.e. Africa, Americas, South-east Asia, Europe, Eastern Mediterranean and 
Western Pacific) (McLean et al. 2008). However, we further divided the Americas 
and Southeast Asia regions into North America and Central/South America and 
Indian sub-continent and South-east/East Asia respectively in an attempt to bring 
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together the populations based on dietary habits, vegetarianism and consumption of 
animal products (Stabler and Allen 2004).  
 
For the ‘Birthweight sub-review’, the included studies reported three different types 
of effect sizes, namely 1) odds of having an adverse birthweight outcome below a 
threshold of maternal/cord B12, 2) comparison of mean/median maternal/cord B12 
values between adverse and normal birthweight, and 3) the effect of maternal/cord 
B12 as a linear variable on birthweight (regression coefficient or correlation 
coefficient). Adverse birth weight outcome was defined as LBW (birthweight 
<2500g) (United Nations Children’s Fund and World Health Organization 2004), 
SGA (birthweight <10th centile for gestational age), intra-uterine growth restriction 
(IUGR) (estimated fetal weight <10%) (Goldenberg and Cliver 1997) or as the lowest 
tertile or quartile of BW in the included studies.  
 
4.2.6. Statistical analysis 
Prevalence sub-review 
To estimate the pooled estimates of the B12 insufficiency rate per trimester, we 
obtained an estimate from each study of the proportion of pregnant women with B12 
below the cut-off level defined in that study. Sub-group analysis was undertaken for 
the studies from the 2nd and 3rd trimesters to determine if the prevalence of B12 
insufficiency in pregnancy varied according the geographical areas. Statistical 
heterogeneity was calculated using the I2 statistic (Higgins and Green 2011). A 
random effects meta-analysis was undertaken using STATA version 13 software 
(DerSimonian and Laird 1986; StataCorp 2011). We assessed publication bias by 
using a funnel plot, Egger’s and Begg’s tests to find out whether there was a bias 
towards publication of studies with positive results among the smaller studies (results 
not shown).  
 
In order to correct for differences in the vitamin B12 measurement assays and cut-off 
levels used by the studies, we calculated a standardised score by dividing the mean 
B12 level used in the study by the cut-off level used to define insufficiency in that 
study (mean B12 ÷ insufficiency cut-off). In the studies where a median B12 value 
was reported, it was used to estimate the mean where sample sizes were large (Hozo 
et al. 2005). Stepwise linear regression was then done to determine the predictors of 
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percentage B12 insufficiency in a model which included the trimester of sampling, 
assay type and geographical region. Log-transformed standardised scores were used 
for this as the variable was not normally distributed. SPSS version 22 was used for the 
analysis (IBM Corp Released 2013). 
 
Birthweight sub-review 
The software Review Manager (2013) was used to conduct meta-analyses from the 
included studies. We obtained an estimate from each study of the adjusted odds ratio 
(OR) with 95% confidence intervals (CIs) using a random effects model. Statistical 
heterogeneity was calculated using the I2 statistic (Higgins and Green 2011). Adjusted 
outcome measures were tabulated where these were reported. Continuous effect 
measures data were expressed as mean difference (SD) of B12 between babies of low 
birthweight or the equivalent (termed as ‘adverse birthweight outcome cases’) and 
normal birthweight outcome. Pooled analyses were not done for the studies reporting 
B12 and BW as linear variables because there was too much heterogenity in the 
reporting of the independent variable and outcome (e.g. some reporting unit values 
and others standard deviation scores).   
 
4.2.7. Risk of bias and quality of evidence 
The methodological quality assessment of the studies was done using a checklist for 
cohort studies adapted from the Scottish Intercollegiate Guidelines Network (Scottish 
Intercollegiate Guidelines Network (SIGN) and Healthcare Improvement Scotland 
2011). The quality assessment focussed on evaluating how minimal the risk of bias 
was in study reporting using 14 key criteria from the checklist (Appendix 1.1). 
However, for certain cross-sectional studies that reported only the point prevalence of 
B12 insufficiency, only 12 relevant criteria were used (criteria relating to drop out 
rate and comparison between full participants and those lost to follow-up were not 
used, as these were not relevant). The overall study quality grade was calculated as 
per standard guidelines according to the proportion of total criteria fulfilled (Scottish 
Intercollegiate Guidelines Network (SIGN) and Healthcare Improvement Scotland 
2011).    
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4.3. Results 
4.3.1. Prevalence of B12 insufficiency sub-review 
Study characteristics 
The electronic database search yielded 4742 citations, of which 153 were selected for 
full-text review (Figure 4.1A). There were six studies identified from the full text 
review, which reported B12 insufficiency rates during pregnancy but without 
specifying a trimester (Ball and Giles 1964; Bondevik et al. 2001; Ipciglu et al. 2007; 
D. J. Vanderjagt et al. 2007) or clearly stating the number of women sampled per 
trimester (Brabin et al. 1986; Haliloglu et al. 2010). These studies were not included 
in further analysis.   
 
 
A total of 57 studies met all the inclusion criteria, comprising of 16 longitudinal 
studies (n=34 results) and 41 cross-sectional studies, giving a total of 75 results 
(Abdelrahim et al. 2009; Ackurt et al. 1995; Areekul et al. 1976; H Baker et al. 1975; 
Balci et al. 2014; Barbosa et al. 2008; Bjorke Monsen et al. 2001; A. K. Black et al. 
!
4785 records screened (title & abstract screening) 
 
4632 records excluded due to failing to meet 
eligibility criteria on title/abstract screening 
 
153 full-text articles assessed for eligibility 
 
4742 records identified through 
database searching 
 
43 of additional records identified through other 
sources: 'Birthweight' sub-review searches 
(n=11), Reference list of relevant articles (n=32) 
 
90 full-text articles excluded due to: duplicate or 
same study population (n=16), no B12 prevalence 
or clear cut-off level (n=42), anaemic subjects only 
(n=4), lactating mothers samples only (n=1), non-
pregnant samples (n=2), review articles (n=5), 
small sample size (n=12), conference abstracts 
(n=3), case-control study/RCT (n=5) 
 
6 studies excluded due to: trimester not specified 
(n=4) or number of women per trimester not 
specified (n=2) 
 !
63 of studies included in qualitative synthesis 
 
57 of studies included in quantitative synthesis (meta-
analysis) 
 
Total of 75 results from 57 studies: 1st trimester (n=12), 
2nd trimester (n=21), 3rd trimester (n=42) 
 
B) A) !
947 records screened after duplicates removed (title & abstract screening) 
 
799 records excluded due to failing to meet 
eligibility criteria on title/abstract screening 
 
 
148 full-text articles assessed for eligibility 
 
1883 records identified through 
database searching 
 
17 additional records identified through other 
sources: 'Prevalence' sub-review searches 
(n=17) 
 
125 full-text articles excluded due to: no B12 
results (n=47), no BW  results (n=10), no de tails on 
B12 and BW association (n=46), re view article 
(n=18), i ntervention trial (n=2), a dolescent 
pregnancies (n=1), dupl icate data (n=1) 
 
11 studies excluded due to: not reporting 
differences in B12 as mean (SD) (n=4), re porting 
only correlation or re gression coefficients (n=7) 
 
 !
23 studies included in qualitative synthesis 
 
12 studies included in quantitative synthesis (meta-
analysis) 
 
Total of 28 results from 12 studies: studies reporting 
differences in mean (SD) of B12 (n= 10 s tudies, 20 results), 
studies reporting odds ratios (n= 5 s tudies, 8 results) 
 
Figure 4.1 PRISMA flow diagram showing the study selection process.            
A) Prevalence of B12 insufficiency in pregnancy sub-review and B) B12 insufficiency in pregnancy and birth 
weight sub-review 
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1994; Bruinse and van den Berg 1995; Cole et al. 1974; Colman et al. 1975; Cook et 
al. 1971; Dwarkanath et al. 2013; Frery et al. 1992; Garcia-Casal et al. 2005; Gibson 
et al. 2008; Giugliani et al. 1984; Goedhart et al. 2011; Guerra-Shinohara et al. 2004; 
Halicioglu et al. 2012; Hall et al. 2007; Heppe et al. 2013; Hinderaker et al. 2002; C. 
H. Ho et al. 1987; House et al. 2000; Hussein et al. 2009; Jacob et al. 1976; 
Jacquemyn et al. 2013; Jiang et al. 2005; Katre et al. 2010; E. M. Knight et al. 1991; 
Koc et al. 2006; Kosus et al. 2012; Krishnaveni et al. 2009; Li et al. 2008; Lowenstein 
et al. 1960; Ma et al. 2004; Marzan et al. 1971; Milman et al. 2006; Murphy et al. 
2007; Osifo and Onifade 1976; Pagán et al. 2002; Park et al. 2004; Pathak et al. 2007; 
Ray et al. 2008; Roberts et al. 1973; Samuel et al. 2013; Schulpis et al. 2004; Shamim 
et al. 2013; Shields et al. 2011; Takimoto et al. 2007; D. Vanderjagt et al. 2009; 
Whiteside et al. 1968; Wu et al. 2013; C. S. Yajnik et al. 2008; Yusufji et al. 1973; 
Zachau-Christiansen et al. 1962). Details of these studies including the country where 
the field work was done, proportion of B12 supplement or multivitamin use, B12 
assay method and insufficiency rates are presented in Table 4.1. For the setting of the 
study, they were broadly categorised into a community or hospital setting (including 
health centres) to reflect where the population was sampled from. In the first, second 
and third trimesters, there were 12, 21 and 42 results, which were obtained by 
sampling 10474, 8621 and 11667 pregnant women respectively.   
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Table 4.1 Prevalence of B12 insufficiency during pregnancy: Key study characteristics and results 
Author, Year of publication 
Country, Year of field study 
Study design1  
No. of participants 
with B12 results 
Setting of Study 
Population 
response rate 
B12 
supplement or 
multivitamin 
use (%)2 
B12 cut-off level 
(pmol/l) 
% B12 
insufficiency 
Mean B12 level, 
pmol/l  
(S.D.) 
1st trimester (n=12) 
a) Microbiological assay 
Whiteside et al. 1968 (a) 
Australia, N/R 
L 
56 
Hospital  
N/R 
N/R <74 5 217 
Roberts et al. 1973 (a)  
England, 1971 
L 
320 
Hospital  
N/R 
N/R <118 35 165 (84.9) 
Jiang et al. 2005  
Nepal, 1998-2001 
CS 
1158 
Community  
89% consented 
None <150 28.3 237.1 (138.3) 
Murphy et al. 2007 (a)  
Spain, 1992-96 
L 
88 
Hospital  
N/R 
27%2 <150 0 267 (144, 449)3 
b) Radioimmunoassay 
Garcia-Casal et al. 2005 (a)  
Venezuela, 2001-02 
CS 
129 
Hospital 
N/R 
N/R <148 43.4 N/R 
Ray et al. 2008  
Canada, 2007 
CS 
3734 
N/R 
N/R 
N/R <125 8.5 249 (244, 255)4 
c) Chemiluminescence 
Kosus et al. 2012  
Turkey, N/R 
CS 
228 
Hospital 
N/R 
N/R <156 12.5 200 (95.6)5 
Dwarkanath et al. 2013  
India, N/R 
L  
1838 
Hospital 
73% consented 
None <150 32 N/R 
Heppe et al. 2013  
Netherlands, 2002-06 
CS 
2173 
Hospital 
N/R 
N/R <150 26 175 (100)5 
Samuel et al. 2013  
India, 2008-10 
CS 
352 
Hospital 
88% consented 
None <150 51.1 149 (109, 205)5 
Shamim et al. 2013  
Bangladesh, 2001-07 
CS 
285 
Community 
N/R 
N/R <150 19.6 206.3 (84.5) 
d) Assay method not described 
Shields et al. 2011 (a)  
Scotland, 2008-09 
CS 
113 
Hospital 
N/R 
N/R N/R 
<156 
16 215 
 37 
2nd trimester (n=21) 
a) Microbiological assay 
Lowenstein et al. 1960 (a)  
Canada, N/R 
L 
59 
N/R 
N/R 
N/R <148 15.2 235 (101) 
Whiteside et al. 1968 (b)  
Australia, N/R 
L 
50 
Hospital 
N/R 
N/R <74 25 127 
Jacob et al. 1976  
USA, 1972-74 
CS 
182 
Hospital 
100% consented 
20% <111 4.5 303 
Murphy et al. 2007 (b)  
Spain, 1992-96 
L 
90 
Hospital 
N/R 
27%2 <150 0 230 (123, 432)3 
Yajnik et al. 2008 (a)  
India, 1994-96   
L 
638 
Community 
92% consented 
N/R <150 60 135 (103, 175)5 
Katre et al. 2010  
India, 2004-06 
L 
163 
Hospital 
97.3% consented 
29%2 <150 73 119 (87, 161)5 
b) Radioimmunoassay 
Marzan et al. 1971 (a)  
Philippines, N/R 
CS 
100 
Hospital 
N/R 
None <59 1.5 270.1 (79) 
Areekul et al. 1976 (a)  
Thailand, N/R 
CS 
71 
Hospital 
N/R 
N/R <111 7 All trimesters: 211 
(106) 
Knight et al. 1991 (a)  
USA, 1985-90 
L 
108 
Hospital 
N/R 
91%2 <148 7 N/R 
Bruinse et al. 1995 (a)  
Netherlands, N/R 
L 
70 
Hospital 
N/R 
None <180 0 N/R 
Ackurt et al. 1995 (a)  
Turkey, 1991 
L 
129 
Hospital 
66% responded to 
invitation 
35% <111 48.8 140.8 (105) 
Pagan et al. 2002 (a)  
USA, 1986-88 
L 
285 
N/R 
N/R 
N/R <148 0.35 357 (131) 
Park et al. 2004 
South Korea,  
CS 
89 
Hospital 
N/R 
42% <258 46.1  N/R 
Garcia-Casal et al. 2005 (b)  
Venezuela, 2001-02 
CS 
430 
Hospital 
N/R 
N/R <148 58.6  N/R 
Li et al. 2008  
Bangladesh, 2002 
L 
753 
Community 
78% consented 
N/R <185 60 N/R 
c) Chemiluminescence 
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Takimoto et al. 2007 (a)  
Japan, 2001-03 
L 
77 
Hospital 
N/R 
N/R <148 8 301 (96) 
Goedhart et al. 2011  
Netherlands, 2003-04 
CS 
2921 
Community 
35% consented 
N/R <148 6 N/R 
d) Enzyme immunoassay       
House et al. 2000  
Canada, 1996-97 
CS 
1424 
N/R 
N/R 
N/R <130 25.3 180 (130, 240)5 
Milman et al. 2006 (a)  
Denmark, 1995-96 
L 
406 
N/R 
N/R 
34%2 <150 15 225 (118, 381)6 
Wu et al. 2013 (a)  
Canada, N/R 
L 
264 
Hospital 
N/R 
N/R <148 10 287 (126) 
e) Others 
Hinderaker et al. 2002  
Tanzania, 1995-96 
CS 
312 
Hospital 
78% consented 
N/R HPLC 
<150 
16.7 N/R 
3rd trimester (n=42) 
a) Microbiological assay 
Lowenstein et al. 1960 (b)  
Canada, N/R 
L 
252 
N/R 
N/R 
N/R <148 19 221 (126) 
Zachau-Christiansen et al. 1962  
Denmark, N/R 
CS 
365 
Hospital 
N/R 
N/R <111 17 177 
Roberts et al. 1973 (b)  
England, 1971 
L 
119 
Hospital 
N/R 
N/R <118 48 134 (70.9) 
Yusufji et al. 1973  
India, N/R 
CS 
998 
Hospital 
N/R 
N/R <103 52 117 (90) 
Baker et al. 1975  
USA, N/R 
CS 
174 
N/R 
N/R 
76%2 <59 23 85 (832) 
Osifo et al. 1976  
Nigeria, N/R 
CS 
50 
N/R 
N/R 
N/R <148 40 208 (123) 
Bjorke-Monsen et al. 2001  
Norway, 1996-97 
CS 
169 
Hospital 
N/R 
36%2 <150 15 245 (175, 323)5 
Murphy et al. 2007 (c)  
Spain, 1992-96 
L 
90 
Hospital 
N/R 
27%2 <150 0 224 (117, 444)3 
Pathak et al. 2007  
India, N/R 
CS 
266 
Community 
94% consented 
N/R <148 74.1  N/R 
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Yajnik et al. 2008 (b)  
India, 1994-96 
L 
594 
Community 
92% consented 
N/R <150 71 122 (94, 160)5 
Krishnaveni et al. 2009  
India, 1997-98 
CS 
774 
Hospital 
N/R 
31%2 <150 43 162 (123,221)5 
b) Radioimmunoassay 
Marzan et al. 1971 (b)  
Philippines, N/R 
CS 
57 
Hospital 
N/R 
None <59 0 286.3 (86) 
Cole et al. 1974  
Australia, N/R 
CS 
130 
Hospital 
N/R 
N/R <148 12.3 272.3 
Colman et al. 1975  
South Africa, N/R 
CS 
106 
Hospital 
N/R 
N/R 
 
<295 
 
0.9 
 
524 (165) 
 
Areekul et al. 1976 (b)  
Thailand, N/R 
CS 
100 
Hospital 
N/R 
N/R <111 13 All trimesters: 211 
(106) 
Frery et al. 1992  
France, N/R 
CS 
188 
Hospital 
N/R 
N/R <148 27.6 175 (74, 397)4 
Giugliani et al. 1984  
Brazil, N/R 
CS 
51 
Hospital 
100% 
51%2 <165 21.6 251 (108) 
Ho et al. 1987  
Taiwan, N/R 
CS 
221 
Hospital 
N/R 
None <110 3.6 228.6 (157.3) 
Knight et al. 1991 (b)  
USA, 1985-90 
L 
218 
Hospital 
N/R 
91%2 <148 11.2 318 (216) 
Black et al. 1994  
Mexico, 1985-87 
CS 
85 
Community 
N/R 
N/R <74 15 228 (451) 
Ackurt et al. 1995 (b)  
Turkey, 1991 
L 
87 
Hospital 
66% responded to 
invitation 
35% <111 80.9 94.6 (107.8) 
Bruinse et al. 1995 (b)  
Netherlands, N/R 
L 
70 
Hospital 
N/R 
None <180 0 N/R 
Pagan et al. 2002 (b)  
USA, 1986-88 
L 
285 
N/R 
N/R 
N/R <148 2.1 285 (100) 
Ma et al. 2004  
China, 1999-2000 
CS 
1019 
Hospital 
N/R 
None <148 10.5  N/R 
Garcia-Casal et al. 2005 (c)  
Venezuela, 2001-02 
CS 
301 
Hospital 
N/R 
N/R <148 68.5 N/R 
Hall et al. 2007  CS Hospital N/R <185 58.9 180.0 (71.5) 
 40 
Bangladesh, 2004-05 95 N/R 
Gibson et al. 2008  
Ethiopia, N/R 
CS 
83 
Community 
N/R 
N/R <150 23  268 (152, 372)5 
c) Chemiluminescence 
Schulpis et al. 2004  
Greece, 1999-2002 
CS 
1933 
Hospital 
N/R 
None <170 52.7  N/R 
Koc et al. 2006  
Turkey, N/R 
CS 
180 
Hospital 
N/R 
19% <118 72 95.9 (45.5) 
Takimoto et al. 2007 (b)  
Japan, 2001-03 
L 
82 
Hospital 
N/R 
N/R <148 16 265 (95) 
Barbosa et al. 2008  
Brazil, 2001-03 
CS 
275 
Hospital 
N/R 
None <179 75 N/R 
Hussein et al. 2009  
Egypt, N/R 
CS 
84 
Hospital 
N/R 
N/R <150 46.4 185.3 (113) 
Vanderjagt et al. 2009  
Nigeria, N/R 
CS 
98 
Hospital 
N/R 
None <148 12.2 208 (25, 739)7 
Halicioglu et al. 2012  
Turkey, 2008 
CS 
208 
Hospital 
88% consented 
57%2 <118 47.6 120 (N/R)5 
Balci et al. 2014  
Turkey, N/R 
CS 
72 
N/R 
N/R 
None <148 70.8 120 (53.1) 
d) Enzyme immunoassay 
Guerra-Shinoara et al. 2004  
Brazil, N/R 
CS 
119 
Hospital 
N/R 
N/R <132 52.9 130 (122,138)4 
Milman et al. 2006 (b)  
Denmark, 1995-96 
L 
256 
N/R 
N/R 
34%2 <150 42.6 161 (71, 284)6 
Wu et al. 2013 (b)  
Canada, N/R 
L 
220 
Hospital 
N/R 
N/R <148 23 224 (96.2) 
e) Others 
Abdelrahim et al. 2009  
Sudan, 2007-09 
CS 
55 
Hospital 
N/R 
N/R Immunofluorescence 
<111 
1.1 159.4 (66.5) 
f) Assay method not described 
Cook et al. 1971  
Latin America,  
CS 
899 
N/R 
N/R 
N/R <59 15.4 N/R 
Shields et al. 2011 (b)  
Scotland, 2008-09 
L 
77 
Hospital 
N/R 
N/R <156 60 153 
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Jacquemyn et al. 2014  
Belgium, 2011 
CS 
78 
Hospital 
N/R 
76%2 <150 13 244 (93.9) 
Table showing the key study characteristics and results from the 57 included studies classified according to the trimesters of pregnancy and 
vitamin B12 measurement assay. The lower case letters in parenthesis in the first column indicate the order of appearance in the table for studies 
which have reported results from more than one trimester. N/R: not reported 
1 L= Longitudinal (i.e. the same participants had more than one B12 measurement during pregnancy); CS=Cross-sectional 
2 Study states explicitly that the women consumed B12 supplements or multivitamins containing B12 (all such values in this column) 
3 Geometric mean (10th, 90th centile) 
4 Geometric mean (5th, 95th centile) 
5 Median (25th, 75th centile or IQR) 
6 Median (5th, 95th centile) 
7 Median (min, max) 
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Prevalence of Vitamin B12 insufficiency in pregnancy 
The overall prevalence of maternal vitamin B12 insufficiency during pregnancy from 
all the studies, across all three trimesters, was 25%. When analysing by trimester, the 
rates were 21%, 19% and 29% for the 1st, 2nd and 3rd trimesters respectively (Figure 
4.2-4.4).  
 
 
Figure 4.2 Meta-analysis of maternal B12 insufficiency in the 1st trimester of pregnancy separated 
by subgroups of geographic regions (n=12 results). The diamonds represent the pooled proportions 
for each subgroup and the overall proportion for the trimester while the solid diamonds in each 
study denote the proportion for that study (bars are 95% CI). The I2 values refer to the statistical 
heterogenity within each subgroup and the whole trimester combined. A random effects model 
using generic inverse variance showed a pooled proportion insufficiency rate of 0.21 (0.14, 0.30). 
ES: effect size, N/A: not applicable 
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Figure 4.3 Meta-analysis of maternal B12 insufficiency in the 2nd trimester of pregnancy 
separated by subgroups of geographic regions (n=21 results). The diamonds represent the pooled 
proportions for each subgroup and the overall proportion for the trimester while the solid 
diamonds in each study denote the proportion for that study (bars are 95% CI). The I2 values 
refer to the statistical heterogenity within each subgroup and the whole trimester combined. A 
random effects model using generic inverse variance showed a pooled proportion insufficiency 
rate of 0.19 (0.10, 0.30). ES: effect size, N/A: not applicable   
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Of the 1st trimester studies, there was insufficient representation from all the 
geographical regions to do a comprehensive sub-group analysis. The four studies 
from the Indian sub-continent showed a high insufficiency rate (pooled estimate 32%, 
Figure 4.2). This observation was once again seen in the 2nd trimester, with the pooled 
insufficiency rate from the Indian sub-continent rising to 64% (Figure 4.3). Apart 
from North America, South-east/East Asia and Europe, the other geographical regions 
Figure 4.4 Meta-analysis of maternal B12 insufficiency in the 3rd trimester of pregnancy 
separated by subgroups of geographic regions (n=42 results). The diamonds represent the pooled 
proportions for each subgroup and the overall proportion for the trimester while the solid 
diamonds in each study denote the proportion for that study (bars are 95% CI). The I2 values 
refer to the statistical heterogenity within each subgroup and the whole trimester combined. A 
random effects model using generic inverse variance showed a pooled proportion insufficiency 
rate of 0.29 (0.21, 0.37). ES: effect size, N/A: not applicable 
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were also poorly represented in the 2nd trimester but there were notably high 
insufficiency rates of 59%, 49%, 46% found from studies carried out in Venezuela 
(Garcia-Casal et al. 2005), Turkey (Ackurt et al. 1995) and South Korea (Park et al. 
2004). 
 
Of the studies included in the 3rd trimester, the pooled insufficiency rate of the studies 
from the Indian sub-continent was 60%. An additional striking finding was the pooled 
insufficiency rate of 65% (I2 95%) from the five studies in the Eastern Mediterranean 
region. (Figure 4.4) (Ackurt et al. 1995; Balci et al. 2014; Halicioglu et al. 2012; Koc 
et al. 2006; Schulpis et al. 2004). On the contrary, rates of <8% insufficiency were 
found in two studies done in Thailand and Sudan where the authors attributed the low 
rates of insufficiency to consumption of fish and animal/fermented products 
respectively (although details of dietary intake were not provided) (Abdelrahim et al. 
2009; Areekul et al. 1976).  
 
Mean vitamin B12 levels across the trimesters 
Eleven studies which we included in this review reported mean B12 results through 
the course of pregnancy and two studies reported median B12 results longitudinally. 
Ten of the 11 studies reporting the mean showed a consistent fall in the B12 levels 
from the 1st to 3rd (Roberts et al. 1973; Shields et al. 2011), 2nd to 3rd (Ackurt et al. 
1995; Ipciglu et al. 2007; Lowenstein et al. 1960; Pagán et al. 2002; D. J. Vanderjagt 
et al. 2007) and from the 1st to 2nd to 3rd trimesters (Murphy et al. 2007; Takimoto et 
al. 2007; Whiteside et al. 1968). The exception was Marzan et al which showed a 
marginal rise in the mean B12 levels across the pregnancy (266, 270 and 286 pmol/l 
in the 1st, 2nd and 3rd trimesters respectively) despite the participants not taking B12 or 
multivitamin supplements (Marzan et al. 1971). The 2 studies which reported median 
B12 values showed a fall of 13pmol/l and 64pmol/l between the 2nd and 3rd trimesters 
(Milman et al. 2006; C. S. Yajnik et al. 2008).  
 
Standardised Score 
A total of 32 of the 57 studies reported mean B12 values in addition to the 
insufficiency rates. Ten of them were longitudinal studies, providing results from 
more than one trimester, thus a total of 43 results were available. Additionally, 12 
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studies reported the median values which were used to estimate the mean. Two of 
these were longitudinal, yielding a total of 14 results. Combining the above two, we 
obtained 57 standardised scores (ratio of mean ÷ cut-off level). Details of these 
studies with their standardised scores and corresponding B12 insufficiency rates are 
shown in Table 4.2.  
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Table 4.2 Calculated Standardised scores and corresponding B12 insufficiency rates 
Study reference Trimester (n) Mean B12 level (pmol/l)1 
B12 cut-off 
level (pmol/l) 
% B12 
Insufficiency 
Standardised 
score 
Katre et al. 2010 2 (163) 1191 150 73 0.79 
Koc et al. 2006  3 (180) 96 118 72 0.81 
Balci et al. 2014  3 (72) 120 148 70.8 0.81 
Yajnik et al. 2008 (b)  3 (594) 1221 150 71 0.81 
Ackurt et al. 1995 (b)  3 (87) 95 111 80.9 0.85 
Yajnik et al. 2008 (a)  2 (638) 1351 150 60 0.9 
Hall et al. 2007  3 (95) 180 185 58.9 0.97 
Guerra-Shinoara et al. 2004  3 (117) 130 132 52.9 0.98 
Shields et al. 2011 (b)  3 (77) 153 156 60 0.98 
Samuel et al. 2013  1 (352) 1491 150 51.1 1 
Halicioglu et al. 2012  3 (208) 1201 118 47.6 1.02 
Milman et al. 2006 (b)  3 (256) 1611 150 42.6 1.07 
Krishnaveni et al. 2009  3 (774) 1621 150 43 1.08 
Roberts et al. 1973 (b)  3 (119) 134 118 48 1.14 
Yusufji et al. 1973 3 (998) 117 103 52 1.14 
Heppe et al. 2013  1 (2173) 1751 150 26 1.17 
Frery et al. 1992  3 (188) 175 148 27.6 1.18 
Hussein et al. 2009  3 (84) 185 150 46.4 1.24 
Ackurt et al. 1995 (a)  2 (129) 141 111 48.8 1.27 
Kosus et al. 2012  1 (228) 2001 156 12.5 1.28 
Shields et al. 2011 (a)  1 (113) 215 156 16 1.38 
Shamim et al. 2013  1 (285) 206 150 19.6 1.38 
House et al. 2000  2 (1424) 1801 130 25.3 1.38 
Roberts et al. 1973 (a)  1 (320) 165 118 35 1.4 
Osifo et al. 1976  3 (50) 208 148 40 1.41 
Vanderjagat et al. 2009 3 (98) 2081 148 12.2 1.41 
Baker et al. 1975  3 (174) 85 59 23 1.44 
Abdelrahim et al. 2009  3 (55) 159 111 1.1 1.44 
Lowenstein et al. 1960 (b)  3 (252) 221 148 19 1.49 
Murphy et al. 2007 (c)  3 (84) 224 150 0 1.49 
Milman et al. 2006 (a) 2 (406) 2251 150 15 1.5 
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Wu et al. 2013 (b)  3 (220) 224 148 23 1.51 
Giugliani et al. 1984  3 (165) 251 165 21.6 1.52 
Murphy et al. 2007 (b)  2 (90) 230 150 0 1.53 
Jiang et al. 2005  1 (1158) 237 150 28.3 1.58 
Lowenstein et al. 1960 (a)  2  (59) 235 148 15.2 1.59 
Zachau-Christiansen et al. 1962  3 (365) 177 111 17 1.59 
Jacquemyn et al. 2014  3 (78) 244 150 13 1.63 
Bjorke-Monsen et al. 2001  3 (169) 2451 150 15 1.63 
Whiteside et al. 1968 (b)  2 (50) 127 74 25 1.72 
Murphy et al. 2007 (a)  1 (88) 267 150 0 1.78 
Colman et al. 1975  3 (106) 524 295 0.9 1.78 
Takimoto et al. 2007 (b)  3 (82) 265 148 16 1.79 
Gibson et al. 2008  3 (83) 2681 150 23 1.79 
Cole et al. 1974  3 (130) 272 148 12.3 1.84 
Pagan et al. 2002 (b)  3 (285) 285 148 2.1 1.93 
Wu et al. 2013 (a)  2 (264) 287 148 10 1.94 
Ray et al. 2008  1 (2490) 249 125 8.5 1.99 
Takimoto et al. 2007 (a) 2 (77) 301 148 8 2.03 
Ho et al. 1987  3 (221) 229 110 3.6 2.08 
Knight et al. 1991 (b)  3 (75) 318 148 11.2 2.15 
Pagan et al. 2002 (a)  2 (285) 357 148 0.35 2.41 
Jacob et al. 1976  2 (182) 303 111 4.5 2.73 
Whiteside et al. 1968 (a) 1 (56) 217 74 5 2.93 
Black et al. 1994  3 (85) 228 74 15 3.08 
Marzan et al. 1971 (a) 2 (100) 270 59 1.5 4.58 
Marzan et al. 1971 (b) 3 (57) 286 59 0 4.85 
Table showing the relationship between the calculated Standardised Score (mean B12 deficiency ÷ cut-off level) and corresponding B12 
insufficiency rate (n=57 pairs of results). The studies are presented according to the standardised score for ease of comparison. The lower case 
letters in parenthesis in the first column indicate the order of appearance in the table for studies which have reported results from more than one 
trimester 
1 Mean estimated from median (all such values) (Hozo et al. 2005) 
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Linear regression was done to test the degree to which standardised score was as a 
predictor of percentage B12 insufficiency reported in each study, in a model that 
included trimester, geographical region and assay type. Two outlying results from a 
single study which gave very high standardised scores of >4.5 (due to a very low B12 
cut-off threshold of 59 pmol/l) were excluded (Marzan et al. 1971).  The model 
explained 72% of variance in the percentage insufficiency and the standardised score 
was the only significant predictor of the former (adjusted B-coefficient (95% CI) = -
136.5 (-159.7, -113.3) p<0.001) (Figure 4.5). This confirms that, after internal 
correction for the assay type and cut-off level, it was the same group of studies with 
the lower standardised scores (from specific geographical regions, namely Indian sub-
continent and Eastern Mediterranean) that also found higher prevalence rates of B12 
insufficiency, giving more weight to the results seen in the Forest plots (Figures 4.2 – 
4.4).  
 
 
Study quality assessment 
Studies were of differing quality and the detailed quality assessments are shown in 
Appendix 1.2. 23 of the 57 of the studies were of good quality with minimal bias in 
reporting, a further 28 of moderate quality and six of poor quality. When the 
breakdown of assessment criteria was looked at, most studies had a clearly defined 
Figure 4.5 Correlation between log-transformed standardised score and corresponding B12 insufficiency rate. 
Data are from 55 pairs of results (2 outlying results from a single study with standardised scores of >4.5 due to 
extremely low B12 thresholds removed). Stepwise linear regression performed with the model adjusted for 
trimester of sampling, geographical region and assay type.  
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question and outcomes but performed poorly in reporting the proportion of eligible 
participants consenting, reliability and validity of biochemical assays used and in 
accounting for confounders in analysis.  
 
4.3.2. B12 insufficiency and BW sub-review 
Study characteristics 
1900 citations were obtained from the electronic database searches and reviewing 
references of articles (Figure 4.1B). 947 records were shortlisted for title and abstract 
screening, of which 148 full-text reviews were done. A total of 23 studies met all the 
inclusion criteria after full text review and were included in the final analysis (Abbas 
et al. 1994; Abraham et al. 2013; H. Baker et al. 1977; Dwarkanath et al. 2013; 
Faintuch et al. 2009; Frery et al. 1992; Furness et al. 2013; Gomes et al. 2010; 
Guerra-Shinohara et al. 2004; Hay et al. 2010; Hogeveen et al. 2010; Krishnaveni et 
al. 2014; Lindblad et al. 2005; Ramoteme L Mamabolo et al. 2006; McGarry and 
Andrews 1972; Muthayya et al. 2006b; Navarro et al. 1984; Pagán et al. 2002; Relton 
et al. 2005; Sukla et al. 2013; Takimoto et al. 2007; Ubeda et al. 2011; C. S. Yajnik et 
al. 2005). Tables 4.3-4.5 provides the characteristics of these studies and their results. 
The studies reported the association between maternal or cord vitamin B12 levels and 
low birthweight in three different ways: a) logistic regression to analyse the odds 
ratios (OR) of having an adverse BW outcome (e.g. LBW, SGA or IUGR) with low 
B12 levels (n=5, Table 4.3); b) comparison of mean/median B12 between adverse 
BW cases and normal BW controls (n=15, Table 4.4) and c) linear regression to study 
the association between B12 and birthweight as continuous variables (n=10, Table 
4.5). Six studies reported their results in a combination of the above three methods 
and were included as appropriate (Abraham et al. 2013; Furness et al. 2013; 
Hogeveen et al. 2010; Krishnaveni et al. 2014; Muthayya et al. 2006b; Sukla et al. 
2013).  
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Table 4.3 Odds of SGA or LBW in low B12 levels 
Author, date Country Trimester1  B12 threshold Birth outcome 
threshold 
Cases 
(n) 
Controls 
(n) 
OR (95% CI) Adjustments 
Muthayya et al. 2006 
(a)  
India 1 Tertile 1 vs. tertile 3 
(median 116 vs. 
224pmol/l) 
IUGR: <10th 
centile for GA 
45 45 5.98 (1.72, 
20.74) 
Maternal age, 
education, parity, 
weight 
Dwarkanath et al. 
2013 (a)  
India 1 Tertile 1 vs. tertile 3 
(median 118 vs. 
284pmol/l) 
SGA: <10th 
centile for GA 
107 103 1.43 (1.02, 
2.17) 
Age, education, 
parity, weight, 
energy intake 
Muthayya et al. 2006 
(b) 
India 2 Tertile 1 vs. tertile 3 
(median 113  vs. 
210pmol/l) 
IUGR: <10th 
centile for GA 
50 54 9.28 (2.90, 
29.68) 
Maternal age, 
education, parity, 
weight 
Furness et al. 2013  Australia 2 N/R EFW <10th 
centile and serial 
tapering down of 
abdominal 
circumference 
21 63 1.001 (0.996, 
1.006) 
Folate, Hcy, age, 
smoking, BMI, DNA 
damage markers (e.g. 
micronuclei, 
nucleoplasmic bridges)  
Dwarkanath et al. 
2013 (b) 
India 2 Tertile 1 vs. tertile 3 
(median 108 vs. 
245pmol/l) 
SGA: <10th 
centile for GA 
96 96 1.45 (0.92, 
2.27) 
Age, education, 
parity, weight, 
energy intake 
Muthayya et al. 2006 
(c) 
India 3 Tertile 1 vs. tertile 3 
(median 111 vs. 
182pmol/l) 
IUGR: <10th 
centile for GA 
49 53 2.81 (1.01. 
7.87) 
Maternal age, 
education, parity, 
weight 
Hogeveen et al. 2010 Netherlands 3 <134pmol/l (Q1) LBW: <3075g 
(Q1) 
92 274 0.70 (0.44, 
1.11) 
GA, smoking, sex 
Sukla et al. 2013 India Cord N/R LBW: <2500g 138 196 2.41 (1.34, 4.5) N/R 
Table showing the study characteristics and results from studies that describe an association between maternal or cord B12 and birth outcomes 
by odds ratios (n=5 studies, 8 results). The studies are presented according to the trimesters of pregnancy. The lower case letters in parenthesis in 
the first column indicate the order of appearance in the table for studies which have reported results from more than one trimester 
1 Refers to trimester of maternal B12 unless specified as Cord; GA – gestational age; IUGR – intrauterine growth retardation; LBW – low birth 
weight; N/R – not reported; Q1 – quartile 1; SGA – small for gestational age 
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Table 4.4 Differences in mean/median B12 levels in normal and adverse birthweight 
Author, date Country Trimester1 Adverse BW outcome threshold Adverse BW outcome Normal birth outcome 
n Mean (SD) pmol/l n Mean (SD) pmol/l 
Muthayya et al. 2006 (a) India 1 LBW: <2500g 
NBW: >3000g 
16 156 (65) 39 173 (58) 
Ubeda et al. 2011 (a)  Spain 1 IUGR: BW <10th centile for GA 7 227.5 (132.4) 48 260.4 (124.8) 
McGarry et al. 1972  UK 2 LBW: <2500g 
NBW: >2950g 
14 120 (33) 331 136 (53) 
Muthayya et al. 2006 (b)  India 2 LBW: <2500g 
NBW: >3000g 
19 139 (33) 44 163 (46) 
Ubeda et al. 2011 (b)  Spain 2 IUGR: BW <10th centile for GA 7 194.6 (75.9) 48 209.5 (105.8) 
Furness et al. 2013  Australia 2 IUGR: EFW <10th centile and serial 
tapering down of abdominal circumference 
21 205 (87.9) 63 243 (135) 
Krishnaveni et al. 2014  India 2 LBW: <2500g 126 191 (93) 528 186 (102) 
Baker et al. 1977 (a)  USA 3 LBW: <2500g 50 95 (13) 50 78 (13) 
Navarro et al. 1984 (a)  France 3 LBW: <2500g 31 295 (90) 26 311 (58) 
Abbas et al. 1994 (a) UK 3 IUGR: abdominal circumference and EFW 
<5th centile 
20 0.1 (0.21)2 20 N/A2 
Lindblad et al. 2005 (a)  Pakistan 3 IUGR: EFW ≤ 11% 46 96 (41)3 82 108 (48)3 
Yajnik et al. 2005  India 3 SGA: <10th centile for sex and GA 30 106 (87, 128)4 50 124 (100, 150)4 
Mamabolo et al. 2006 South 
Africa 
3 Tertile 1 vs. tertile 3 66 176 (74) 75 175 (78) 
Muthayya et al. 2006 (c) India 3 LBW: <2500g 
NBW: >3000g 
19 137 (38) 42 156 (45) 
Ubeda et al. 2011 (c) Spain 3 IUGR: BW <10th centile for GA 7 139.9 (44.0) 48 161.0 (95.6) 
Abraham et al. 2013  India 3 LBW: <2500g 58 207 (94) 58 203 (87) 
Baker et al. 1977 (b)  USA Cord LBW: <2500g 50 281 (43) 50 439 (35) 
Navarro et al. 1984 (b) France Cord LBW: <2500g 32 223 (61) 26 255 (56) 
Abbas et al. 1994 (b) UK Cord IUGR: abdominal circumference and EBW 
<5th centile 
20 0.9 (0.28)2 20 N/A2 
Lindblad et al. 2005 (b)  Pakistan Cord IUGR: EFW ≤ 11% 46 190 (142)3 82 171 (81)3 
Muthayya et al. 2006 (d) India Cord LBW: <2500g 
NBW: >3000g 
20 195 (63) 47 236 (94) 
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Gomes et al. 2010 Sri Lanka Cord (preterm 
infants) 
SGA: BW <10th centile for GA and sex 96 394 (169.3) 113 409 (224.5) 
Hay et al. 2010 (a) Norway Cord 
(nulliparous) 
Quartile 1 vs. quartile 4 180 363 (341, 420)5 180 242 (221, 311)5 
Hay et al. 2010 (b) Norway Cord 
(multiparous) 
Quartile 1 vs. quartile 4 180 365 (301, 423)5 180 258 (224, 297)5 
Sukla et al. 2013 India Cord LBW: <2500g 138 142.4 (60.5) 196 157.9 (53.9) 
Table showing the characteristics and results from studies that describe mean maternal or cord B12 levels in adverse and normal birth outcome 
groups (n=15 studies, 25 results). The studies are presented according to the trimesters of pregnancy. The lower case letters in parenthesis in the 
first column indicate the order of appearance in the table for studies which have reported results from more than one trimester 
1 Refers to trimester of maternal B12 unless specified as Cord 
2 Mean difference (SEM) in SD between cases and controls 
3 Mean (SD) estimated from median (range) (Hozo et al. 2005)  
4 Geometric mean (25th, 75th centile) 
5 Geometric mean (95% CI) 
BW - birth weight; EFW – estimated fetal weight; GA – gestational age;  IUGR – intrauterine growth retardation; LBW – low birth weight; N/A 
– not applicable; SGA – small for gestational age  
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Table 4.5 Effect of B12 levels across the spectrum on birthweight  
Author, date Country Trimester1 n Unit B12 Effect size (95% CI) P 
value 
Adjustments 
Relton et al. 2005 (a) UK 1 500 1 unit log B12 (pg/ml) BW z-score 
β = 0.03 (-0.05, 0.12) 
0.41 None  
 
Takimoto et al. 2007 (a) Japan 1 51 1 pmol/l B=-1.05 0.08 Age, parity, BMI 
Pagan et al. 2002 (a) USA 2 285 1 pmol/l B=-0.2 0.52 GA, race, BMI, smoking, gender 
Takimoto et al. 2007 (b)  Japan 2 77 1 pmol/l B=-5.35 0.38 Age, parity, BMI 
Faintuch et al. 2009  Brazil 2 (Post-bariatric 
surgery) 
13 1 pg/ml r= -0.846 <0.001 None 
Frery et al. 1992 (a)  France 3 (All) 188 1 unit log B12 r=-0.05 NS Parity, ethnicity 
3 (Smokers) 25 B=-507 0.03 
Pagan et al. 2002 (b)  USA 3 285 1 pmol/l B=-0.2 0.53 GA, race, BMI, smoking, gender 
Guerra-Shinoara et al. 2004 (a)  Brazil 3 117 1 pmol/l r= -0.05 0.52 None 
Takimoto et al. 2007 (c)  Japan 3 82 1 pmol/l B=0.776 0.44 Age, parity, BMI 
Hogeveen et al. 2010  Netherlands 3 366 1 SD (69pmoll/l) B= -37 (-100, 29) NS Age, GA, parity, smoking, 
sex, folate supplement 
Abraham et al. 2013  India 3 116 1 pmol/l β=0.22 0.65 Diet, socio-economic 
status 
Krishnaveni et al. 2014  India 3 654 1 SDS unit log B12 BW SDS 
β= 1: 0.02 (-0.05,0.10) 
     2: 0.07 (-0.003,0.15) 
NS 1: Sex, gestational age 
2: 1 + BMI, GDM, SES, 
parity, religion 
Frery et al. 1992 (b)  France Cord (All) 154 1 unit log B12 r= -0.16 <0.04 Parity, ethnicity 
Cord (Smokers) 22 B= -414 0.06 
Guerra-Shinoara et al. 2004 (b)  Brazil Cord 117 1 pmol/l r= -0.02 0.80 None 
Relton et al. 2005 (b)  UK Cord 522 1 unit log B12 (pg/ml) BW z-score 
β= -0.09 (-0.17, -0.01) 
0.02 None  
 
Muthayya et al. 2006  India Cord (37-39/40) 76 1 pg/ml r= 0.28 0.01 None 
India Cord (>40/40) 36 1 pg/ml r= -0.13 0.45 None 
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Table showing the characteristics and results from studies that describe an association between maternal or cord B12 and birth outcomes by 
correlation/regression analysis (n=10 studies, 19 results). The studies are presented according to the trimesters of pregnancy. The lower case 
letters in parenthesis in the first column the order of appearance in the table for studies which have reported results from more than one trimester 
1 Refers to trimester of maternal B12 unless specified as Cord  
BMI – body mass index; BW - birthweight; GA – gestational age; GDM – gestational diabetes mellitus; N/R – not reported; SDS – standard 
deviation score; SES – socio-economic status 
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Odds of SGA or LBW in low B12 levels 
Five studies across the trimesters (Dwarkanath et al. 2013; Furness et al. 2013; Hogeveen 
et al. 2010; Muthayya et al. 2006b) and cord blood (Sukla et al. 2013) (eight results) 
reported the odds ratio (ORs) of SGA or LBW in lower B12 levels compared to higher 
levels (Table 4.3). Meta-analysis (n=1482; 598 cases, 884 controls) of all of these studies 
showed that the odds of having a SGA/LBW baby was 1.70 (95% CI 1.16, 2.50) with 
lower B12 levels (Figure 4.6).  
 
There were too few results from different countries and trimesters to provide sub-group 
analysis. Therefore, we only did the following three analyses: 1) removal of the study 
reporting only cord blood B12 levels (Sukla et al. 2013) (because B12 is actively 
transported across the placenta (Obeid et al. 2005) and is expected to higher than that of 
maternal B12); 2) combining the five results from India (from three studies) (Dwarkanath 
et al. 2013; Muthayya et al. 2006b; Sukla et al. 2013) due to the high prevalence of both 
B12 insufficiency and SGA/LBW babies (United Nations Children’s Fund and World 
Health Organization 2004); and 3) removal of the Muthayya et al study as it reported 
large effect sizes and contributed 21.5% to the pooled analysis (Muthayya et al. 2006b) . 
The ORs (95% CI) were 1.59 (1.07, 2.36), 2.42 (1.50. 3.92) and 1.23 (0.90, 1.67), 
respectively in these sub-group analyses. There were only two other results (from 
Australia and Holland), which did not show any association between B12 and BW 
(Furness et al. 2013; Hogeveen et al. 2010).  
Figure 4.6 Meta-analysis of OR’s of adverse birth weight (BW) in low maternal (or cord) B12 cases and controls 
(n=8 results). The letters in parantheses after the Study ID refer to results from different trimesters within each 
study. The black diamond represents the pooled OR while the squares in each study denote the OR for that study 
(bars are 95% CI). Pooled analysis and heterogenity analysis was done on log-transformed ORs using a random 
effects model. The pooled OR (95% CI) was 1.70 (1.16, 2.50). * B12 measured in cord blood  
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Differences in mean/median B12 levels and adverse birthweight 
Fifteen studies reported either mean or median B12 values between normal and 
LBW/SGA groups. There were eight cross-sectional and seven longitudinal studies, 
yielding a total of 25 results (Table 4.4). Two sub-group meta-analysis by maternal levels 
(n=1969; 487 cases and 1482 controls; 14 results) (Figure 4.7A) and cord blood levels 
(n=896; 382 cases and 514 controls; six results) (Figure 4.7B) were conducted. Although 
the pooled estimates showed lower maternal B12 levels in the adverse birthweight group 
(particularly in the second trimester), these were not statistically significant (Figure 
4.7A). Similarly, the pooled meta-analysis of cord blood B12 levels were not different 
between the birthweight groups (Figure 4.7B).  
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Three other studies (n=880; 430 cases and 450 controls; 5 results), from the 3rd trimester 
and cord blood showed differences in B12 levels between the normal and adverse BW 
groups in terms geometric mean (Hay et al. 2010; C. S. Yajnik et al. 2005), or mean 
difference in SD (Abbas et al. 1994) (Table 4). One showed non-significantly lower 
geometric mean B12 level in third trimester in SGA (C. S. Yajnik et al. 2005) but none of 
the other studies showed the positive association expected.  These studies were not 
included in the pooled analysis of Figures 6A and 6B because the effect sizes could not 
be converted to a mean (SD).  
A) 
B) 
Figure 4.7 Meta-analysis of difference in mean B12 between adverse and normal birth weight 
babies. A) B12 measured in maternal blood (divided in subgroups according to trimesters of 
pregnancy) (n=14 results) and B) B12 measured in cord blood (n=6 results).  
The black diamonds represent the pooled difference for each subgroup and overall while the 
squares in each study denote the mean difference for that study (bars are 95% CI). The I2 values 
refer to the statistical heterogenity within each subgroup and overall. A random effects model using 
generic inverse variance showed a pooled mean difference (95% CI) of  -9.12 (-21.25, 3.01) in 
pregnancy and -41.51 (-107.96, 24.93) in cord blood between adverse and normal birth weight 
babies.  
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Effect of B12 levels across the spectrum on birthweight 
Ten studies examined B12 and birthweight as continuous variables (Table 5). Where the 
studies performed both unadjusted linear correlations and adjusted regression coefficients 
we reported the latter (as B- or β-coefficients) but if only unadjusted correlations were 
carried out, we reported the former (as r-coefficients). One showed a significant positive 
correlation (Muthayya et al. 2006a) and 9 showed no association between B12 and birth 
weight. Of these 9, 2 showed positive but non-significant (Abraham et al. 2013; 
Krishnaveni et al. 2014), 5 negative (Faintuch et al. 2009; Frery et al. 1992; Guerra-
Shinohara et al. 2004; Hogeveen et al. 2010; Pagán et al. 2002) and 2 varying 
associations at different time points (Relton et al. 2005; Takimoto et al. 2007).  
 
Study quality assessment 
Nine of the 23 studies were of good quality with minimal bias in reporting, a further 10 of 
moderate quality and four of poor quality (Appendix 1.3). Although the studies generally 
did well in reporting an appropriate study question and describing the source population, 
more than half them did not report the number of eligible participants who consented, the 
rates of mothers/neonates lost to follow-up or do a comparison between participants with 
available and missing data.  
 
4.4. Discussion 
Prevalence of B12 insufficiency 
One of the striking findings of our systematic review was the high rates of B12 
insufficiency among certain populations such as those from India, Nepal, Turkey, Greece 
and parts of South America. The high rates in the studies from the Indian sub-continent 
can be explained by a predominant vegetarian diet (Krishnaveni et al. 2009). In 3 of the 
series from this region, only 7 -15% consumed animal products more frequently than 
every alternate day (Katre et al. 2010; C. S. Yajnik et al. 2008; Yusufji et al. 1973). Sub-
group analysis from another Indian cohort found lower B12, higher folate and Hcy levels 
amongst Hindu women compared to Muslim participants, which can be attributed to their 
increased intake of non-vegetarian foods (Krishnaveni et al. 2009). 
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However, we also found high rates of B12 insufficiency in four studies from Turkey and 
one from Greece (Ackurt et al. 1995; Balci et al. 2014; Halicioglu et al. 2012; Koc et al. 
2006; Schulpis et al. 2004). The “Mediterranean diet” contains plenty of fruits, vegetables 
and pulses compared to meat (Willett et al. 1995). It has been shown to confer health 
benefits such as increased life expectancy and lower cardiac disease in adults and 
increased placental and offspring birthweight when consumed by pregnant women 
(Timmermans et al. 2012; Willett et al. 1995). However one Turkish series found that 
stricter adherence to the Mediterranean diet among the sub-group of pregnant women 
exacerbated B12 deficiency (mean B12 in women consuming animal products weekly or 
less was 123pmol/l vs. 178 pmol/l if consumed every 2-3 days) (Balci et al. 2014). In 
addition, obesity rates are high in these regions, which are shown to be associated with 
low B12 (Adaikalakoteswari et al. 2015b; Delibasi et al. 2007; B. A. Knight et al. 2015; 
Krishnaveni et al. 2009; Pinhas-Hamiel et al. 2006). The link between obesity, gestational 
diabetes and low B12 levels has not been fully explored but since the former two 
conditions are independently associated with fetal macrosomia, they may partly 
compensate for or mask the associations between B12 and LBW (Gaudet et al. 2014; He 
et al. 2015).  
 
Additionally, rates of metabolic syndrome in non-pregnant adults from Turkey are in the 
order of 30 to 45%, particularly in women (Gundogan et al. 2013; Kozan et al. 2007). It is 
possible that one of the reasons for this could be due to repercussions of B12 
insufficiency during child-bearing years as these women may have preference for 
carbohydrate-rich foods over animal products (thereby exacerbating micronutrient 
insufficiency levels), or to the elevation of homocysteine (Yaman et al. 2009). None of 
the studies from this region reported the early pregnancy BMI of their participants, but 2 
series reported the mean 1st and 3rd trimester weights of their participants, which was 
66kg (Kosus et al. 2012) and 77kg (Schulpis et al. 2004) respectively, considerably 
higher than the 47 - 49 kg women from the Indian cohorts (Katre et al. 2010; Rao et al. 
2001; Samuel et al. 2013). This suggests that the aetiology of B12 insufficiency may be 
different in these 2 groups of women, which needs to be explored further.  
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Plausible reasons for the observed fall in B12 during pregnancy are hemodilution, active 
transport to the fetus and changes in binding proteins (Bruinse and van den Berg 1995; 
Koebnick et al. 2002). Holotranscobalamin (holoTC), the functional form of B12, is 
positively correlated with total cobalamin and the two biomarkers negatively correlate 
with methylmalonic acid (a marker of tissue level B12 insufficiency) during pregnancy 
(Murphy et al. 2007). While serum cobalamin decreases across the trimesters, holoTC has 
been shown to decrease in some studies and remain unchanged in others (Greibe et al. 
2011; Murphy et al. 2007). Therefore, the fall in cobalamin may be due to a reduction in 
the fraction bound to haptocorrin (holo-haptocorrin (holoHC)) (Greibe et al. 2011). The 
tissue-level effects and clinical implications of a fall in holoHC during pregnancy are 
unknown and warrant further studies. There is an argument for the more pervasive use of 
holoTC measuring assays during pregnancy, which has similar sensitivity and specificity 
as total cobalamin measurement and may be superior in identifying early and “true” 
cobalamin deficiency (Hvas and Nexo 2005; Nexo et al. 2002).  
 
B12 insufficiency and birth weight (BW) 
Our review showed that the odds of LBW is 1.7 when B12 insufficiency was present in 
maternal or cord blood (Figure 4.6). However, our results cannot confirm the association 
between low B12 and LBW across the world as any positive observations may be isolated 
to Indian populations. Whilst all the studies adjusted for most of the known confounding 
factors, the overall effect was driven by one study in India (Muthayya et al. 2006b). It is 
important to note that only 27% of the women recruited into the study had B12 levels 
measured although the authors reported that they did not differ from the study population 
in their baseline characteristics. The three results from this study contributed a total of 
21.5% to the pooled results (Figure 4.6) and when they were removed from the analysis 
the OR decreased from 1.70 to 1.23 (95% CI 0.90, 1.67). Given the potential importance 
of the problem, further studies are needed to replicate or refute the magnitude of 
association found in this study.  
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With regards to the two studies from Australia and Holland with negative results, it is 
notable that when compared to the Indian studies, the maternal B12 concentration in the 
Australian study was considerably high (median 239pmol/l) while in the Dutch study a 
higher threshold was used to define LBW (<3075g). Additionally, the population 
characteristics differed (e.g. mean BMI of women in the Australian study  was 28.5 kg/m2 
compared to 22.0 kg/m2 in the Indian studies), which may have influenced their risk of 
having LBW/SGA babies (Dwarkanath et al. 2013; Furness et al. 2013; Muthayya et al. 
2006b). 
 
In the studies reporting mean levels of B12, a non-significant trend of lower B12 levels 
was observed in women who delivered LBW or SGA babies with a larger effect size 
found in the 1st and 2nd compared to the 3rd trimester. Since the heterogenity between the 
studies was high and there were differences in the populations and B12 assays, it was not 
possible to make meaningful conclusions about a B12 ‘threshold’ which would be 
associated with lower fetal BW. In the 2 studies which reported results from more than 
one trimester, the difference in maternal B12 between normal and low BW babies was 
greater in the 1st or 2nd trimester compared to the 3rd  (-33 vs. -21 and -24 vs. -19pmol/l 
respectively) suggesting that lower B12 earlier in pregnancy may be more detrimental for 
offspring weight (Muthayya et al. 2006b; Ubeda et al. 2011). 
 
The link between exposure to low B12 conditions during pregnancy, BW and non-
communicable diseases in the offspring can be explained by the developmental origins of 
health and disease (DOHaD) hypothesis, which suggests that the fetus is programmed to 
adapt to its in-utero environment and if this is altered, can result in disease (C. S. Yajnik 
and Deshmukh 2012). The epigenetic modifications associated with low B12 levels 
influence placental development from the early embryonic stage, so it is possible that 
B12 has an effect on fetal growth and BW through this mechanism (Koukoura et al. 
2012; Waterland and Jirtle 2004). B12 also plays an important role in myelination of fetal 
neurons, which maximally occurs from mid-gestation until two years of age (M. M. 
Black 2008). Hence the critical window for B12 adequacy continues throughout 
pregnancy and lactation. 
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Impact of maternal B12 insufficiency on neonatal and childhood health 
Aside from BW, B12 insufficiency during pregnancy has been linked to other adverse 
neonatal outcomes such as preterm delivery and pre-eclampsia, which may further 
compound the problem of sub-optimal BW and poor neonatal outcomes in these babies 
(Makedos et al. 2007; Ronnenberg et al. 2002). Additionally, cobalamin deficiency in 
infants can lead to neurological disturbances such as developmental regression and poor 
intellectual performance in the long-term (Graham et al. 1992).  
 
Although low birthweight is itself a marker for increased risk of cardiometabolic disease 
in adulthood, authors have also tried to prove an association between exposure to low 
B12 levels in utero and associated adverse outcomes in childhood or adolescence. The 
follow-up of the Pune study found that low maternal B12 at 18 weeks gestation (more 
specifically the combination of low B12 and high folate) was related to insulin resistance 
in 6 year old offspring and a similar positive association between 1st trimester B12 
deficiency and HOMA-IR in children aged 6-8 years was found in a study from Nepal 
(Stewart et al. 2011; C. S. Yajnik et al. 2008). However, another cohort study from India 
was not able to replicate these findings when the children were examined up to 13.5 years 
(although maternal Hcy was positively associated with offspring glucose) (Krishnaveni et 
al. 2014). What is notable is that in the former 2 studies, the B12 was measured in before 
20 weeks gestation compared to 30 weeks gestation in the latter study so it is plausible 
that fetal exposure to sub-optimal B12 early in pregnancy may have the most deleterious 
effect on future metabolic health, especially if coupled with high maternal folate towards 
to the end of pregnancy (Krishnaveni et al. 2014; C. S. Yajnik et al. 2008). In keeping 
with this theory are the results of our meta-analysis, which found that the strongest 
association between low B12 levels and LBW was found in the 2nd trimester. 
 
Changes in biomarkers related to B12 during pregnancy 
Previous studies have shown an independent inverse relationship between maternal 
homocysteine levels and LBW (OR 1.25, B-coefficient=-31g per 1 SD increase in Hcy) 
and hyperhomocysteinaemia has been causally linked to LBW (Hogeveen et al. 2012; C. 
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S. Yajnik et al. 2014). In our Prevalence sub-review, 14 of the 57 studies reported Hcy 
levels (Barbosa et al. 2008; Bjorke Monsen et al. 2001; Gibson et al. 2008; Guerra-
Shinohara et al. 2004; Hall et al. 2007; Katre et al. 2010; Milman et al. 2006; Pagán et al. 
2002; Park et al. 2004; Samuel et al. 2013; Takimoto et al. 2007; D. Vanderjagt et al. 
2009; Wu et al. 2013; C. S. Yajnik et al. 2008). While a detailed discussion of the 
associations between B12 and Hcy is beyond the scope of this review, it is notable that 
among the studies with high B12 insufficiency rates (>40%), the average Hcy was >6 
umol/l and in one study, up to 40% of the women had Hcy >10 umol/l (Hall et al. 2007; 
Park et al. 2004; Samuel et al. 2013; C. S. Yajnik et al. 2008). It is therefore possible that 
the association of low B12 status and LBW may be, at least in part, mediated through 
hyperhomocysteinaemia during pregnancy.  
 
Since serum homocysteine (Hcy) is elevated in both B12 and folate deficiency, it has a 
lower specificity in the presence of B12 deficiency while serum methylmalonic acid 
(MMA) is more specific to detect B12 deficiency specifically (D. Vanderjagt et al. 2009). 
10 studies in our review reported MMA levels (Barbosa et al. 2008; Bjorke Monsen et al. 
2001; Gibson et al. 2008; Guerra-Shinohara et al. 2004; Hall et al. 2007; Milman et al. 
2006; Samuel et al. 2013; D. Vanderjagt et al. 2009; Wu et al. 2013; C. S. Yajnik et al. 
2008). One study that did detailed analysis on the biochemical consequences of 
cobalamin insufficiency found that maternal B12 was the strongest predictor of low B12 
(OR 7.5, p<0.001), high Hcy (OR 11.8, p<0.001) and high MMA (OR 5.2, p<0.001) in 
newborns (Bjorke Monsen et al. 2001). A robust statistical method to determine at which 
point on the range of B12 concentrations tissue level deficiency would develops is by 
doing receptor operator curve analysis. A study which did this in pregnancy (also 
included in our review) showed that a combination of elevated Hcy and SAM:SAH ratio 
had the highest sensitivity and specificity to detect B12 deficiency and the corresponding 
cut-off level of B12 was 132 pmol/l (Guerra-Shinohara et al. 2004). 
 
In the absence of folate deficiency, B12 deficiency is the strongest driver of high Hcy 
levels (Selhub et al. 2007b). In 12 studies with high rates of B12 insufficiency, folate 
deficiency was less than 10% (Balci et al. 2014; A. K. Black et al. 1994; Gibson et al. 
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2008; Giugliani et al. 1984; Hall et al. 2007; House et al. 2000; Katre et al. 2010; Koc et 
al. 2006; Krishnaveni et al. 2009; Park et al. 2004; Schulpis et al. 2004; C. S. Yajnik et al. 
2008). This observation was possibly due to adequate dietary intake and antenatal 
consumption of folic acid (Balci et al. 2014; Hall et al. 2007; Katre et al. 2010; Park et al. 
2004; Schulpis et al. 2004; C. S. Yajnik et al. 2008). This imbalance between B12 and 
folate is associated with lower neonatal BW and anthropometry as well as insulin 
resistance in offspring (Gadgil et al. 2014; C. S. Yajnik et al. 2008). Therefore it is 
essential to address maternal B12 status in addition to folate during pregnancy. 
 
A meta-analysis of multiple micronutrient supplementation trials (typically containing 
one recommended daily allowance of B12) done in 12 low-income countries showed that 
supplementation was associated with modest increase in BW (effect size +22g. p=0.002) 
and reduced LBW and SGA (Fall et al. 2009). While this may not be due to optimising 
levels of B12 per se, it suggests that micronutrients in general are likely to contribute to 
increasing BW. Folic acid supplementation has been associated with higher BW, 
supporting the above explanation (Christian et al. 2003; Hodgetts et al. 2015). 
 
The strengths of our study are that this is the first review, to our knowledge, to consider 
the B12 status of pregnant women on a global level and link this to BW. We were able to 
demonstrate patterns in B12 insufficiency rates and associations with BW in populations 
who broadly share dietary habits and inherent risk although finer differences may exist. 
One key limitation of our report is the vast heterogenity between the studies in terms of 
B12 measurement assays and cut-off levels. This was partly addressed by devising the 
‘standardised score’ which allowed comparisons to be made between the studies, after 
controlling for geographical region, trimester and assay type. Another limitation is that 
despite the large number of studies, the numbers were small in sub-groups (such as 
individual trimesters), highlighting the need for adequately powered longitudinal, cohort 
studies with LBW or SGA as outcomes. 
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4.5. Conclusion 
Our systematic review and meta-analysis in pregnant women showed that rates of vitamin 
B12 insufficiency are high in certain populations (e.g. the Indian sub-continent and 
Eastern Mediterranean), including in non-vegetarian ones. The possible association 
between B12 insufficiency and LBW/SGA warrants further investigation through larger 
cohort studies and randomised controlled trials.  Even if the effect size of maternal B12 
on BW is modest, it has potential to influence the health of future generations if a link is 
proven. The results of further studies will dictate practice with regards to B12 
supplementation in pre-conception and pregnancy but until then, it would be sensible at 
least to measure B12 levels when pregnant women first present to antenatal facilities 
across the world. 
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Vitamin B12 status among pregnant women in the UK 
and its association with obesity and gestational diabetes 
  
Chapter 5 
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5.1. Introduction 
The burden of maternal obesity (defined as body mass index (BMI) greater than 30 
kg/m2) is rapidly increasing, affecting nearly 20% of pregnant women in the UK 
(Heslehurst et al. 2010). High BMI is associated with adverse pregnancy outcomes 
including recurrent miscarriages and maternal deaths (Lewis 2007). In parallel, the 
incidence of gestational diabetes (GDM) has also risen affecting 5-18 % of all 
pregnancies depending on the diagnostic criteria applied (Buckley et al. 2012; Cundy et 
al. 2014). 
 
In Chapter 3, it was described how the mitochondrial conversion of methylmalonyl-CoA 
to succinyl-CoA requires B12 as a coenzyme and in its absence, accumulation of the 
former compound inhibits fatty acid oxidation, thereby promoting lipogenesis 
(Adaikalakoteswari et al. 2014; Brindle et al. 1985). Therefore it can be postulated that 
low B12, at a cellular level, may be linked to adipocyte dysfunction and obesity-related 
complications by modulating lipid metabolism, cellular inflammation (Kumar et al. 2013) 
and causing hypomethylation of cholesterol biosynthesis pathways (Adaikalakoteswari et 
al. 2015b). 
 
Low B12 during pregnancy has implications for materno-fetal health including maternal 
adiposity, maternal and offspring insulin resistance (Krishnaveni et al. 2009; Stewart et 
al. 2011; C. S. Yajnik et al. 2008) and adverse lipid profile in neonates 
(Adaikalakoteswari et al. 2015a; Adaikalakoteswari et al. 2015b). The first two 
observations were replicated in a cohort of women without gestational diabetes mellitus 
(GDM) from South West England (B. A. Knight et al. 2015) but there are no data 
available on the role of B12 in GDM in the UK.  
 
Aside from the possible association with low birthweight (LBW) seen in Chapter 4, 
suboptimal B12 levels in pregnancy has also been shown to be independently associated 
with adverse lipid profile in neonates (Adaikalakoteswari et al. 2015a) and higher insulin 
resistance in children (C. S. Yajnik et al. 2008). LBW or small for gestational age (SGA) 
are outcomes of particular interest as they are well-established surrogate markers for 
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metabolic disorders such as obesity, type 2 diabetes and metabolic syndrome in later life 
in many populations (Hales and Barker 2001; Whincup et al. 2008; C.S. Yajnik et al. 
1995). At the other end of the spectrum, maternal obesity and insulin resistance are well-
known to be associated with higher fetal birthweight (Gaudet et al. 2014; He et al. 2015). 
Since B12 may be inversely associated with maternal BMI (B. A. Knight et al. 2015; 
Krishnaveni et al. 2009), it is possible that B12 is an independent mediator or a 
confounder for high birthweight. 
 
The hypothesis of this chapter is that B12 insufficiency is common among pregnant 
women in a UK population and it may be associated with GDM and other surrogate 
materno-fetal factors.  
 
The primary aim of our study is to investigate B12 and folate status of pregnant women 
in the UK and their relationship with obesity and GDM and secondarily to assess their 
relationship with fetal birthweight.  
 
5.2. Methods 
5.2.1. Study design and justification 
A retrospective case-control study of pregnant women attending the antenatal clinic in a 
district general hospital in the West Midlands, UK, between 2010 and 2013 was 
conducted.  The justification for selecting this method of study is because there is no data 
available, in a UK population, about B12 status among pregnant women at high risk of, 
or diagnosed with GDM and associated effects. Therefore, a pilot study such as this 
would be informative prior to conducting any prospective studies investigating the same. 
 
5.2.2. Participant selection 
Using the hospital information database which had routine materno-fetal records of all 
deliveries during this period, we identified women who had a diagnosis of GDM and 
those who did not (labelled as no-GDM) and had their B12 levels measured in the 2nd or 
3rd trimesters of the pregnancy. The no-GDM group consisted predominantly of women 
attending the medical obstetrics clinic for varying medical conditions. B12 and folate 
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levels were measured routinely for screening for anaemia by the medical obstetric lead 
(VP), in addition to haemoglobin and ferritin. The physician (PS) running the antenatal-
diabetes clinic measured these micronutrient levels for similar reasons in their first visit 
after the diagnosis of GDM. The following women were excluded from our analysis: pre-
gestational diabetes (Type 1 and 2), multiple pregnancies and those on vitamin B12 
supplements at the time of blood sampling.  
 
5.2.3. Data collection and laboratory analysis 
Clinical information about the women including medical and pregnancy history, smoking 
status and BMI at booking was recorded from the database. Fetal outcomes such as 
birthweight, sex and gestation were obtained for the secondary outcome analysis. 
Analysis of glucose was done by a hexokinase enzymatic method in the hospital 
laboratory and serum B12 and folate by an electrochemiluminescent immunoassay using 
a Roche Cobas immunoassay analyser (Roche Diagnostics UK, Burgess Hill, UK).   
 
5.2.4. Definitions of outcomes 
A selective screening approach was used to screen high-risk women for GDM according 
to the NICE guidelines (i.e. BMI >30kg/m2, previous GDM, previous macrosomia, first 
degree relative with diabetes, ethnic minority race) (National Institute for Health and 
Care Excellence 2008). This consisted of a 2-hour 75g glucose tolerance test between 26-
28 weeks of gestation. The modified WHO 1999 criteria was used to diagnose GDM 
(fasting glucose ≥6.1mmol/l or 2-hour glucose ≥7.8mmol/l) during the study period. The 
reference range for serum B12 was 150 - 489 pmol/l and serum folate 7.0 – 42.4 nmol/l 
respectively. Insufficiency of the two micronutrients were defined as <150pmol/l and <7 
nmol/l respectively (B. A. Knight et al. 2015; Krishnaveni et al. 2009). Birthweight 
centiles and z-scores were calculated using gestational age at delivery and sex-specific 
reference standards published by the Intergrowth calculator 21st Project (Villar et al. 
2014). Macrosomia was defined as birthweight >4000g, large for gestational age (LGA) 
as > 90th centile for sex and gestational age, LBW as <2500g and small for gestational 
age (SGA) as <10th centile for sex and gestational age.  
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5.2.5. Statistical analysis 
Based on pilot data, the required sample size in each group to demonstrate a 15% 
difference in mean B12 with 90% power and at 5% significance, was calculated to be 
144. Statistical analysis was performed using SPSS version 22.0 (IBM Corp Released 
2013). Since BMI, serum B12 and folate were not normally distributed, they were log-
transformed for statistical purposes. For comparison of GDM and no-GDM mothers, the 
Student’s t-test was used for continuous variables (e.g. B12, folate and BMI) and the chi-
square test for categorical variables. Stepwise multiple linear regression was performed 
with B12 and folate as the dependent variables with the predictors entered or removed 
from the model according to the following criteria: Probability-of-F-to-enter ≤0.050, 
Probability-of-F-to-remove ≥0.100. Logistic regression was done to determine the odds 
of maternal obesity and GDM according to B12/folate insufficiency status and the risk of 
macrosomia, LGA, LBW and SGA according to quartiles of B12/folate. The regression 
models included the following co-variates: age, parity, ethnic origin, smoking, gestation 
of bloods, BMI, B12 and folate (where appropriate). For macrosomia and LBW, sex and 
gestational age were additionally added to the models. 
 
5.2.6. Ethics approval 
Our institution has obtained ethics approval to collect B12 and folate data from pregnant 
women in an anonymised form (NHS ethics committee reference number 12/LO/0239). 
 
5.3. Results 
5.3.1. Overall study parameters 
Out of approximately 8400 deliveries in the hospital between 2010-13 which were 
screened, 344 women (143 GDM, 201 no-GDM) who met the inclusion criteria and had 
B12 levels measured in the 3rd trimester of pregnancy were included. The clinical 
characteristics of the whole cohort and by GDM status are provided in Table 5.1. Of the 
201 no-GDM women, 45% had OGTT as per NICE selective screening criteria (National 
Institute for Health and Care Excellence 2008) and the characteristics of all the no-GDM 
women are summarised in Appendix 2.1. 
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Table 5.1 Maternal characteristics according to GDM status. 
Variables Total GDM No GDM 
Number (%) 344 (100) 143 (41.6) 201 (58.4) 
Age (yrs) 30.3 ± 5.88 31.4 + 5.8 29.6 ± 5.9 **a 
BMI (kg/m2) § 28.8 ± 7.46 31.7 ± 7.0 26.7 ± 7.1 *** 
Obesity (BMI >30 kg/m2) (%) 38.0 60.6 22.0 *** 
Current smokers (%)  18.7 15.2 19.9 
Parity 1.1 ± 1.18 1.2 ± 1.18 1.0 ± 1.18 
Ethnicity (%)       
European 86.9 86.0 87.6 
South Asian 9.3 11.2 8.0 
Afro-Caribbean 1.2 0.7 1.5 
Other 1.2 1.4 1.0 
Gestation of GTT (weeks)b 26.6 ± 3.95 26.4 ± 4.40 26.8 ± 3.10 
Mean fasting glucose (mmol/l) § 4.9 ± 1.01 5.2 ± 1.15 4.4 ± 0.39 *** 
Mean 2hr glucose (mmol/l) § 7.5 ± 1.94 8.7 ± 1.26 5.6 ± 1.13 *** 
Gestation of B12 bloods (weeks) 26.9 ± 5.3 28.0 ± 4.3 26.2 + 5.7 ** 
Vitamin B12 (pmol/l) § 
 
187.5 (146.9, 235.4) 169.0 (140.2, 217.7) 195.6 (157.9, 244.6)  ** 
Vitamin B12 deficiency (<150pmol/l), n (%) 90 (26.2) 46 (32.2) 44 (21.9) * 
Serum folate (nmol/L) § 21.3 (14.0, 34.4) 21.5 (13.5, 34.5) 20.8 (14.5, 34.4) 
Serum folate deficiency (<7nmol/l), n (%) 5 (1.5) 3 (2.1) 2 (1.0) 
Folic acid supplements taken (%) 91.4 90.9 91.5 
Continuous variables are mean ± SD (or median (IQR)), categorical variables are percentages; a: p-value as compared to GDM group, *p<0.05, **p<0.01, 
***p<0.001; b: GTT results available in 90 / 201 (44.8%) of no-GDM women; §: Log-transformed for statistical comparison, GDM: gestational diabetes 
mellitus, BMI: body mass index, GTT: glucose tolerance test 
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For the whole cohort, the mean gestation of serum vitamin B12 and folate measurements 
was at 26.9 weeks and GTT was at 26.6 weeks. B12 levels were lower in women with 
GDM (169.0 vs. 195.6 pmol/l, p<0.001) and a significantly higher proportion of women 
with GDM had B12 insufficiency compared to no-GDM (Table 5.1). Folate deficiency 
was rare and 91% of the whole cohort was taking folate supplements. Serum folate levels 
were not different in the two groups.  
 
5.3.2. Vitamin B12, folate status and maternal BMI and GDM 
Women with B12 insufficiency had higher 1st trimester BMI than those without 
(30.9±7.56 vs. 28.0±7.30 kg/m2, p<0.05). After adjusting for age, parity, ethnicity, 
smoking status and gestation of blood tests, BMI was a significant negative predictor of 
B12 (β coefficient -0.21; 95% CI -0.47, -0.13; p=0.001) whilst serum folate showed a 
positive association with B12 (Table 5.2, Figure 5.1). BMI was also negatively associated 
with serum folate after adjustment although the strength of association was weaker (β 
coefficient -0.12; 95% CI 0.00, 0.33; p=0.05). Third trimester vitamin B12 insufficiency 
was additionally associated with a 2.4 times higher odds of first trimester obesity (Table 
5.3). 
Table 5.2. Predictors of vitamin B12 and folate 
Variables Serum B12§ Serum folate § 
β-coefficient p-value β-coefficient p-value 
Age - NS 0.32 <0.001 
Parity - NS -0.24 <0.001 
BMI § -0.21 0.001 -0.12 0.05 
Ethnicity - NS - NS 
Smoking - NS - NS 
Gestation of B12/folate 
bloods - NS -0.28 <0.001 
Serum B12 §     0.12 0.05 
Serum folate § 0.23 <0.001     
Folic acid supplements - NS - NS 
§Log-transformed for statistical calculations; NS: non-significant 
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Figure 5.1. Scatterplot of correlation between BMI and serum B12. §Log-transformed for 
statistical comparisons; Regression model included age, parity, ethnicity, smoking, gestation of 
bloods, folic acid supplements and serum folate 
 
B12 deficient women were at 2.59-times higher odds of having a diagnosis of GDM after 
adjusting for age, parity, ethnic origin, smoking, gestation of bloods and serum folate 
(Table 5.3). The effect size was weaker when maternal BMI was added into the model 
(aOR 2.05, p=0.04). Folate deficiency was not significantly associated with risk of GDM. 
There was also no association seen between folate thresholds and obesity. 
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Table 5.3. Relationship of maternal B12 and folate with obesity and gestational 
diabetes 
  n (%) Obesity, n(%) GDM, n(%) 
Vitamin B12 deficiency    
Yes 90 44 (49.4) 46 (51.1) 
No 254 86 (34.0) 97 (38.2) 
Model 1 OR (95% CI)a  2.40 (1.31, 4.40) 2.59 (1.35, 4.98) 
adjusted p  0.004 0.004 
Model 2 OR (95% CI)b  N/A 2.05 (1.03, 4.10) 
adjusted p  N/A 0.042 
Folate deficiency     
Yes 5 4 (80.0) 3 (60.0) 
No 332 125 (37.9) 139 (41.9) 
Model 1 OR (95% CI)a  6.29 (0.48, 82.79) 1.93 (0.17, 22.23) 
adjusted p  NS NS 
Model 2 OR (95% CI)b  N/A 0.89 (0.07, 11.38) 
adjusted p   N/A NS 
Table showing the proportions and odds ratio of obesity and development of GDM according to 
thresholds of B12 and folate (reference categories are 'No B12 / folate deficiency'); a: Model 1 
adjusted for age, parity, ethnic origin, smoking, gestation of bloods and serum folate (or B12, 
respectively); b: as for Model 1 plus gestational BMI; N/A: not applicable; NS: non-significant. 
 
5.3.3. Vitamin B12 and folate and birth outcomes 
Birth outcome data were available in 335 women (97% of total cohort) and one baby born 
at less than 32 weeks gestation was excluded from this analysis. 54.5% of the babies were 
male and mean birthweight was 3353g. GDM women delivered 10 days earlier than no-
GDM women and their mean offspring birthweight was 180g lower (3250 vs. 3428g, 
p<0.01) (Table 5.4). Due to the likely confounding effects of treatment in GDM women, 
the relationship between maternal B12 and folate and birth outcomes were analysed only 
in no-GDM women (Table 5.5). Women in the lowest quartile of B12 had higher rates of 
macrosomic babies compared to the highest quartile (22.9% vs. 8.0%). After adjustment 
for age, parity, ethnicity, smoking, serum folate, gestation of B12 bloods and newborn 
sex and gestational age, the relative risk (RR) of fetal macrosomia was higher in women 
in the lowest quartile (RR 5.26, 95% CI 1.26, 21.91, p=0.02). The significance was 
attenuated when gestational BMI was added to the model. A similar trend for the risk of 
LGA was observed although the result did not reach statistical significance. There was no 
association between B12 thresholds and outcomes of LBW or SGA. The impact of serum 
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folate on fetal macrosomia showed the reverse pattern for all these outcome measures. 
Women in the highest quartile of folate had significantly higher risk of fetal macrosomia 
compared to those in the lowest quartile (RR 4.99, 95% CI 1.15, 21.62, p=0.03), which 
remained significant after adjusting for maternal BMI (RR 6.60, 95% CI 1.42, 30.71, 
p=0.02).   
 
Table 5.4 Birth outcomes of offspring according to maternal GDM status 
Variables Total GDM No GDM 
Number (%) 334 (100) 141 (42.2) 193 (57.8) 
Mean fasting glucose 
(mmol/l) § 4.9 ± 1.01 5.2 ± 1.15 4.4 ± 0.39 ***a 
Mean 2hr glucose (mmol/l) § 7.5 ± 1.94 8.7 ± 1.26 5.6 ± 1.13 *** 
Birthweight (g) 3353 ± 528 3250 ± 411 3428 ± 588** 
Sex, n (%) male 182 (54.5) 76 (53.9) 106 (54.9) 
Gestation at birth (days) 274 ± 10.7 268 ± 6.4 278 ± 11.3 *** 
Macrosomia, n (%) 42 (12.6) 8 (5.7) 34 (17.6)** 
LGA, n (%) 68 (20.4) 29 (20.6) 39 (20.2) 
Low birthweight, n (%) 14 (4.2) 5 (3.5) 9 (4.7) 
SGA, n (%) 19 (5.7) 5 (3.5) 14 (7.3) 
Continuous variables are mean ± SD (or median (IQR)), categorical 
variables are percentages. §: log-transformed for statistical comparison 
a: p-value as compared to GDM group, *p<0.05, **p<0.01, ***p<0.001 
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Table 5.5 Relationship between maternal B12 on birth outcome measures in no-GDM women. 
 
 n 
Range of values  
(pmol/l) 
Macrosomia, n 
(%) LGA, n (%) LBW, n (%) SGA, n (%) 
Vitamin B12 (quartiles)             
1 48 71.6, 157.2 11 (22.9) 12 (25.0) 1 (2.1) 4 (8.3) 
2 48 158.7, 195.6 10 (20.8) 12 (25.0) 2 (4.2) 2 (4.2) 
3 47 196.3, 244.3 9 (19.1) 10 (21.3) 3 (6.4) 3 (6.4) 
4 50 245.0, 512.2 4 (8.0) 5 (10.0) 3 (6.0) 5 (10.0) 
Relative risk (95% CI)a     5.26 (1.26, 21.91) 3.18 (0.96, 10.56) 0.10 (0.002, 5.75) 1.35 (0.28, 6.47) 
pb     0.02 0.06 0.27 0.71 
pc     0.05 0.13 0.37 0.52 
              
Folate (quartiles)             
1 44 4.5, 14.3 5 (11.4) 7 (15.9) 4 (9.1) 4 (9.1) 
2 47 14.5, 20.6 7 (14.9) 9 (19.1) 1 (2.1) 2 (4.3) 
3 48 20.8, 34.2 11 (22.9) 10 (20.8) 1 (2.1) 3 (6.3) 
4 48 34.4, 45.3 10 (20.8) 12 (25.0) 3 (6.3) 5 (10.4) 
Relative risk (95% CI)a     4.99 (1.15, 21.62) 2.32 (0.74, 7.34) 0.21 (0.01, 9.64) 1.52 (0.26, 8.93) 
pb   0.03 0.15 0.42 0.64 
pc     0.02 0.06 0.41 0.90 
a: Relative risk of birthweight outcome in quartile 1 vs. quartile 4 of B12 and quartile 4 vs. quartile 1 of folate; b: adjusted for age, parity, ethnic origin, smoking, gestation of 
bloods and serum folate (or B12, respectively), plus sex and gestational age for macrosomia and LBW; c: as for Model b plus gestational BMI
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5.4. Discussion 
Our study, although retrospective in nature, showed three key findings. Firstly, it is 
the first to show that low B12 status in pregnancy is associated with higher risk of 
GDM in a UK population. Secondly, higher first trimester BMI was an independent 
predictor of later B12 insufficiency. Thirdly, low B12 levels were associated with 
macrosomia in the subgroup of no-GDM women, which seems to be partly mediated 
by maternal BMI. 
 
The only other study that examined the link between B12 and GDM by Krishnaveni 
et al was in an Indian cohort (Krishnaveni et al. 2009). The magnitude of association 
found in that study was similar to ours but the significance was lost after adjusting for 
maternal BMI. In our study, although the effect size was reduced when adjusted for 
BMI (aOR 2.59 vs. 2.05; Table 3), the significance persisted suggesting a potential 
independent effect of B12. Higher numbers of women with GDM in our cohort and a 
‘case-control’ design might explain the larger effect size. The recent finding by 
Knight et al, albeit in no-GDM women, also supports the inverse link between B12 
levels and insulin resistance in pregnant White Caucasian women (B. A. Knight et al. 
2015). Indeed, higher insulin resistance in the context of low B12 has been shown by 
other authors in obese adolescents(M. Ho et al. 2014), non-pregnant adults (Baltaci et 
al. 2013; Kaya et al. 2009) as well as in women with polycystic ovarian syndrome 
(Kaya et al. 2009). Prospective longitudinal studies are needed to investigate whether 
the presence of low B12 status in early pregnancy independently increases the risk of 
incident GDM. 
 
We found no relationship between folate levels and risk of obesity or GDM but in the 
study by Krishanveni et al, the incidence of GDM increased with increasing folate 
concentrations in the subgroup of women with B12 deficiency (5.4%, 10.5% and 
10.9% from lowest to highest tertile respectively, p for trend = 0.04).  
 
The aetiology of the inverse relationship between B12 and BMI found in our study is 
an intriguing one. While confounding factors such as dietary habits, socioeconomic 
status and hemodilution may be present, other studies that have corrected for these 
still show an independent link between B12 and BMI (B. A. Knight et al. 2015; 
Krishnaveni et al. 2009). Interestingly, frying and roasting of meat products reduces 
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the bioavailability of B12 by 20-40% (United States Department of Agriculture 
2007), so higher consumption of processed foods may increase the risk of both B12 
insufficiency and metabolic diseases. Additionally, B12 has been shown to be 
negatively associated with other markers of obesity such as triglycerides 
(Adaikalakoteswari et al. 2014), blood pressure (Karatela and Sainani 2009) and the 
metabolic syndrome (Guven et al. 2005), which lends support to a possible 
pathological association between them. In one trial, supplementation of B12 and 
folate in adults with metabolic syndrome improved insulin resistance by ameliorating 
endothelial dysfunction, providing further insight into how these conditions may be 
linked (Setola et al. 2004). Further studies are needed to determine the direction of 
association and a potential reverse causality.  
 
This is the first study that has demonstrated a relationship between maternal B12 and 
macrosomia, which seem to be mediated in part by maternal obesity. We 
demonstrated this only in no-GDM women as the treatment of GDM is a major 
confounder for macrosomia. Unfortunately, we did not have adiposity measures or a 
bigger sample size to assess the interactions between B12 status and maternal 
BMI/adiposity with offspring size and adiposity.  
 
The rates of B12 insufficiency observed in our no-GDM population was similar to 
that was observed in Knight et al (B. A. Knight et al. 2015) (22% vs. 20%) suggesting 
that such higher rates of insufficiency are not limited to Indian populations (Sukumar 
et al. 2016). It must be noted that a fall in B12 during pregnancy may be physiological 
due to a decrease in the fraction bound to inactive haptocorrin (Koebnick et al. 2002), 
but the evidence is equivocal with regards to whether there is also a fall in the active 
form, holotranscobalamin (Greibe et al. 2011; Murphy et al. 2007). In the absence of 
specific cut-off values to define B12 deficiency in pregnancy, we used the non-
pregnant reference range (<150pmmol/l). It is noteworthy that associations with 
adverse maternal metabolic outcomes (Krishnaveni et al. 2009) and elevation in Hcy 
during pregnancy (Guerra-Shinohara et al. 2004) were found by other authors at B12 
thresholds similar to this. 
 
It was reassuring to see that folate deficiency was rare, albeit in this selected hospital-
based cohort. However, the combination of low B12 and high folate has been shown 
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to be associated with lower neonatal birthweight (Gadgil et al. 2014) as well as central 
adiposity and insulin resistance in 6-year old offspring (C. S. Yajnik et al. 2008). 
Whilst our sample size was not large enough to do detailed subgroup analysis, we 
observed that women in the lowest quartile of B12 and highest quartile of folate had 
similar risks of macrosomia (aRR of 5.3 and 4.99; Table 4). Therefore, it is possible 
that the women with such a B12-folate imbalance are particularly at high risk of 
having larger babies. This phenomenon (high folate / low B12), is increasingly 
common in populations with mandatory folic acid fortification such as USA and 
Canada (Ray et al. 2003; Wyckoff and Ganji 2007) and is related to adverse clinical 
outcomes in the elderly population (Morris et al. 2007). 
 
Although we have identified associations between B12, maternal obesity, risk of 
GDM and fetal macrosomia, our study does not prove causation or the direction of 
relationship between these factors. Some of the important limitations were that this 
was a single-centre, retrospective study involving pregnant women attending a 
hospital clinic. Therefore it was not possible to obtain early pregnancy B12/folate 
levels. We adjusted for gestation of bloods in all the regression analysis, to reduce 
some of the bias due to longitudinal changes in B12 during pregnancy. We did not 
have markers of adiposity, and therefore it was not possible to study the potential 
differential association of low B12 status with obesity and adiposity in pregnant 
women as well as their offspring. Lack of functional measures of B12 insufficiency, 
such as Hcy and methylmalonic acid (MMA), or holotranscobalamin, which is the 
active fraction of B12 available for uptake by tissues, limits the ability to study 
thresholds of B12 sufficiency during pregnancy and should be measured in future 
studies. Additionally, there are variables which were not measured in this study that 
have been shown to affect maternal B12 levels (eg. socioeconomic status and inter-
pregnancy intervals), which should be accounted for in further prospective studies. 
 
5.5. Conclusion 
This study shows, for the first time in a UK population, that B12 deficiency in 
pregnancy is common particularly in obese women, is independently associated with 
GDM and may contribute to macrosomia. As the prevalence of maternal obesity and 
GDM is rapidly increasing, our findings warrant longitudinal cohort studies to 
understand the interplay between B12 and these outcomes. If early pregnancy B12 
  81 
status found to be independently predictive of incident GDM, such findings could 
potentially offer simple intervention to improve the metabolic health of pregnant 
women and their offspring. 
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6.1. Introduction 
As reviewed in Chapters 3-5, it is well known that vitamin B12 (B12) necessary for 
the synthesis of DNA, RNA, lipids and protein and an essential step in this process is 
the conversion of homocysteine to methionine, Therefore, a deficiency of either B12 
or folate leads to increased homocysteine (Hcy) which can have significant clinical 
implications such as cardiovascular disease and atherosclerosis in adults (Wald et al. 
2002; Zhou and Austin 2009). Vitamin B12 insufficiency was previously perceived to 
be a problem affecting the elderly, due to malnutrition or intrinsic-factor mediated 
malabsorption (Stabler and Allen 2004) and has been related to anaemia, dementia 
and cognitive dysfunction  (Clarke et al. 1998; Refsum and Smith 2003). 
 
Although hyperhomocysteinaemia (most commonly due to B12 or folate deficiency) 
has been identified as an independent risk factor for atherosclerotic vascular disease  
(Boushey et al. 1995; Homocysteine Studies 2002), a systematic review showed no 
definite association between B12 insufficiency in adults and composite cardiovascular 
endpoints (Rafnsson et al. 2011). 
 
One of the most serious effects of low B12 and folate during early pregnancy is the 
development of neural tube defects and the possible mechanisms for this were 
discussed in Chapter 3. Folic acid supplementation is effective in reducing the risk of 
NTD by over 40% (de Jong-van den Berg 2008) but because more than half of 
pregnancies are unplanned, mandatory folic acid fortification of wheat flour and 
cereal products was introduced in North America in 1997 and many other parts of the 
world in the early 2000s (L. B. Finer and Zolna 2011). This resulted in halving of 
NTD due to folate deficiency in 10 years (Centers for Disease Control and Prevention 
2004). However, the number of NTD attributable to B12 deficiency has tripled in this 
time (Ray et al. 2007). 
 
The implications of B12 deficiency during pregnancy as a risk factor for obesity and 
gestational diabetes (GDM) as well as associations with extremities of birthweight 
have been discussed in Chapters 4 and 5. Maternal hyperhomocysteinaemia has been 
linked to early pregnancy losses, pre-eclampsia  and small for gestational age babies 
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(Hogeveen et al. 2012; Nelen et al. 2000; Vollset et al. 2000). Although the exact 
mechanisms are not known, some of these effects may be mediated by vascular 
compromise to the fetus and insufficient placental development which occurs in the 
early embryonic period (Koukoura et al. 2012).  
 
Therefore, it is important to optimise the nutrient status of women in the 
preconceptional period. In the UK, there is no national programme for mandatory 
folic acid fortification but all women planning a pregnancy are advised to take at least 
400mcg of folic acid supplements until the end of their first trimester. However there 
is no evidence or guidelines for the use of B12 supplements in pre-conception or early 
pregnancy so it is necessary to refer to the national recommended nutrient intake 
(RNI) guidelines to inform us about the adequacy of this micronutrient’s intake. Thus 
far, there have been no studies in the UK that assessed the B12 intake or circulating 
levels in women of reproductive age prior to conception.  
 
The UK Department of Health (DOH) has stipulated that the RNI for B12 and folate 
in adults is 1.5mcg and 200mcg per day respectively, with no different 
recommendations for women (pregnant or otherwise) and the elderly (COMA 
(Committee on Medical Aspects of Food Policy) 1991). These recommendations were 
published in 1991 and state that the RNI for B12 “represent the level of intake 
considered likely to be sufficient to meet the requirements of 97.5% of the group” 
(Whitehead 1992). The evidence for this RNI is from reports in the 1970’s, which 
estimated the average requirement to prevent diet-related B12 deficiency and 
megaloblastic anaemia (S. J. Baker and Mathan 1981; Cooper and Lowenstein 1966; 
EFSA NDA Panel (EFSA Panel on Dietetic Products 2015). B12 deficiency in these 
studies was arbitrarily defined as <150pmol/L without use of any functional markers 
of B12 deficiency (Doets et al. 2012; Institute of Medicine 1998).  
 
Based on the above, it is obvious that there is little contemporary data to support how 
accurately the recommended intakes correlate with serum values of B12 and 
functional indicators such as Hcy. The primary aim of this study is to determine the 
serum B12, folate and Hcy status of women of child-bearing age in the UK and to 
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assess the correlation between estimated B12 intake and blood concentrations of B12 
and Hcy utilising the data from two British National Diet and Nutrition Survey 
(NDNS) in 2000/01 and 2008/12. The secondary aim is to compare the nutritional 
intake between the two NDNS cohort to provide more recent data on B12 intake.  
 
6.2. Methods 
6.2.1. Study design and justification 
Since the aim of this study was to evaluate B12 and folate intake among women of 
child-bearing age in the UK, a national survey which collected this information and 
additionally measured biomarker levels was an ideal way to meet the objectives. The 
NDNS has publically available datasets which were downloaded and statistical 
analysis done by myself to answer the study questions.  
 
Data collected from the two British NDNS between July 2000 and June 2001 and 
2008-2012 were collected. The surveys provide detailed quantitative assessment of 
nutritional status and laboratory results of the participants. The methods used in the 
survey have previously been described in detail (Bates et al. 2014; Henderson et al. 
2002; Henderson et al. 2003). The samples were made up of randomly selected adults 
aged 19-64 years living in private households who were representative of the UK 
adult population. Their selection was done by a multi-stage, stratified, probability 
sampling with postal sectors as first stage units. If there were more than one adult in 
the same household one was selected randomly. Women who were pregnant or 
breastfeeding were excluded.  
 
 
6.2.2. Participant selection 
The selection of the participants included in our analysis is provided in Figures 6.1 A-
B. For the first survey (2000/01), the fieldwork was carried out over a 12-month 
period, with respondents being surveyed over four three-month periods to account for 
seasonal variations in nutritional behavior and content. Out of 3,704 potentially 
eligible adults identified for the study, 299 women between 19 and 39 years of age 
(known as women of ‘child-bearing age’ for the purpose of our analysis) with 
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complete dietary and biomarker information were included in the final analysis. In an 
independent study (Skinner CJ 2002), no evidence of  was found of non-response bias 
in this NDNS data. Although ‘childbearing years’ is usually defined as 15 to 44 years 
(Office for National Statistics 2016), our study was limited to women from 19 to 39 
years because this was a national survey of adults aged 19 to 64 years so teenagers 
aged 15 to 18 were not included. Advancing maternal age is an independent risk 
factor for NTD (De Marco et al. 2011) so it is possible that older women have 
different B12 and folate requirements in periconception or pregnancy to prevent such 
complications. Therefore the upper age limit was set as 39 years.  
 
The second survey (2008/12) consisted of 2424 adults of whom 395 were women of 
child-bearing age. Unfortunately, blood samples were only obtained from 157 of these 
women (i.e. 39.7% of all females aged 19 to 39 years). The main reasons for this low 
return of blood samples were “no nurse visit”, “participant refused” and “blood 
sample inapplicable”. Due to the potential bias from a sample of women not 
representative of the larger NDNS cohort, we only included and compared the 
micronutrient intakes from the two surveys to assess the secular trend.  
 
A) B) 
Figure 6.1 Flow diagram illustrating the selection of the final cohort in the A) NDNS 2000/01 and B)  NDNS 
2008/12 survey   
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6.2.3. Assessment of dietary intake 
This has been described in detail elsewhere (Henderson et al. 2002). Briefly, dietary 
assessment for each participant was done by a two-stage process: 1) two face-to-face 
interviews using computer assisted personal interviewing methods and 2) a seven-day 
dietary record using weighed food diaries. Each participant was provided with a set of 
Soehnle Quanta digital food scales and two recording diaries (for use at home and 
outside). Additional information was obtained about the use of medicines, vitamin 
and mineral supplements. Information provided in the food diaries was later used to 
determine nutrient intakes by linking to the Food Standards Agency nutrient database, 
which holds details for 56 nutrients for each of 6000 food codes (Henderson et al. 
2002).  
 
6.2.4. Laboratory methods 
Venous blood samples were taken at the non-fasting state by trained phlebotomists in 
participants’ homes. Serum folate and B12 measurements were performed on the 
Abbott IMx semi-automated analyser, which uses Microparticle Enzyme 
Immunoassay (MEIA) technology (z). Quality control consisted of an internal pooling 
of serum samples with each run for use as a drift control, and an external quality 
assessment by the United Kingdom National External Quality Assessment Service 
(NEQAS). Outlying results were defined as serum B12 level greater than 1000pmol/L 
and serum folate greater than 60nmol/L and were excluded. Plasma homocysteine 
measurements were performed by the Abbott IMx assay on the IMx analyser. Quality 
control consisted of participation in an international external quality assessment 
scheme based in Denmark (Moller et al. 1997) and by the manufacturer’s QV 
samples. 
 
6.2.5. Statistical analysis 
Statistical analysis was performed with SPSS version 22.0 (IBM Corp Released 
2013). For continuous variables (e.g. mean B12/folate intakes and levels between RNI 
threshold groups) the Students t-test and for categorical variables (e.g. B12 and folate 
deficiency rates), the chi-squared test for independence or the Fisher’s exact test were 
used. Stepwise multiple linear regression analysis with each of serum B12, folate and 
plasma homocysteine as the dependent variable was done, with predictors were 
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entered or removed following the criteria: Probability-of-F-to-enter ≤0.050, 
Probability-of-F-to-remove ≥0.100. The regression models included the following 
covariates: age, body mass index (BMI), total cholesterol: high density lipoprotein 
ratio, alcohol intake, smoking status, oral contraceptive use, vegan/vegetarian, serum 
folate and where appropriate daily folate intake (with supplements), daily B12 intake 
(with supplements) and serum B12 levels. Race was not included in the analysis as 
the majority of the participants (95%) were white. To determine the trend of B12 and 
Hcy across the spectrum of B12 intakes, we divided the cohort into quintiles of B12 
intake. One-way ANOVA with Tukey’s post-hoc test was applied to compare the 
serum levels against the lowest quintile. Logistic regression was then done for 
incremental B12 intake thresholds of 0.25mcg to determine predictors of B12 
deficiency and hyperhomocysteinaemia. In order to estimate the prevalence of 
inadequate B12 intake in our population and observe how this was related to 
abnormal biomarker levels, we utilized the Estimated Average Requirement (EAR) 
cut-point method (Beaton 1994). The EAR was calculated as 1.25mcg/day based on a 
coefficient of variation of 10% below the UK RNI (Doets et al. 2012).  
 
The definitions for micronutrient deficiencies were as follows: serum B12 
≤150pmol/L (Carmel 2011); serum folate ≤10nmol/L (WHO 2008) and red cell folate 
<350nmol/L (WHO 2008). The upper limit of normal for plasma Hcy in non-pregnant 
adults aged 15 to 65 has been variably defined as 12umol/L in non-pregnant adults 
with folic acid fortification or supplementation and 15umol/L in those without 
fortification or supplementation, which applies to our population (Refsum et al. 
2004). However, Hcy levels above 10.7 umol/L in women during pre-conception has 
been associated with pre-eclampsia, prematurity and very low birthweight infants if 
they become pregnant (Vollset et al. 2000). In addition, other experts recommend 
<12umol/L for all adults (Fokkema et al. 2001). Therefore, I have presented results 
for both 12umol/L and 15umol/L and stated these clearly throughout.  
 
6.2.6. Ethics approval 
Ethical approval was obtained from a multi-centre Research Ethics Committee and 
the Oxfordshire A Research Ethics Committee for the 1st and 2nd surveys respectively 
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and all Local Research Ethics Committees covering areas where the fieldwork was 
conducted. 
 
6.3. Results 
6.3.1. Overall study parameters 
From the NDNS 2000/01 cohort, 299 women of child-bearing age had complete 
dietary and serum micronutrient level results. The demographics and clinical 
characteristics of these women are shown in Table 6.1. Their mean age was 31.6 years 
and BMI 25.3kg/m2. To determine how the B12/folate intakes women of child-
bearing age compared to older women from the same NDNS survey, we analysed 
these parameters in women aged 40-64 years.  The younger women consumed 
significantly less B12 and folate (median 3.83 vs. 5.16 and 237 vs. 279 mcg/day 
respectively, p<0.001 for both) and consisted of more vegetarians/vegans (8.7 vs. 
4.2%, p<0.05) and less B12 supplement users (10.4 vs. 16.2%, p<0.05). Folic acid 
supplement use was the same (data not shown).  
 
Table 6.1 Demographics and B12 and folate intakes of women of child-bearing age 
(NDNS 2000/01 cohort) 
FEMALE 19-39 Years All subjects (n=299) 
Age (yrs) 31.6 ± 5.7  
BMI (kg/m2) 25.4 ± 5.2 
Obesity, n (%) 46 (15.7) 
Current smokers, n (%)  117 (39.1) 
Regular alcohol drinkers, n (%) 267 (89.3) 
Oral contraceptive pill use, n (%) 103 (34.4) 
Ethnicity, n (%)   
White 283 (94.6) 
Afro-Caribbean 3 (1.0) 
Asian 8 (2.7) 
Other 5 (1.7) 
Vegetarians, n (%) 26 (8.7) 
B12 supplement users, n (%) 31 (10.4) 
B12 intake, diet only (mcg/day) 3.82 (2.75, 5.02) 
B12 intake, diet + supplements (mcg/day) 3.83 (2.82, 5.20) 
Folic acid supplement users, n (%) 32 (10.7) 
Folate intake with supplements (mcg/day) 237 (177, 315) 
Continuous variables are mean ± SD or median (IQR) 
Categorical variables are n(%) 
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6.3.2. B12, folate and homocysteine status in women of child-bearing age 
The blood levels of B12, folate and homocysteine in women of child-bearing age and 
according to categories of UK RNI for B12 intake (adequate/inadequate) are given in 
Table 6.2. The median serum B12 concentration was 241pmol/l. Overall, 12% of 
women were B12 deficient (<150pmol/L), despite the median B12 intake of the 
deficient women being nearly two times the UK RNI (2.96mcg/day) (data not shown).  
3.7% of the surveyed population had both B12 <150pmol/L and Hcy >12umol/L, with 
a significantly higher proportion having the combination of abnormalities when their 
estimated was lower than the UK RNI (9.1% vs. 3.5%, p=0.001). There is evidence 
that B12 levels <258 pmol/l may be indicative of B12 deficiency in certain 
individuals with concomitant elevation of Hcy and MMA (Lindenbaum et al. 1994). 
44.0% of women had B12 levels in this borderline range of 150 – 258 pmol/l. In this 
subgroup, mean Hcy levels were significantly higher than the group with B12 
>258pmol/l (10.4 vs. 9.2umol/L, p=0.02) despite similar folate levels (21.4 vs. 
22.0nmol/L, p=NS).  
 
The plasma Hcy concentrations were higher in the lower intake group (11.9 vs. 
9.2umol/L, p<0.05) although hyperhomocysteinemia (Hcy >12umol/L) was present in 
20% of women with apparently adequate B12 intake (Table 6.2). Serum and red cell 
folate deficiency rates were 6.1% and 4.4% respectively in the whole population. 
There were no differences in the folate deficiency rates between above and below the 
UK RNI B12 intake groups. 34.4% of the women were taking the oral contraceptive 
pills and their B12 values were lower than those who were not (median 211.5 vs. 
267.5 pmol/L, p<0.001).  
 
8.7% of women in the whole cohort were vegetarian or vegan and their median 
dietary intake of B12 was non-significantly lower than non-vegetarians (2.95 vs. 3.87 
mcg/day) while folate consumption in the former group was higher (Table 6.3). 
Vegetarians had lower serum B12 concentrations (median 192 vs. 248pmol/L, 
p<0.01) but their folate or Hcy concentrations did not vary significantly.  
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Table 6.2 Comparison of B12, folate and plasma homocysteine concentrations in women according to UK RNI for vitamin B12 intake 
FEMALE 19-39 Years All subjects UK RNI (mcg/day) Pa 
<1.5 ≥1.5 
Number (%) 299 (100) 11 (3.7) 288 (96.3)   
B12 intake, diet only (mcg/day) 3.82 (2.75, 5.02)b 1.29 (0.64, 1.46) 3.86 (2.86, 5.09) <0.001 
B12 intake, diet + supplements (mcg/day) 3.83 (2.82, 5.20) 1.29 (0.98, 1.46) 3.92 (2.88, 5.32) <0.001 
Serum B12 (pmol/L) 241 (188, 324) 169 (153, 256) 244 (189, 325) 0.05 
B12 deficiency (<150pmol/L), n (%) 36 (12.0) 2 (18.2) 34 (11.8) NS 
Serum folate (nmol/l) 19.5 (14.1, 26.7) 14.3 (13.6, 21.3) 19.7 (14.2, 27.0) NS 
Serum folate deficiency (<10nmol/L), n (%) 18 (6.1) 0 (0) 18 (6.3) NS 
Red cell folate (nmol/L) 584 (473.9, 750.6) 460 (372, 739) 585 (478, 751) NS 
Red cell folate deficiency (<350nmol/L), n)%) 13 (4.4) 2 (18.2) 11 (3.8) NS 
Homocysteine (umol/L) 9.4 (9.1, 9.8) 11.9 (9.6, 14.3) 9.2 (7.8, 11.4) <0.05 
High Hcy (>12 umol/L), n (%) 62 (21.2) 5 (50) 57 (20.1) <0.05 
High Hcy (>15 umol/L), n(%) 24 (8.2) 2 (20) 22 (7.8) NS 
a: Comparison between lower and higher B12 intake groups. For categorical variables, Student's 
t-test was used (after log-transformation); for continuous variables Fisher's exact test was used 
b: Median, 25th -75th centile in parentheses (all such values) 
NS: not significant 
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Table 6.3 Biochemical indices in vegetarian and vegan women of child-bearing age compared to non-vegetarians 
  Vegetarian / vegan Non-vegetarian Pa 
Number (%) 26 (8.7) 273 (91.3) NS 
B12 supplements taken, n (%) 5 (19.2) 26 (9.5) NS 
B12 intake, diet only (mcg/day) 2.95 (2.63, 3.96)b 3.87 (2.81, 5.09) NS 
B12 intake, diet + supplements (mcg/day) 3.07 (2.65, 4.37) 3.92 (2.86, 5.30) NS 
Serum B12 (pmol/L) 192.0 (138.9, 248.2) 248.3 (190.5, 328.3) <0.01 
B12 insufficiency (<150pmol/L), n (%) 8 (30.8) 28 (10.3) <0.01 
Folic acid supplements taken, n (%) 3 (11.5) 29 (10.6) NS 
Folate intake, diet only (mcg/day) 279.2 (234.6, 324.0) 232.2 (169.3, 292.0) <0.05 
Folate intake, diet + supplements (mcg/day) 284.2 (234.6, 337.5) 233.9 (175.8, 310.2) NS 
Serum folate (nmol/L) 21.8 (18.5, 30.8) 19.2 (13.8, 26.2) <0.05 
Serum folate deficiency (<10nmol/L), n (%) 1 (3.8) 17 (6.3) NS 
Homocysteine (umol/L) 9.60 (7.74, 11.90) 9.24 (7.63, 11.46) NS 
High Hcy (>12 umol/L), n (%) 5 (19.2) 57 (21.3) NS 
High Hcy (>15 umol/L), n(%) 1 (3.8) 23 (8.6) NS 
a: Comparison between vegetarian/vegan and non-vegetarian groups. For categorical variables, Student's t-
test was used (after log-transformation); for continuous variables Fisher's exact test was used 
b: Median, 25th -75th centile in parentheses (all such values) 
NS: not significant 
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6.3.3. Predictors of B12, folate and homocysteine levels 
There was a positive correlation between serum B12 values and daily B12 intake 
(Pearson’s r=0.27, p<0.001) (Figure 6.2). Simple linear regression analyses of the 
predictors of B12, folate and homocysteine are shown in Table 6.4. After adjusting 
for the likely confounders, daily B12 and folic acid intakes were positive predictors of 
serum B12 (β = 0.28, p<0.001) and serum folate (β = 0.33, p<0.001) respectively. 
Along with age, serum B12, serum folate and B12 intake were independent predictors 
of homocysteine though it would appear that serum folate is strongest based on the 
value of the β coefficient. 
 
 
Figure 6.2 Correlation between daily B12 intake and serum B12 values. §Log transformed for statistical 
comparisons.   
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Table 6.4 Multiple linear regression analysis of predictors of serum B12, folate and homocysteine 
Variables Serum B12§ Serum folate Homocysteine§ 
β-coefficient p-value β-coefficient p-value β-coefficient p-value 
Age - NS - NS 0.18 0.001 
BMI - NS - NS - NS 
Smoking -0.12 <0.05 - NS - NS 
Alcohol - NS - NS - NS 
Oral contraceptive use -0.29 <0.001 0.11 <0.05 - NS 
TC:HDL ratio§ - NS - NS - NS 
Vegetarian or vegan diet -0.18 <0.01 - NS - NS 
B12 supplement use - NS Not included N/A - NS 
Daily B12 intake§ 0.28 <0.001 Not included N/A -0.16 0.001 
Folic acid supplement use Not included N/A 0.18 <0.01 - NS 
Daily folate intake§ Not included N/A 0.33 <0.001 - NS 
Serum B12§     - NS -0.20 <0.001 
Serum folate§ - NS     -0.35 <0.001 
§: Log-transformed for statistical comparison 
-: Tested but not significant in the model 
NS: Non-significant
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6.3.4. Relationship between B12 intake and associated biomarkers 
5/299 (1.7%) of women consumed below the EAR of 1.25mcg/day but none of them 
had B12 levels <150pmol/L.  Conversely, in the 98.3% of women with ‘adequate’ 
EAR category for B12 consumption, 12.2% of them had serum levels below 
150pmol/L. 
 
In order to determine the trend of blood B12 and Hcy concentrations with increasing 
intakes of B12, we divided the cohort in quintiles of B12 intake. The median levels in 
each quintile and associated biomarker levels for B12 and Hcy are represented in 
Figures 6.3A-B respectively. Women in quintiles 4 and 5 (median intake 4.9 and 
7.1mcg/day) had significantly higher mean B12 and lower mean Hcy concentrations 
than quintile 1 (291pmol/L and 322pmol/L vs. 229pmol/L; 9.0umol/L and 9.0umol/L 
vs. 11.4 umol/L respectively). Additionally, the Hcy levels appears to level off 
between quintiles 4 and 5, suggesting that increasing intakes above 5mcg/day is 
unlikely to provide higher B12 at the tissue level (Figure 6.3B). To confirm this, we 
performed logistic regression to determine the intake threshold at which the odds of 
hyperhomocysteinaemia would reduce significantly after correcting for confounders. 
Using 0.25mcg increments, a threshold of 4.75mcg/day significantly reduced the odds 
of Hcy>12umol/L (aOR 0.35, 95% CI 0.14-0.88). When serum B12 was added to the 
model, the significance was lost suggesting that the influence of dietary B12 intake on 
circulating Hcy is mediated through serum B12 values in a folate-replete population 
(data not shown). 
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6.3.5. Micronutrient intake: comparisons between NDNS 2000/01 and 
2008/12 data 
Comparison of the mean nutrient intake among young women between the two 
surveys is shown in Table 6.5. The proportion of women consuming below the UK 
RNI for folate increased in the more recent survey (44 vs. 33%, p<0.01) and median 
intake levels fell by 14% (206 vs. 235 pmol/L, p<0.001). There were no significant 
differences in the B12 intake values.  
A) B) 
Figure 6.3 Relationship between B12 intake in quintiles and A) mean serum B12 and B) mean plasma homocysteine 
concentrations. Mean±SEM values are plotted against the median B12 intake in each quintile. One-way analysis of 
variance (ANOVA) test used to compare the means between the quintiles (after log transformation) and Tukey’s post 
hoc analysis done. Mean biomarker levels differed as compared with quintile 1 as follows: *p<0.05; **p<0.01; 
***p<0.001.   
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Table 6.5 Comparison between folic acid and B12 intakes between the NDNS 2000/01 and 2008/11 cohorts  
Female 19-39 Years NDNS 2000/01 Cohort NDNS 2008/11 Cohort 
Number 299 395 
Folic acid supplement users, n (%) 32 (10.7) 12 (3.0)***b 
Folate intake, diet only (mcg/day) 234.9 (175.7, 302.7)a 205.8 (162.3, 261.2)*** 
n (%) consuming below UK RNI of folate 99 (33.1) 173 (43.8)** 
B12 supplement users, n (%) 31 (10.4) 33 (8.4) 
B12 intake, diet only (mcg/day) 3.82 (2.75, 5.01)  3.78 (2.64, 4.84)  
n (%) consuming below UK RNI of B12 11 (3.7) 24 (6.1) 
a: Median, 25th -75th centile in parentheses (all such values) 
b: p-values from independent samples t-test for continuous variables (after log-transformation) or chi-
square test for categorical variables 
Significance: **p<0.01; ***p<0.001 
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6.4. Discussion 
This study shows contemporary data of B12 and folate intakes and serum levels in 
population-based nutritional surveys involving women of child-bearing age, who are 
selected from the general UK population. The key findings are that, despite an 
apparent adequate daily intake of B12, a high proportion of women have B12 
deficiency and hyperhomocysteinaemia.  
 
Optimum B12 intake and biomarker levels  
This data showed positive correlation between B12 intake and blood levels with a 
trend of increasing B12 concentration even in intakes up to 7mcg/day, although the 
corresponding reductions in Hcy levels level off around the intake of 5-7mcg/day. 
Additionally, the consumption of around 4.75mcg/day was independently associated 
with a decrease in the odds of hyperhomocysteinaemia. Our findings are supportive of 
the dose-response relationship between intake and blood levels of B12 found 
previously, which showed doubling B12 intakes would increase B12 concentrations 
by around 10% (Dullemeijer et al. 2013). 
 
A daily intake of 4-10mcg has been suggested by other studies to stabilise levels of 
B12, Hcy and the associated MMA in adults (Bor et al. 2010; Vogiatzoglou et al. 
2009) but more evidence is needed before extrapolating these figures to women of 
child-bearing age due to the different requirements and implications should they 
become pregnant. In a randomised control trial where all subjects consumed 
8.6mcg/day of B12, pregnant women had higher holotranscobalamin : total B12 ratios 
than non-pregnant, non-lactating controls suggesting that such high intakes were 
required to provide sufficient supply to the developing fetus (Bae et al. 2015). More 
research is required to decide on the upper limit of B12 intake in women before and 
during pregnancy, as higher B12 intake in the 3rd trimester was positively associated 
with offspring birthweight in high BMI women (who are already at high risk of 
having macrosomic babies) although circulating B12 levels were not reported here 
(Horan et al. 2015). There is also no consistent evidence that increased B12 intake or 
supplementation is associated with reduction in the prevalence of subclinical B12 
deficiency in adults (particularly neurocognitive decline in the elderly) (A. D. Smith 
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et al. 2010; A. D. Smith and Refsum 2012). Therefore, until the availability of further 
studies, our data calls for revision of the UK RNI (and EAR) for B12 to be at least in 
line with the current European recommendations (4.5mcg/day) (EFSA NDA Panel 
(EFSA Panel on Dietetic Products 2015). 
 
The estimated B12 intake in pre-conceptional or women in early pregnancy, and 
specifically its relationship with serum levels has not been widely studied. In 
developing countries, over 50% of women of reproductive age do not meet the RNI’s 
for B12 (Arsenault et al. 2013; Nguyen et al. 2014) and separate surveys from three 
developing countries (Turkey, Iran and China) found B12 deficiency rates of 21-23% 
(Abdollahi et al. 2008; Karabulut et al. 2015; Zhu et al. 2010). An Australian study on 
young females found a similar rate to ours (11.4%) albeit using a lower threshold of 
120pmol/L (Fayet-Moore et al. 2014). As the B12 levels fall by around 10% from 
pre-conception to early pregnancy (Murphy et al. 2007), if we extrapolate our 
findings, the proportion of pregnant women with B12 levels below 150 pmol/L is 
likely to be much higher. More than a third of vegetarian/vegan women in our study 
had B12 deficiency, which was in keeping with studies from other UK adult 
population (Gilsing et al. 2010) and elsewhere (Pawlak et al. 2013). Thus these 
findings highlight the need for specific advice for the vegetarian/vegan population 
about potential sources of B12, as well as recommending them to have their B12 
levels checked (and corrected) if they are planning pregnancy. 
 
Folate intake 
Our study shows that consumption of dietary folate has fallen by around 14% in the 
10 years between the two surveys and nearly 50% of women are now consuming 
below the UK RNI.  The Scientific Advisory Committee on Nutrition within the UK 
Food Standards Agency has recommended mandatory folic acid fortification of food 
products to the UK DOH (Scientific Advisory Committee on Nutrition 2006) which, 
if implemented, would increase folate intake and consequently serum levels in the 
population as it did in USA (Pfeiffer et al. 2007). However if mandatory fortification 
does occur, it is possible that improving folate levels can reduce B12 levels due to 
utilization of the available B12 (Selhub et al. 2009). In addition, B12 deficiency is the 
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strongest driver of homocysteine in a folate-replete population (Selhub et al. 2007b). 
Therefore, it is sensible to consider fortification of food products with B12 together 
with folate should there be a policy change in the UK or as a minimum, recommend 
B12 supplements in women in the periconceptional period especially if they are at 
high risk of B12 deficiency.  
 
The strengths of our study are that this is the first study of its kind from the UK to 
evaluate B12 and folate among women in the pre-conceptional stage. Extensive data 
on these women including anthropometry, biochemical markers and dietary 
information allowed comparison of intake and serum levels adjusted for possible 
confounders. There were four important limitations of this dataset: a) limitations in 
sample size and potential selection bias; b) lack of sufficient biochemical data in the 
second survey; c) lack of data on other biomarkers such as holoTC or methylmalonic 
acid (MMA) and d) lack of haematological and clinical information relevant to the 
effects of B12.  These will be discussed in turn. 
 
Although the NDNS is meant to be a national survey representative of the UK 
population, inability to contact individuals, participant refusal to participate or obtain 
bloods and insufficient blood samples, information was only obtained from a third of 
the 3704 potentially eligible individuals in the first survey, from which the majority of 
our analysis is based on. From this, complete data was available from 299 women of 
child-bearing age who met our inclusion criteria so caution must be exercised when 
extrapolating the results to the wider UK population. A more up-to-date survey with a 
larger sample size of women sampled from populations representative of the whole of 
UK should be carried and their results considered prior to any national policy change 
with regards to B12 and folate intake recommendations.  
 
Since we were able to compare the nutrient intakes between the two cohorts, which 
was predictive of serum levels in the earlier survey, we believe the that availability of 
serum B12 in the latter cohort may not necessarily change the findings. Hcy is a 
readily available marker in clinical practice as opposed to holoTC and MMA. 
Therefore, our findings are applicable to wider clinical practice. Any future 
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prospective studies involving preconceptional or pregnant women should include 
more clinical information as well as these biomarkers for a better evaluation of B12 
status. 
 
6.5. Conclusion 
In conclusion, this study supports revision of the UK RNI to at least match the 
European recommendations and also calls for assessing maternal B12 status in pre-
conception or early pregnancy.  
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7.1. Incretin hormones 
The incretin effect is described as the amplification of insulin secretion, which is 
observed when glucose is taken in orally as opposed to via an intravenous infusion to 
maintain the same plasma glucose concentrations (J.J. Holst and Gromada 2004). This 
potentiating effect of the incretin hormones accounts for around two-thirds of the 
insulin response after an oral glucose load. The 2 primary hormones responsible for 
this incretin effect are glucagon-like peptide 1 (GLP-1) and glucose-dependent 
insulotropic polypeptide (GIP).  
 
GLP-1 is secreted by the enteroendocrine L-cells in the distal ileum and colon in 
response to a meal and its secretion is proportional to the energy intake of the meal 
(Field et al. 2010; C. Herrmann et al. 1995). It is formed from the cleavage of 
proglucagon, a hormone expressed in the pancreas, gastrointestinal (GI) tract and 
brain (Figure 7.1) (Seino et al. 2010). Tissue-specific cleavage of proglucagon occurs 
with glucagon being the predominant type produced in the pancreas and GLP-1, GLP-
2 and oxyntomodulin produced in the GI tract and brain. Secretion of GLP-1 is 
stimulated directly by ingested gut contents coming into contact with receptors 
expressed on the surface of the L-cells as well as gut neuronal signals involving the 
vagus nerve (Rocca and Brubaker 1999). GLP-1 has a half life of around 2 minutes 
due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and it is 
estimated that only 10-15% of newly secreted GLP-1 reaches the circulation due to 
metabolism by the gut and liver (Deacon et al. 1996). 
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GLP-1 has a multitude of effects on the body in addition to its primary function, 
which is glucose-dependent insulin secretion by the pancreatic beta-cells (Figure 7.2) 
(Baggio and Drucker 2007). These are not exhaustive but include inhibition of 
glucagon secretion by the alpha-cells, delayed gastric emptying and increasing satiety. 
The ability of GLP-1 agonists to cause sometimes dramatic weight loss has created 
plenty of interest its role as a regulator of energy balance. GLP-1 production has been 
discovered in the medulla and GLP-1 receptors in the hindbrain and hypothalamus 
(Goke et al. 1995; Merchenthaler et al. 1999). The hypothesis is that intraluminal 
GLP-1 secretion stimulates intestinal vagal nerve  which provides positive feedback 
in hindbrain nuclei (central GLP-1 secretion may also contribute to this) (Barrera et 
al. 2011).  These stimuli, in addition to those from gastric distension, are synthesised 
by the hindbrain which then produce efferent signals to reduced portion sizes.   
Figure 7.1 Production of GIP and GLP-1 proteins. The glucose-dependent insulinotropic 
polypepide (GIP) gene is localized on human chromosome 17q21.3–q22 and comprises 6 
exons. Proteolytic processing of preproGIP generates GIP that is secreted from K cells. 
The proglucagon gene is localized on human chromosome 2q36– q37 and comprises 6 
exons. In the intestine, proteolytic processing of proglucagon generates glucagon-like 
peptide (GLP)-1 and GLP-2, whereas glucagon is produced in the pancreas. (from Seino et 
al. 2010) 
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GIP is secreted by the K-cells of the upper small intestine and although some of its 
effects on the beta-cells of the pancreas are similar to GLP-1 (i.e. increasing insulin 
secretion and beta-cell proliferation), other effects it has on the body, particularly in 
the periphery are different. It causes increase in glucagon secretion by the pancreas, 
increase in fat accumulation in adipose tissue and bone formation (Seino et al. 2010). 
However, it does not reduce meal size similar to GLP-1, presumably because the 
location of GIP receptors in the brain are distinct from GLP-1 (Nyberg et al. 2005).  
 
7.2. GLP-1 levels in type 2 Diabetes and insulin resistant states 
GLP-1 in type 2 diabetes 
In type 2 diabetes (T2D) patients, there only appears to be a slight decrease in 
postprandial GIP concentrations when compared to weight-, age- and sex-matched 
non-diabetic controls (M. B. Toft-Nielsen et al. 2001b) but the insulotropic effects of 
this hormone are significantly reduced or even lost (Krarup et al. 1987). The latter 
effects may be due to a decreased expression of the GIP receptor in the pancreatic 
beta-cells or defects in postreceptor mechanisms, particularly those involved with the 
second phase of insulin secretion (Vilsbøll et al. 2002).  
 
Figure 7.2 GLP-1 actions in peripheral tissues. The majority of the effects of GLP-1 are mediated by 
direct interaction with GLP-1Rs on specific tissues. However, the actions of GLP-1 in liver, fat and 
muscle most likely occur through indirect mechanisms (from Baggio and Drucker 2007). 
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However, the situation with GLP-1 seems to be somewhat reversed. Investigators who 
have done experiments by giving infusions of GLP-1, whilst maintaining a constant 
glucose by way of a hyperglycaemic clamp, have found that T2D patients clear the 
glucose load as efficiently as healthy controls, suggesting that the beta-cells are 
responsive to GLP-1 in T2D (Vilsbøll et al. 2002).  
 
So if the insulotropic action of GLP-1 is maintained in T2D, is there submaximal 
release of GLP-1 to account for the impairment in incretin effect? The answer to this 
is less straightforward which may, in part, be due to heterogeneity in the studies 
conducted in terms of the glucose challenge given (e.g. glucose tolerance test (GTT), 
mixed meal tests) and assays used to measure GLP-1 (e.g. total GLP-1, intact GLP-1, 
etc.) (Calanna et al. 2013).  
 
Some studies show that postprandial GLP-1 concentrations (as measured by total area 
under the curve (tAUC)) are significantly reduced by 20 – 50% in T2D as compared 
to controls (Elza Muscelli et al. 2008b; M. B. Toft-Nielsen et al. 2001b). However a 
recently conducted meta-analysis concluded that there was no difference in various 
measured of postprandial GLP-1 measures in T2D compared to controls (Calanna et 
al. 2013). Furthermore, subgroup analyses even showed increased GLP-1 responses in 
these patients during liquid mixed meal tests and 50g GTT and the authors suggested 
that the secretion pattern of GLP-1 may change in the course of the disease with 
hypersecretion early on followed by ‘exhaustion’ of the GLP-1 producing cells later 
on (Calanna et al. 2013). Indeed other studies have found that HbA1c and fasting 
plasma glucose (FPG) were independent negative predictors of GLP-1 secretion and 
the meta-analysis also corroborated this (Calanna et al. 2013; M. B. Toft-Nielsen et al. 
2001b).  
 
GLP-1 in insulin resistance states 
Although the abovementioned studies demonstrated an association between 
deteriorating glycaemic control and a reduction in GLP-1 levels / its effect, there is 
another school of thought that the impairment of incretin effect is observed at the 
onset of insulin resistance too. In an experiment where insulin resistance was induced 
in healthy individuals by 5 days of dexamethasone treatment, the investigators found 
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that the subjects who developed insulin resistance showed a reduction in the incretin 
effect from 71% to 58% (a change of 18%) before and after the treatment during a 
75g GTT/isoglycaemic intravenous glucose test (Jensen et al. 2010). Additionally, 
those who developed impaired glucose tolerance as well demonstrated a reduction in 
their incretin effect from 67% to 32% (a change of 52%) suggesting that there is an 
impairment in β-cell response to incretins early on but its secretory capacity does not 
decrease till later (Holst  et al. 2011; Jensen et al. 2010).  
 
These observations may, of course, be due to obesity which has been shown to be an 
independent negative predictor of GLP-1 response in several studies (Elza Muscelli et 
al. 2008b; M. B. Toft-Nielsen et al. 2001b). Even among subjects with NGT, obese 
individuals had significantly lower incremental AUC for total GLP-1 compared to 
lean individuals during GTT (Knop FK 2008). The former group in this study also 
demonstrated a reduced incretin effect although they did not differ from lean 
individuals in terms of fasting plasma glucose, post-GTT glucose excursion or HbA1c 
once again suggesting that impairment of the incretin effect may be a very early 
pathophysiological trait before the development of impaired glucose tolerance (IGT) 
or T2D (Knop FK 2008). 
 
7.3. GLP-1 levels in gestational diabetes 
From the above, it seems to be evident that there is an impairment of the incretin 
effect in insulin resistance states, particularly when accompanied by obesity. So it is 
probable that a similar effect will be observed in pregnancy, which is a physiological 
state of insulin resistance.  
 
A search on PubMed found 6 articles which measured GLP-1 levels or the incretin 
response in pregnancy (Bonde et al. 2013; Cypryk et al. 2007; Gonzalez et al. 2011; 
Kosinski et al. 2013; Lencioni et al. 2011; Reyes-Lopez et al. 2014). Table 7.1 shows 
a summary of these studies. It is difficult to draw any definite conclusions from these 
studies due to the wide heterogeneity in gestation of GLP-1 measurement, the glucose 
challenge used and type of GLP-1 measurement done (e.g. mean GLP-1, AUC GLP-
1, total GLP-1 all measured in different studies). These will be discussed in more 
detail in Chapter 8. 
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Table 7.1 Summary of studies which have measured glucagon-like peptide-1 (GLP-1) levels or incretin response in gestational 
diabetes and normal glucose tolerance pregnancies  
GDM: gestational diabetes mellitus, NGT: normal glucose tolerance, TT: third trimester, PP: post-partum, AUC: area under the curve, GTT: glucose tolerance test, 
IV: intravenous, GIGD: gastrointestinally mediated glucose disposal, RIA: radioimmunoassay, ELISA: enzyme-linked immunosorbant assay, HOMA-IR: 
homeostasis model assessment of insulin resistance 
Reference Participants 
(n) 
Stage of 
pregnancy 
Glucose 
challenge 
Components of GLP-
1 response analysed 
(analytical method) 
Key findings 
Bonde et al. 
2013 
GDM (11) 
NGT (8) 
Third trimester 
(TT) & 
3-4 months 
post-partum 
(PP) 
4-hour liquid 
meal 
Total AUC, fasting 
GLP-1 (RIA)  
- GDM vs. NGT in TT: non-significant ↓ total AUC GLP-1 (5.5 
vs.7.3 nM x min) 
- GDM at TT vs. PP: ↓ total AUC GLP-1 (5.5 vs. 8.4 nM x min, 
p=0.005) 
- GDM vs. NGT in TT and PP: ↓ fasting GLP-1 levels at both 
time-points (p=0.03 and 0.04) 
-GDM at TT and PP vs. NGT: ↑ GIP levels 
Lencioni et 
al. 2011 
GDM (12) 
NGT (16) 
TT (mean 27 
weeks) & 12-18 
months PP 
3-hour 100g 
GTT 
Mean GLP-1, total 
AUC (RIA kit for 
active GLP-1) 
- GDM vs. NGT at TT: no difference in GLP-1 AUC; ↓ mean  
GLP-1/mean glycaemia ratio 
-GDM vs. NGT at PP:  ↓ GLP-1 AUC (2542 vs. 10092, p<0.05) 
Cypryk et 
al. 2007 
GDM (13) 
NGT (13) 
TT (mean 27-29 
weeks) 
75g GTT Active GLP-1 and total 
AUC (RIA) 
- GDM vs. NGT: ↑ fasting GLP-1 levels; no difference in total 
AUC 
- GDM vs. NGT: positive correlations between fasting GLP-1 
and insulin concentration and resistance (r=0.54, p=0.004 and 
r=0.43, p=0.029) 
Kosinski et 
al. 2013 
GDM (10) 
NGT (8) 
TT & 
3-4 months PP 
4-hour 50g 
GTT and IV 
glucose  
No GLP-1 levels 
measured. Incretin 
effect for AUC insulin, 
GIGD (N/A) 
- GDM at TT vs. PP: ↑ incretin effect at PP (31 vs. 56%, 
p=0.02); GIGD reduced to diabetic levels in GDM but ↑ PP 
(37% vs. 58%, p=0.03); no difference in NGT 
Reyez-
Lopez et al. 
2014 
GDM (90) 
NGT (108) 
TT Fasting bloods Mean GLP-1 (RIA) - GDM vs. NGT: ↑ fasting GLP-1 levels (p=0.004) 
Gonzalez et 
al. 2001  
GDM (15) 
NGT (22) 
Delivery  Random 
bloods at C-
section 
Active GLP-1 (ELISA) -GDM vs. NGT: No difference in GLP-1 levels; positive 
correlation between GLP-1and HOMA-IR 
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7.4. GLP-1 and GLP-1 receptor agonists in the treatment of diabetes and 
associated complications 
7.4.1. Clinical use of GLP-1 receptor agonists 
The first GLP-1 receptor agonist (GLP-1 RA) developed and approved for clinical use 
was exenatide, which is synthetically prepared from exendin-4, an incretin mimetic 
derived from the saliva of the Gila monster (Eng et al. 1992). It is 53% homologous to 
native GLP-1 and is resistant to degradation by DPP-4 due to an amino acid 
substitution. Liraglutide, the second GLP-1 RA to come into clinical practice has 97% 
homology to native GLP-1 but has a longer half-life than Exenatide due to its 
resistance to DPP-4 inhibition being mediated by binding to serum albumin (Tahrani 
et al. 2016). Due to this, it can be administered once a day via a subcutaneous 
injection of 0.6, 1.2 or 1.8mg.  
 
Multi-national randomised control trials, head-to-head comparisons with other GLP-1 
RA’s and meta-analyses have shown remarkable benefits of Liraglutide in terms of 
glycaemic control and weight loss, amongst other benefits. Mean haemoglobin A1c 
(HbA1c) decrease is 1.27% (95% CI 1.13 -1.41) after 26 weeks treatment and mean 
fasting a postprandial blood glucose decrease 1.82 mmol/l (1.57 – 2.07) and 1.7 – 2.1 
mmol/l (monotherapy only) (Tahrani et al. 2016). Mean weight loss on liraglutide 
1.8mg was 1.51 (2.67 – 0.31) kg (Potts et al. 2015).  
 
Three further GLP-1 RA’s have recently become available (Lixisenatide, Albiglutide 
and Dulaglutide) which vary slightly in their composition and duration of action. 
Long-term cardiovascular outcome data are eagerly awaited on these drugs. 
 
7.4.2. Non-glycaemic effects of GLP-1 receptor agonists 
While the GLP-1 RA class of drugs initially garnered a lot of attention for their 
dramatic effects on glycaemic control and weight loss, more recent attention has also 
been on the cardiovascular protection it confers. This might be an indirect effect of its 
glucose- and weight-lowering effect but recent body of evidence suggests that it 
might have a direct effect on the endothelium too.  
 
Clinical studies have shown that in patients with ischaemic heart disease and heart 
failure, the infusion of GLP-1 improved left ventricular function, myocardial oxygen 
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consumption and quality of life, an observation which was noticed in diabetics and 
non-diabetics (Nikolaidis et al. 2004; Sokos et al. 2006). Meta-analysis data is 
available supporting the benefit of Liraglutide and other GLP-1 RAs in lowering 
systolic blood pressure (-4.2mmHg compared to insulin) and total cholesterol, LDL 
and triglycerides but there is no benefit on HDL (Katout et al. 2014; F. Sun et al. 
2015a; F. Sun et al. 2015b). There is also good evidence that GLP-1 improves 
endothelial dysfunction, as measured by flow-mediated dilatation of the brachial 
artery in diabetic patients (Nystrom et al. 2004). I will discuss these observations in 
more detail, together with possible mechanisms below and in Chapter 9.  
 
7.5. GLP-1 receptor agonists in the alleviation of hyperglycaemia-oxidative 
stress in endothelial cells: focus on molecular mechanisms 
7.5.1. Endothelial dysfunction 
Vascular disease is central to the pathogenesis of several complications of diabetes 
mellitus (DM); small vessel disease is responsible for retinopathy, nephropathy and 
neuropathy while atherosclerosis in large vessels accounts for coronary, carotid and 
peripheral vascular disease (Schalkwijk and Stehouwer 2005). Macrovascular disease 
is responsible for 50 – 75% of mortality in DM, mainly due to ischaemic heart disease 
and cerebrovascular disease.  The clinical features of vascular involvement in diabetic 
patients and the key signaling insults implicated in them are summarised in Figure 7.3 
(Kolluru et al. 2012). 
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The vascular endothelium is a layer of biologically active cells lining the inner wall of 
blood vessels and plays an important role in the regulation of vascular tone, 
hemostasis and inflammation (Schalkwijk and Stehouwer 2005). The tonicity of the 
endothelium is a balance between vasoconstricting factors (such as endothelin-1, 
prostaglandin H2, reactive oxygen species (ROS) and angiotensin 2) and vasorelaxing 
factors, the main one being endothelial nitric oxide (NO) (Dai et al. 2013). NO, which 
is produced by endothelial nitric oxide synthase (eNOS), has several protective 
functions in endothelial cells, conferring protection against atherosclerosis and plaque 
build-up (reviewed in Kim et al) (J. A. Kim et al. 2006). These include inhibiting 
platelet adhesion and aggregation, decreasing the expression of proteins involved in 
atherogenesis (e.g.VCAM-1, ICAM-1, MCP-1), reducing vascular permeability, 
inhibiting the oxidation of low density lipoprotein to its proatherogenic form and 
scavenging superoxide (X. L. Du et al. 2001).  
Figure 7.3 Diabetic vascular disease effects and symptoms. Various pathophysiological 
conditions affected in the body due to diabetic vascular disease are illustrated. Prominent 
symptoms of diabetes mediated abnormalities are indicated for each condition. (See text for 
details on selected pathways) 
(from Kolluru et al. 2012). 
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Nitric oxide synthase (NOS) exists in 3 isoforms in endothelial cells: neuronal NOS 
(nNOS), inducible NOS (iNOS) and eNOS. Some factors which stimulate eNOS 
production are sheer stress due to increased endothelial blood flow and the 
phosphatidyl-inositol-3 kinase (PI3K)-Akt pathway by insulin and vascular 
endothelial growth factor (VEGF) (Fulton et al. 1999). Activation of the PI3K-Akt 
system phosphorylates eNOS at Ser(1177). 5’-adenosine monophosphate activated 
protein kinase (AMPK) is also shown to phosphorylate eNOS at more than one site 
(discussed in detail below).  
 
Endothelial dysfunction is defined as a diseased state in the endothelium whereby it 
transforms into a vasoconstrictor, proinflammatory and prothrombotic state (G. Yang 
et al. 2010). Importantly, it has been shown that endothelial dysfunction is associated 
with the release of pro-inflammatory cytokines, such as tumour necrosis factor α 
(TNF-α) and interleukin 6 (IL-6), which is an early initiating factor of atherosclerosis 
in DM (Dai et al. 2013). One of the main insults in endothelial dysfunction is a 
decrease in NO-mediated vasorelaxation, which can be due to reduced eNOS 
phosphorylation/activation, eNOS uncoupling (i.e. greater production of 
monomerised eNOS which generates superoxide anions instead of NO that is 
produced by the homodimer eNOS), increased arginase (which cleaves L-arginine, 
the precursor of NO) and reduced tetrahydrobiopterin (BH4, a compound which 
stabilises eNOS in its active homodimer form) [reviewed in Kolluru et al] (Kolluru et 
al. 2012). 
 
The signaling mechanisms implicated in the development of endothelial dysfunction 
due to hyperglycaemia are discussed in more detail in the next section. 
 
7.5.2. Generation of oxidative stress in endothelial cells 
Oxidative stress, which occurs when the rate of production of ROS exceeds their 
scavenging, has been linked to many of the vascular complications of DM, including 
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endothelial dysfunction (King and Loeken 2004). On a tissue level, ROS has been 
shown to affect blood flow in the retina and reduce conduction in peripheral nerves 
(Hounsom et al. 2001; Kowluru and Kennedy 2001; Kunisaki et al. 1995). 
 
The endothelium is particularly sensitive to the damaging effects of ROS due to its 
negative effects on NO synthesis among other factors (Son 2007). There are three 
main sources of ROS production in vascular cells, namely (1) xanthine oxidase, (2) 
NADH/NADPH oxidase (i.e. nicotinamide adenine dinucleotide phosphate hydrogen) 
and (3) eNOS (reviewed in Cai and Harrison) (Cai and Harrison 2000). The most 
toxic of ROS are the superoxide anion (O2-), hydroxide peroxide (H2O2) and 
additionally O2- can combine with nitric oxide to produce peroxynitrite (ONOO-). 
Superoxide dismutase (SOD), catalase and glutathione peroxidase are protective 
enzymes that break down the ROS. The formation and clearance of ROS are 
summarised in Figure 7.4 (Droge 2002). 
 
Chronic hyperglycaemia in the context of DM causes increased oxidative stress in 
several tissues due to excess production of ROS and impaired clearance (Nishikawa et 
al. 2000). Figure 7.5 shows how increased intracellular glucose increases ROS 
production and inhibits its clearance through several interacting pathways (King and 
Loeken 2004; Schalkwijk and Stehouwer 2005). In summary, the 4 main pathways 
Figure 7.4 Pathways of reactive oxygen species (ROS) production and clearance. GSH: glutathione, 
GSSG: glutathione disulfide (from Droge 2002) 
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activated are:  
1) Polyol pathway  (causing increased production of sorbitol by aldose reductase) 
2) Hexosamine pathway (i.e. production of glucosamine-6-phosphate from fructose-6-
photose) 
3) Protein kinase C (PKC) pathway 
4) Formation of advanced glycation end-products (AGE) by non-enzymatic reactions 
 
 PKC is a stimulator of NADPH oxidase, which is responsible for the oxidation of 
NADPH to NADP+. The resulting reduced NADPH/ NADP+ ratio contributes to the 
generation of ROS by (1) reducing the regeneration of an antioxidant glutathione 
(GSH) from oxidised glutathione (GSSG) and (2) decreasing the activity of catalase, 
the enzyme which converts H2O2 to H2O. The generation of PKC and its toxic effects 
on cells are summarised in Figure 7.6 (King and Loeken 2004). These processes 
affect vascular tissue as well because glutathione scavenging and NADPH levels have 
been shown to be reduced in endothelial cells exposed to high glucose (Kashiwagi et 
al. 1996).   
Figure 7.5 Potential mechanisms by which hyperglycaemia and its immediate biochemical sequelae 
induce hyperglycaemic damage (See text for details on selected pathways) (from Schalkwijk and 
Stehouwer 2005) 
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7.5.3. Consequences of oxidative stress in the vascular endothelium: 
cellular damage and apoptosis 
Oxidative stress leads to cellular death and damage directly by causing DNA strand 
breaks and cell death (X. Du et al. 2003) or indirectly by altering expression of 
proapoptotic and antiapoptotic genes. Some of the genes which are activated by 
oxidative stress are those involved in the p38/mitogen activated protein kinase 
pathway, caspase and poly-ADP-ribosyltransferase which lead to cell death (reviewed 
in King et al). Oxidative stress also causes altered DNA biding of transcription factors 
such as nuclear factor kappa beta (NF-κB) and p53, which are responsible for the 
expression of several proapoptotic genes (Marshall et al. 2000; B. Schisano et al. 
2011).  
 
Peroxynitirite (ONOO-), another ROS which is generated by iNOS acting on 
endothelial macrophages and smooth muscle cells, further contributes to cellular 
damage by increasing lipid peroxidation and oxidation of LDL (Griendling and 
FitzGerald 2003). 
 
Figure 7.6 Schematic diagram of pathways that contribute to oxidative stress in response to increased 
glucose flux (See text for details of selected pathways) (from King and Loeken 2004) 
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Hou et al studied the mechanism of ROS-induced apoptosis in endothelial cells and 
found upregulation of Nox 4, an isoform of NADPH oxidase, phosphatase and tensin 
homolog deleted on chromosome 10 (PTEN) expression/phosphorylation and 
caspase-3 proteins in a concentration-dependent manner when exposed to 
hyperglycaemia (Figure 7.7) (Hou et al. 2015). Further experiments with silencing of 
Nox4 and PTEN genes showed that activation of PTEN by ROS led to apoptosis by 
decreasing intergrin-like kinase (ILK) activity, Akt phosphorylation and increasing 
Bcl-2 associated X protein (BAX) expression and caspase activation. However, this 
study showed that PTEN overexpression and caspase-3 activation are the main, but 
not only molecules upregulated by Nox4-induced ROS suggesting that other signaling 
pathways mediating cell damage/apoptosis need to be elucidated.  
 
Oxidative stress is only one of the mechanisms by which hyperglycaemia leads to 
endothelial dysfunction. Other possibilities include direct inhibition of the 
PI3K/phospho-AKT/eNOS pathway (discussed below). 
  
Figure 7.7 Signaling pathways activated by glucose. A) Representative Western blots. Glu20: 20 mM 
glucose. siPTEN: PTEN siRNA transfection; siNox4: Nox4 siRNA transfection. B) Diagram of high 
glucose activated signaling. High glucose increased Nox4 expression and reactive oxygen species 
production. Reactive oxygen species increased PTEN phosphorylation and decreased Bcl-2 expression. 
PTEN- inhibited ILK activity and Akt S473 phosphorylation. The decreases in Bcl-2 expression and Akt 
phosphorylation lead to an increase in Bax expression and activation of caspase-3 (from Hou et al, 2015) 
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7.5.4. PI3K/phospho-Akt signaling pathway 
Activation of receptor tyrosine kinases stimulate PI3K either directly or through 
phosphorylation of intermediate receptors, such as insulin receptor substrate (IRS). 
PI3K then phosphorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to produce 
phosphatidylinositol-3,4,5-trisphosphate (PIP3), and the latter directly phosphorylates 
Akt at Ser(473) and Thr(308), by co-binding with PDK-1 (Manning and Cantley 
2007).  The PIP2 to PIP3 conversion can be reversed by the PIP3 phosphatase PTEN. 
Additionally, PIP3 indirectly phosphorylates Akt at Ser(473) alone by activating ILK.  
 
The PI3K-Akt pathway which is stimulated by insulin, via the insulin receptor 
substrate, plays an essential role in controlling the pleiotropic effects of insulin on 
vascular function (Song et al. 2007). Some of the important downstream effects of 
Akt (and its active phosphorylated form phospho-Akt) on the cells are increasing 
glucose uptake by GLUT-4 translocation and activating mouse double minute 2 
homolog (MDM2) (which is the main negative regulator of p53, an important pro-
apoptotic factor (B. Schisano et al. 2011; Q. Wang et al. 1999)). In relation to 
protecting endothelial cell function, Akt is a powerful activator of eNOS synthesis 
(Dimmeler et al. 1999) and in pathological states such as DM, the eNOS can become 
uncoupled and contribute to formation of reactive nitrogen species (RNS) (Kolluru et 
al. 2012). Figure 7.8 summarises some of the other mechanisms by which of that Akt 
promotes cell survival and proliferation (Manning and Cantley 2007).  
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The generation of ROS contributes to insulin resistance by inhibiting activation of 
IRS by insulin and consequently there is less Akt phosphorylation/activation. Since 
Akt is an important negative mediator of forkhead box class O (FOXO) and the cell 
damage associated with this, one can understand how hyperglycaemia can worsen the 
damage caused by ROS by reducing Akt activation (Ponugoti et al. 2012). The main 
negative regulator of Akt is PTEN and a study has shown that hyperglycaemia causes 
Akt inhibition by liver kinase B1 (LKB1) dependent PTEN activation which is 
mediated by peroxynitrite, a type of RNS (Song et al. 2007). 
 
7.5.5. Phospho-AMPK signaling pathway 
AMPK is activated in situations of increased adenosine monophosphate : adenosine 
triphosphate (AMP:ATP) ratio (e.g. hypoxia, glucose deprivation). It serves to inhibit 
anabolic processes which consume ATP (e.g. fatty acid and protein synthesis) and 
stimulate catabolic ones (e.g. glucose uptake, fatty acid oxidation) (Shirwany and Zou 
2010). Other factors which lead to AMPK stimulation are cytokines (e.g. leptin, 
adiponectin) and drugs such as metformin, thiazolidinediones (Batchuluun et al. 2014; 
Shirwany and Zou 2010). Activation of AMPK is dependent on its phosphorylation 
by either LKB1 (a serine/threonine tumour suppressor kinase) or CaMKK-β 
(calcium/calmodulin-dependent protein kinase kinase-beta). However, the 
Figure 7.8 Cellular Functions of Akt Substrates. Akt-mediated phosphorylation of these proteins leads to 
their activation (arrows) or inhibition (blocking arrows). Regulation of these substrates by Akt 
contributes to activation of the various cellular processes shown (i.e., survival, growth, proliferation, 
glucose uptake, metabolism, and angiogenesis). As illustrated by these ten targets, a high degree of 
functional versatility and overlap exists amongst Akt substrates (see text for details of selected pathways) 
(from Manning and Cantley 2007). 
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downstream targets of AMPK are diverse and yet to be completely elucidated. In 
summary, they include stimulation of lipid metabolism (by downregulating acetyl-
CoA carboxylase) and influencing other cell signaling (e.g. eNOS and IRS-1) (Z. P. 
Chen et al. 1999; Jakobsen et al. 2001).  
 
There is convincing evidence that AMPK has beneficial effects on the vascular 
endothelium, which is mediated in part by the phosphorylation of eNOS on more than 
one site, namely Ser(1177) and Ser(633) (Z. P. Chen et al. 1999; Z. Chen et al. 2009). 
Such AMPK-stimulated eNOS phosphorylation occurs following stimulation by 
VEGF, peroxisome proliferator-activated gamma agonists (e.g. thiazolidinediones), 
AICAR and metformin. Of these, the best studied pathway is AMPK activation by 
metformin, which is mainly PI3K-dependent, although NO may also directly 
stimulate AMPK (Zhang et al. 2008; Zou et al. 2004).  
 
Aside from its effect on eNOS, AMPK has been shown to exert a protective effect in 
the endothelium by inhibiting the production of ROS by NAPDH oxidase and 
reducing activation or signaling by c-JUN N-terminal kinases (JNK), NF-κB and 
VCAM-1 following exposure to oxidants such as H2O2 or TNF-α (Cacicedo et al. 
2004; Dixit et al. 2008; Fisslthaler and Fleming 2009). Additionally, silencing of 
AMPK decreases expression of antioxidants such as SOD and catalase (Colombo and 
Moncada 2009). 
 
Some of the processes associated with endothelial cell apoptosis due to high glucose 
exposure, such as inhibition of fatty acid oxidation, increase in diacylglycerol (DAG) 
synthesis (the precursor of PKC) and reduced insulin mediated phosphorylation of 
Akt were all reduced in the presence of an AMPK activator (Ido et al. 2002). In the 
same experiment, AMPK activation prevented caspase-3 activity, providing further 
evidence of its protective role in hyperglycaemia.  
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7.5.6. Anti-inflammatory effects of GLP-1  
From the clinical studies quoted in Section 7.4.2, it is apparent that the cardiovascular 
benefit of GLP-1 RAs are partly due to direct effects on the myocardium and 
endocardium. Indeed, GLP-1 receptors have been found in both animal and human 
myocardia as well as in parts of the brain involved in autonomic function, such as the 
hindbrain and hypothalamus (Bullock et al. 1996; Wei and Mojsov 1995). Some of 
the cardiovascular benefits of direct GLP-1 activation of the hearts of animal models 
include reduction in left ventricular (LV) end-diastolic pressure, improved LV 
contractility and improved myocardial reperfusion following ischaemia (Gros et al. 
2003; Matsubara et al. 2011). The myocardial protection provided by GLP-1 is in part 
an anti-apoptotic effect mediated through the activation of cAMP and PI3K via its 
binding to the GLP-1 receptor (Buteau et al. 1999). This observation suggests that Akt 
may be an important downstream target of the GLP-1 signaling pathway. However, a 
GLP-1 receptor independent pathway has also been proposed for improved left 
ventricular function after ischaemic injury by causing vasodilatation due to NO 
release (Ban et al. 2008). Animal studies support a role for GLP-1 acting on GLP-1 
receptors to cause renal artery relaxation and reduce systolic blood pressure in 
hypertensive rats, which was mediated by the protein kinase A/AMPK/NO pathway 
(Liu et al. 2012). 
 
7.5.7. Amelioration of endothelial dysfunction by GLP-1 / GLP-1 
receptor agonists 
Endothelial cells have also been shown to possess GLP-1 receptors, which  are 
stimulated by agonists such as Liraglutide (Dai et al. 2013; Ishibashi et al. 2010). 
 
The potential mechanisms by which GLP-1 acts on endothelial cells is summarised in 
Figure 7.9 (Saad et al. 2015). Most of the studies investigating the action of GLP-1 
RA on endothelial cells have attributed its benefits to enhanced eNOS production and 
consequent NO-mediated vasodilatation and anti-inflammatory effects. However, 
other mechanisms such as inhibition of endothelin-1 (a potent vasoconstrictor) and 
decreased cell apoptosis may also be present (Dai et al. 2013; Saad et al. 2015).  
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Initial studies investigating the benefit of GLP-1 RAs on endothelial function showed 
that their antioxidant and anti-inflammatory effects were mediated by inhibition of 
PKC- α translocation to the cell membrane, NADPH-oxidase and NF-κB (Shiraki et 
al. 2012). However in this study, oxidative stress was induced by TNF-α so although 
it provides some insight into the downstream effects of GLP-1 RA’s it cannot be 
ascertained if the same mechanisms are at play in a hyperglycaemia or diabetic 
milieu.  
 
7.6. Next steps 
I will now show, via a prospective case-control study, how GLP-1 levels may be used 
as a biomarker in diagnosing and risk stratifying GDM pregnancies (Chapter 8) and in 
a laboratory project on endothelial cells, possible mechanisms by which liraglutide 
can ameliorate endothelial dysfunction in a hyperglycaemic environment (Chapter 9).  
  
Figure 7.9  Biochemical mechanisms by which GLP-1exerts its protective effect in endothelial cells and 
erythrocyte progenitor cells (EPCs). The ‘+’ signs indicate the pathways that GLP-1 activates and the ‘-’ 
signs ones that it inhibits (see text for details of selective pathways) (from Saad et al 2015). 
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GLP-1 profile during glucose tolerance test in 
gestational diabetes: a prospective case-control study 
  
Chapter 8 
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8.1. Hypothesis and aims 
The hypothesis of this clinical study is that impairment of the GLP-1 response is 
present in women diagnosed with gestational diabetes mellitus (GDM) compared to 
those with normal glucose tolerance (NGT) and that this is particularly associated 
with hyperglycaemia following a glucose tolerance test (GTT). 
 
The primary aim of the study was to determine a difference in GLP-1 response (as 
measured by total area under the curve) between GDM and NGT women during a 2–
hour 75g GTT.  
 
Secondary aims were to examine the GLP-1 profile by half-hourly sampling during 
the GTT, specifically for any differences between GDM cases and controls and 
determine if GLP-1 levels were predictive of high glucose levels 2-hours after a oral 
GTT.  
 
8.2. Methods 
8.2.1. Study design and justification 
A prospective case-control study of pregnant women was conducted with the 
participants recruited during their glucose tolerance test (known as the ‘PRiDE-GLP-
1’ study). 
 
Such a prospective design was thought to be the best study method to answer the 
research questions because, at the time of the GTT and sampling of GLP-1 levels, 
neither the patient nor the research team knew whether she was going to test positive 
for GDM thereby minimising selection bias. Since the primary aim of the study was 
to detect differences in GLP-1 levels between GDM and normal glucose tolerance 
(NGT) women, recruitment of women at the time of their GTT was the optimal time 
point to identify GDM cases and controls. The National Institute for Health and Care 
Excellence (NICE) 2015 selective screening criteria was used to screen high-risk 
pregnant women with a GTT (see Section 8.2.2), which also would minimise 
exposure bias because both cases and controls had similar risk factors for the 
development of GDM.  
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8.2.2. Participant selection 
The pregnant women for this study were recruited from the larger cohort of the 
‘Micronutrients in pregnancy as a risk factor for gestational diabetes and effects on 
mother and baby’ (PRiDE Study) cohort. The primary research question of the PRiDE 
study is, “what is the role of B12, folate and homocysteine on the risk of GDM and 
markers of metabolic disease in the offspring?”. It is a prospective longitudinal cohort 
in early pregnancy (n=4500) of two ethnic groups who are at high metabolic risk and 
are eligible to undergo a GTT at 24-28 weeks gestation. Detailed pheno- and 
genotyping of mothers (history, anthropometry, psychological well-being, blood and 
urine sampling) and neonates (anthropometry, cord blood, cord and placenta) is being 
done. The advantage for conducting my study on the cohort of women already 
enrolled in PRiDE is that these women and their infants are very well characterised 
throughout pregnancy, which will enable me to study several secondary outcomes that 
are potentially relevant to GLP-1 profile and glycaemia in pregnancy. 
 
I conducted the PRiDE GLP-1 study over a 2-year period (October 2014 to September 
2016) in 2 NHS Trusts in the West Midlands (George Eliot Hospitals NHS Trust and 
University Hospitals of Coventry and Warwickshire). The Participant Information 
Sheet and Consent form are provided in Appendix 3.1-3.2. The inclusion criteria for 
selection of participants for this study are:- 
x Pregnant women between 15 and 30 weeks gestation 
x Age 18 – 45 years 
x High-risk group for GDM (at least 1 of the following risk factors): BMI >30 kg/m2; 
previous GDM; previous unexplained still birth or baby >4.5kg; first degree relative 
with diabetes, ethnic minority group (South Asians, Middle-Eastern, Afro-
Caribbean), age >35 years 
The abovementioned definition of high-risk group for GDM is derived from the NICE 
2015 guidelines and is used by several NHS Trusts in the country (National Institute 
for Health and Care Excellence 2015a) . According to a report from the Office of 
National Statistics in 2014, the proportion of older women having babies has been 
steadily rising in the last 4 decades, which was the reason for expanding the inclusion 
criteria to include pregnant women up to 45 years (Office for National Statistics 
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2015). Since older age is also an independent risk factor for GDM, this age range 
would additionally identify women with the highest risk of the condition.  
 
Exclusion criteria are as follows 
x Pre-gestational diabetes mellitus (Type 1 or 2) 
x Multiple pregnancies 
x Withdrawal of consent from the parent PRiDE study during the GTT 
 
Pregnant women meeting the eligibility criteria were approached for the study when 
they attended for their GTT. I explained the study to them in person and provided the 
participant information sheet. Informed written consent was obtained before 
proceeding with the blood collection. 
 
The timing of the GTT, and thereby recruitment into the PRiDE GLP-1 study, was in 
accordance with the NICE 2015 guidelines. It recommends that pregnant women 
meeting the selective screening criteria be offered a 75g oral GTT at 24-28 weeks 
gestation except if the women had a diagnosis of GDM in a previous pregnancy as a 
risk factor. In that subgroup of patients, the guidelines state recommend either self-
monitoring of capillary blood glucose from early pregnancy or an ‘early GTT’ soon 
after booking. Therefore some women in my cohort were recruited during their ‘early 
GTT’ but if that was normal, the women were still offered a second GTT at the later 
gestation.  
 
8.2.3. Blood sampling protocol 
The GTT protocol involves women attending the maternity department in the morning 
after fasting for at least 10 hours the previous night (plain water only is permitted). A 
fasting blood test for serum glucose was obtained followed by the consumption of 
200ml of Procal (containing 75g of anhydrous glucose) over a maximum of 2 
minutes. The women were then asked to sit in the waiting room of the antenatal clinic 
before another serum sample for glucose was taken at 2 hours.  
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For the women who had consented to take part in the GLP-1 study, a 22G or 24G 
cannula was inserted in the fasting state. Blood samples for plasma (to measure GLP-
1 and other gut hormones, such as GIP and glucagon) and serum (to measure glucose 
and insulin) were drawn from this intravenous cannula a t=0, 30, 60, 90 and 120 
minutes of the GTT. At each time point, around 5mls of blood was obtained which 
was divided equally into 1 plasma and 1 serum tube. The tubes were centrifuged at 
2000 rpm for 15 minutes at room temperature within 5 minutes of collection and 
separated into 2 aliquots each of plasma and serum. These aliquots were kept in a 4oC 
fridge until the end of the GTT, when they were transferred to a -80oC freezer for 
storage until analysis.  
 
Due to the short half-life of plasma GLP-1 (T1/2 4 – 24 hours in a ethylene diamine 
tetra-acetic (EDTA) tube at room temperature) (Adaikalakoteswari et al. 2015b), 40ul 
of a DPP-4 inhibitor, Diprotin A (Enzo LifeSciences, catalogue number ALX-260-
036), was added to each EDTA blood tube (final concentration 40ul/ml plasma or 
0.1mmol/ml). Addition of the DPP-4 inhibitor has been shown to prolong the T1/2 to 
over 96 hours which will ensure preservation of the peptides for future analysis 
(Adaikalakoteswari et al. 2015b). Appendix 3.3 has more details on the preparation of 
Diprotin A, plasma tubes and blood collection protocol for this study.   
 
The diagnosis of GDM was made according to the NICE 2015 criteria: fasting plasma 
glucose (glucose0min) ≥ 5.6 mmol/l or 2-hour plasma glucose (glucose120min) ≥ 7.8 
mmol/l (National Institute for Health and Care Excellence 2015a). Women who tested 
positive were contacted and seen by the diabetes specialist midwife within 3 days of 
their GTT and were managed in a joint obstetric-diabetes antenatal clinic for the 
remainder of their pregnancy. Women whose GTT results were negative followed 
routine care.  
 
  127 
8.2.4.  Data collection and anthropometry measurement 
Baseline demographic characteristics, anthropometric measurements and neonatal 
birth data were obtained from the parent PRiDE study database. A detailed medical 
history was recorded during recruitment into the study at 8 to 12 weeks gestation. 
Maternal weight was recorded using digital scales at baseline and during the GTT and 
gestational weight gain (GWG) between these 2 time-points calculated. Waist 
circumference was measured at baseline using a tape measure and triceps and 
subscapular skinfold thickness via calipers at both visits.  
8.2.5.  Laboratory analysis 
Analysis of glucose was done by a hexokinase enzymatic method in the hospital 
laboratory. Plasma samples were stored at -80oC until the end of the study when they 
were transferred to University of Copenhagen for analysis of GLP-1 on dry ice. A 
radioimmunoassay (RIA), which has been well-developed and previously described 
by Professor Jens Holst and colleagues, was used for the analysis of GLP-1 (Orskov 
et al. 1994; M.-B. Toft-Nielsen et al. 2001a). Briefly, the amidated forms of GLP-1, 
namely the bioactive GLP-1 (7-36) and its N-terminal truncated metabolite GLP-1 (7-
37) were measured against standards of synthetic GLP-1 (7-36) using antibody (code 
number 89390) (M.-B. Toft-Nielsen et al. 2001a). Since these standards are specific 
for the amidated C-terminus of the hormone, they do not cross react with other GLP-1 
containing peptides from the pancreas. It is essential to determine the concentrations 
of both intact GLP-1 (7-36) and the inactive (7-37) metabolite because of the rapid 
degradation of the former. The detection limit of the assay is 1pmol/l and intra-assay 
and inter-assay coefficient of variation less than 6% at 20 pmol/l and 10% 
respectively.  
 
8.2.6. Statistical analysis 
There have been 2 studies which compared GLP-1 AUC between GDM and NGT 
population (Table 7.1, discussed in more detail below) (Bonde et al. 2013; Lencioni et 
al. 2011). The first one found a non-significant 25% lower mean AUC in GDM 
compared to NGT women (Bonde et al. 2013). However, this was measured at a 4 
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hour liquid meal test which is not easily reproducible in a clinical setting. The other 
study found a non-significant 10.4% lower mean AUC in GDM than NGT women 
during a 100g 3-hour GTT(Lencioni et al. 2011). 
 
To demonstrate a 25% lower mean AUC for GLP-1 in GDM compared to control 
with 80% power at 5% significance (2-tailed), the estimated sample size is 20 cases. 
In the PRiDE study, the detection rate of GDM was around 15% during GTT so I will 
planned to recruit 133 women into the study during their GTT. 
Total area under the curve (AUC) for GLP-1 was calculated using the trapezoidal rule 
and incremental AUC calculated as the change from baseline GLP-1 levels. 
 
Statistical analysis was performed using SPSS version 22.0 (IBM Corp Released 
2013). BMI, and glucose values were log-transformed for statistical purposes as they 
were no normally distributed. For comparison of baseline characteristics of GDM and 
NGT women, the Student’s t-test was used for continuous variables (e.g. BMI, age, 
gestational weight gain) and the chi-square test for categorical variables. Comparison 
of detailed anthropometry, glucose variables and GLP-1 parameters between cases 
and controls was done by analysis of variance (ANOVA) after adjusting for 
confounders. Stepwise multiple linear regression was performed with glucose120min as 
the dependent variables with the predictors entered or removed from the model 
according to the following criteria: probability of F Probability-of-F- to-enter ≤0.050, 
Probability-of-F-to-remove ≥0.100. The regression models included the following co-
variates: age, BMI, ethnicity and smoking as standard. Where appropriate, other 
variables such as fasting glucose and gestation of bloods when evaluating associations 
of glucose120min or GLP0min when GLP30min was entered as a predictor of glucose120min 
were added to the models.   
 
8.2.7.  Ethics approval 
Ethical approval from the National Research Ethics Committee (South Birmingham) 
(see Appendix 3.4) and permissions from the local Research and Development 
departments of the 2 NHS trusts where the study was conducted were obtained prior 
to commencement of the study.  
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8.3. Results 
8.3.1. Selection of GDM cases and controls 
A total of 145 women were recruited into the study but one woman did not complete 
the GTT due to vomiting. Therefore data from 144 women, from whom complete 
glucose values at 0 and 120 minutes were available, was used for analysis. Their 
mean (±SD) age was 29.5 ± 4.7 years and mean first trimester BMI 32.5 ± 8.13 
kg/m2.  
 
The selection of cases and controls for this study is summarised in Figure 8.1. The 
pre-study intention was to analyse GLP-1 response in the lowest and highest quartile 
for glucose120min (n=35 and n=38 respectively). However, I excluded 15 outliers with 
unexpectedly low glucose120min results (defined as the lowest 10th centile for 
glucose120min, range 2.7 to 3.9 mmol/l) from further analysis. This was on the basis 
that there could have been a laboratory error in measuring the glucose values (since 
these results were obtained from routine measurements in the NHS Trusts) or the 
possibility that some of these women may have exaggerated insulin responses which 
may be pathological. 
 
 
Recruited into PRiDE GLP-1 study (n=145) 
Complete GTT results available (n=144) 
Diagnosis of GDM (n=22) 
GDM ‘cases’ (n=19) 
Final cohort available for analysis of GLP-1 results (n=129) 
No diagnosis of GDM (n=107) 
NGT ‘controls’ (n=19) 
Highest quartile for glucose120min [range 6.8-7.8mmol/l] 
(n=19)  
Excluded: isolated fasting 
hyperglycaemia (n=3) 
NGT ‘controls’ (n=19) GDM ‘cases’ (n=19) 
Excluded: incomplete GTT 
(n=1) 
Excluded: Outlying lowest 10th centile of 
glucose120min [range 2.7-3.9 mmol/l] (n=15) 
Primary 
analysis (n=38) 
Secondary 
analysis (n=57) 
Figure 8.1 Flow diagram illustrating the selection of gestational diabetes mellitus (GDM) and normal glucose tolerance (NGT) controls for the 
primary and secondary analyses of the study   
  130 
 
Of the remaining 129 women, 22 women were diagnosed with GDM using the NICE 
2015 criteria and their mean (±SD) fasting and 2-hour post-challenge glucose values 
were 5.15 ± 1.02 and 8.45 ± 2.00 mmol/l respectively. The corresponding GTT results 
from the remaining 122 women were 4.33 ± 0.33 and 5.40 ± 1.19 mmol/l 
respectively. 
 
Out of the 22 cases of GDM diagnosed, 19 had glucose120min at or above the 
diagnostic threshold of 7.8 mmol/l and were labelled as ‘GDM cases’ for purposes of 
this study. The 0 and 120 minute glucose values of the other 3 women were 7.2 and 
3.3 mmol/l, 5.9 and 4.9 mmol/l and 6 and 5.9 mmol/l respectively. These 3 women 
were not considered as having GDM for purposes of this study for the following 2 
reasons: 1) isolated fasting hyperglycaemia in pregnancy is likely to have a different 
pathogenesis from the insulin resistance typically seen in GDM [(Chakera et al. 2015; 
S. J. Yang et al. 2013) and 2) the hypothesis of this study is that reduced GLP-1 
response is responsible for impairment insulin secretion or action following a glucose 
load thereby leading to post-load hyperglycaemia.  
 
The 19 cases of GDM had glucose120min values between 7.8 and 12.1 mmol/l. The 
controls were made up of 19 women in the lowest quartile with glucose120min values 
above 4.0 mmol/l (range of glucose120min: 4.0 to 4.5 mmol/l inclusive) and are referred 
to the normal glucose tolerance (NGT) group. The cut-off of 4.0 mmol/l was 
determined after excluding the outliers in the lowest 10th centile as described above.  
 
It has been shown in several studies that the morbidity associated with GDM is 
continuous with increasing glucose values with no clear threshold effect (Hapo Study 
Cooperative Research Group et al. 2008). This is partly the reason that there are 
several diagnostic criteria for GDM in use across the world with no definite consensus 
(International Association of et al. 2010; Meek et al. 2015). Thus, a secondary aim of 
this study was to measure how the GLP-1 response varied with glucose120min as a 
continuous variable.  We measured the GLP-1 levels of the additional 19 women who 
were in the highest quartile of glucose120min values but did not meet the threshold for 
GDM diagnosis (range of glucose120min: 6.8 to 7.7 mmol/l). Therefore, the total 
sample size used for the secondary GLP-1 analysis was 57.  
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8.3.2. Characteristics of GDM and NGT women at baseline and during 
GTT 
The baseline characteristics of the 38 women (19 GDM, 19 NGT) included in the 
primary outcome analysis are presented in Table 8.1. This data was recorded in the 
late 1st trimester (mean gestation 12+1 weeks). The mean (±SD) age of the women was 
29.0 ± 4.93 years, 13.9% were smokers and 81.6% of White Caucasian (or white 
European) origin, with no significant difference in any of these parameters between 
the 2 groups.  
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Table 8.1 Baseline participant characteristics according to GDM status 
Variables GDM NGT p-value 
Number 19 19   
Age (yrs) 29.5 ± 5.2 28.4 ± 4.7 NS 
Baseline weight 100.1 ± 19.2 81.2 ± 16.6 0.003 
Body mass index (kg/m2)  37.6 ± 8.1 29.1 ± 5.3 0.001 
Triceps thickness (mm) 30.0 ± 5.9 27.7 ± 8.1 NS 
Subscapular thickness (mm) 32.7 ± 7.7 27.7 ± 8.2 NS 
Waist circumference (cm) 115.6 ± 16.5 96.0 ± 12.9 <0.001 
Current smokers (%)  4 (21.1) 1 (5.9) NS 
Ethnicity (%)       
European 17 (89.5) 14 (82.4) NS 
South Asian 2 (10.5) 2 (11.8)   
Afro-Caribbean 0 1 (5.9)   
Table showing the baseline characteristics and anthropometry of GDM and NGT women recorded in early pregnancy (mean ± SD gestation 85.2±14.5 days, 
12+1 weeks). Continuous variables are mean ± SD, categorical variables are percentages. Comparisons done by Student's t-test (for continuous variables) or 
Pearson ci-square test (for categorical variables). GDM: gestational diabetes mellitus, NGT: normal glucose tolerance, NS: non-significant 
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Table 8.2 Participant characteristics and glucose values according to GDM status during GTT 
Variables GDM NGT p-value Adj p-valueBMI, age, ethnicity, smoking 
Gestation of GTT (weeks) 26±6 (15+6, 30+2) 26±6 (15+6, 29+5) NS   
Gestational weight gain (kg) 3.44 ± 3.82 5.94 ± 3.31 0.05 NS 
Triceps thickness (mm) 34.2 ± 4.5 27.4 ± 8.6 0.01 NS above + early pregnancy triceps thickness 
Subscapular thickness (mm) 34.9 ± 4.5 26.1 ± 6.5 <0.001 NS above + early pregnancy subscapular thickness 
Glucose0min (mmol/l) § 4.95 ± 0.94 4.18 ± 0.27 0.002 NS 
Glucose120min (mmol/l) § 9.04 ± 1.34 4.29 ± 0.15 <0.001 <0.001above +fasting glucose 
Participant characteristics and anthropometry at recruitment into PRiDE GLP-1 study (during 75g 2-hour GTT). Data are mean (±SD) or median (range). Comparison of 
means by Student's t-test or ANOVA after adjustment for covariates (age, BMI, ethnicity, smoking and where appropriate triceps and subscapular skinfold thickness and 
glucose0min). GTT: glucose tolerance test, GDM: gestational diabetes mellitus, NGT: normal glucose tolerance, NS: non-significant, BMI: body mass index 
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The women who went onto develop GDM had a higher baseline weight and BMI than 
the controls, which was not unexpected (100.1 ± 19.2 vs. 81.2 ± 16.6 kg, p=0.003 and 
37.6 ± 8.1 vs. 81.2 ± 16.6 kg/m2, p=0.001). The former group also had a higher waist 
circumference (115.6 ± 16.5 vs. 96.0 ± 12.9 cm, p<0.001) although other 
anthropometry (e.g. triceps and subscapular skinfold thickness) did not differ.  
 
Both groups of women had their GTT (and GLP-1 blood sampling done) at a median 
of 26+6 weeks and the results are summarised in Table 8.2. Fasting glucose was 
marginally higher in the GDM group than NGT (4.95 ± 0.94 vs. 4.18 ± 0.27 mmol/l, 
p=0.002) but the difference lost significance after correcting for age, BMI, ethnicity 
and smoking. However the mean glucose level 2 hours after the GTT was 
significantly higher in the former group even after adjusting for co-variates, including 
fasting glucose (9.04 ± 1.34 vs. 4.29 ± 0.15 mmol/l, p<0.001). Other anthropometry 
(gestational weight gain, triceps and subscapular skinfold thickness) were all higher in 
the GDM group although any observed difference became insignificant after 
adjustment, likely due to the effect of BMI as a confounder.  
 
8.3.3. GLP-1 profile of GDM and NGT women 
The results of the GLP-1 measurements of GDM and NGT women at the time of GTT 
are presented in Table 8.3. The GLP-1 concentrations at 0, 30, 60, 90 and 120 minutes 
of the GTT are referred to as GLP0min, GLP30min, GLP60min, GLP90min and GLP120min 
respectively.  
Table 8.3 Results of GLP-1 response during GTT according to GDM status 
Variables GDM NGT p-value Adjusted p-value 
GLP0min (pmol/l) 13.6 ± 4.46 15.7 ± 4.08 NS NS 
GLP30min (pmol/l) 15.9 ± 3.89 19.8 ± 4.52 0.01 0.041 
GLP60min (pmol/l) 18.1 ± 4.96 20.6 ± 4.44 NS NS 
GLP90min (pmol/l) 18.3 ± 4.49 20.2 ± 4.84 NS NS 
GLP120min (pmol/l) 18.2 ± 4.61 18.8 ± 4.66 NS NS 
Mean GLP (pmol/l) 16.8 ± 3.33 18.8 ± 3.23 NS NS 
Total AUC (pmol/l.120min) 2024 ± 422 2321 ± 408 0.036 0.048 
Incremental AUC (pmol/l.120min) 384 ± 464 427 ± 474 NS NS 
Participant characteristics and anthropometry at recruitment into PRiDE GLP-1 study (during 75g 2-
hour GTT). Data are mean (±SD), comparison of means by Student's t-test or ANOVA after adjustment 
for covariates (age, BMI, ethnicity and smoking). GTT: glucose tolerance test, GDM: gestational 
diabetes mellitus, NGT: normal glucose tolerance, NS: non-significant, AUC: area under the curve 
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Mean GLP0min concentrations did not differ between the 2 groups. However GDM 
women had 19.7% lower mean GLP30min concentrations than NGT women, which 
remained significant even after adjusting for age, BMI, ethnicity and smoking (15.9 ± 
3.89 vs. 19.8 ± 4.52 pmol/l, p=0.01 and adjusted p=0.04) (Table 8.3, Figure 8.2). The 
former group had a tendency to lower GLP-1 levels at 60, 90 and 120 minutes as well 
although none of these results reached statistical significance.  
 
 
Other markers of the GLP-1 response which were calculated from the individual 
levels at the 5 time points were the mean overall GLP-1 concentration, total AUC for 
GLP-1 response and incremental AUC from basal. These results are presented in 
Table 8.3 and Figure 8.3 (a) – (c). The overall GLP-1 response to a glucose challenge 
as measured by total AUC was 12.8% lower in GDM women than controls, which 
weakened but still remained significant after adjusting for confounders (2024 ± 422 
vs. 2321 ± 408 pmol/l.120min, p=0.036, adjusted p=0.048). The other 2 parameters 
measured were non-significantly lower in GDM than NGT. 
 
Figure 8.2 Line chart of the plasma GLP-1 concentrations during a glucose tolerance test (GTT) in women diagnosed with gestational diabetes 
mellitus (GDM, red diamonds) and normal glucose tolerance (NGT, blue squares). The points represent the mean (±SEM) plasma GLP-1 
concentration measured at 30 minute intervals during a 2-hour 75g GTT. *: p<0.05   
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8.3.4. GLP-1 as a predictor of glucose120min  
To determine if the GLP-1 response reduces linearly with increasing glucose levels, 
we considered a larger cohort of 57 women who had all the relevant parameters 
analysed. On bivariate correlation, glucose120min was negatively associated with 
GLP30min and total AUC (Pearson’s r -0.29, p=0.04 and -0.34, p=0.01 respectively) 
(data not shown).  However there was no association with GLP0min, GLP60min, 
GLP90min and GLP120min or mean GLP-1 levels. There was also no correlation with any 
of the above GLP-1 parameters and glucose0min confirming that GLP-1 only 
influences glycaemic control in response to an oral glucose load.  
 
The next step was to examine if the negative associations between glucose120min and 
the GLP-1 variables remained after correcting for confounders. The results of the 
multiple linear regression analysis with glucose120min as the dependent variable are 
presented in Tables 8.4 (a) to (c). In a model with total AUC, only that and 
glucose0min  predicted glucose120min after adjusting for age, BMI, ethnicity, smoking 
and gestation of GTT (Table 8.4 (a)). However, when gestational weight gain was 
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Figure 8.3 Bar charts of 3 markers of GLP-1 response during a glucose tolerance test (GTT) in pregnant women diagnosed with gestational 
diabetes mellitus (GDM) and those with normal glucose tolerance (NGT). A) Mean of 5 GLP-1 levels measured at 30 minute intervals during a 
2-hour GTT; B) total area under the curve (AUC) of GLP-1 response calculated using trapezoidal rule; C) incremental AUC calculated as AUC 
above basal. Data are mean + SEM. *: p<0.05 
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added to the model, the former lost significance. A similar observation was found for 
GLP0min with the exception that the association strengthened after adjusting for 
gestational weight gain (β-coefficient -0.25, p=0.04 and p=0.02 in the 2 models 
respectively) (Table 8.4 (b)). In the regression analysis with GLP30min, GLP0min was 
also added as a co-variate because I was interested in looking at GLP30min as an 
independent variable. The results confirmed the independent negative association 
with glucose120min, with a stronger effect size than the abovementioned 2 GLP-1 
parameters (β-coefficient -0.31, p=0.02 before and after adding gestational weight 
gain into the model). GLP-1 levels at 60, 90 or 120 minutes were not associated with 
glucose120min in any of the models and neither was mean GLP-1 levels (data not 
shown). 
 
Table 8.4 (a) - (c) Multiple regression analysis of predictors of Glucose120min using 
various GLP-1 parameters as co-variates1 
a) Total AUC 
    Predictors of Glucose120min § B-coefficient2 Standardised β2 p-value3 p-value4 
Glucose0min § 1.18 0.49 < 0.001 < 0.001 
Total AUC -8.40-5 -0.25 0.047 0.08 
Age - - NS NS 
BMI § - - NS NS 
Ethnicity - - NS NS 
Smoking - - NS NS 
Gestation of GTT - - NS NS 
     b) GLP0min 
    Predictors of Glucose120min § B-coefficient Standardised β p-value3 p-value4 
Glucose0min § 1.25 0.52 <0.001 <0.001 
GLP0min -0.01 -0.25 0.039 0.021 
Age - - NS NS 
BMI § - - NS NS 
Ethnicity - - NS NS 
Smoking - - NS NS 
Gestation of GTT - - NS NS 
     c) GLP30min 
    Predictors of Glucose120min § B-coefficient Standardised β p-value3 p-value4 
Glucose0min § 0.96 0.40 0.003 NS 
GLP30min -0.01 -0.31 0.017 0.016 
BMI § 0.535 0.435 NS 0.002 
Age - - NS NS 
Ethnicity - - NS NS 
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Smoking - - NS NS 
Gestation of GTT - - NS NS 
GLP0min - - NS NS 
Tables showing multiple linear regression results of the predictors of Glucose120min using 3 
parameters of GLP-1 measurements as co-variates: a) Total AUC, b) GLP0min and c) GLP30min  
1: sample size is n=57 from the total cohort who had complete GTT and GLP-1 results measured 
2: unstandardised B and standardised β-coefficients are with reference to model 3 unless stated otherwise 
3: Model includes glucose0min, BMI, age, ethnicity, smoking, gestation as additional co-variates (plus 
GLP0min for the GLP30min analysis) 
4: As for Model 3 + gestational weight gain 
5: Unstandardised B and standardised β-coefficients are from model 4 
§: log-transformed for statistical comparison, -: tested but not significant in the model, NS: non-
significant, BMI: body mass index, GTT: glucose tolerance test 
 
 
8.3.5. Variables associated with thresholds of GLP-1 parameters 
Since there is no data on what constitutes an adequate GLP-1 response or optimal 
levels, I was interested to find out if there were any factors associated with different 
thresholds of GLP-1. I selected GLP30min and total AUC to examine this since they 
were the 2 which had the strongest link to glycaemia in the previous analyses. These 
women were divided into 2 groups based on the median of these 2 parameters and the 
variables compared between the women with GLP30min and total AUC below and 
above the median are shown in Tables 8.5 (a) and (b). Glucose120min, was significantly 
higher in women total AUC and GLP30min in the lower half of the distribution 
confirming the inverse relationship between them. Lower total AUC levels seemed to 
have a stronger relationship with impaired post-prandial glycaemia on the basis that 
the difference remained significant after adjusting for confounders. Other maternal 
factors, including fasting glucose, BMI, waist circumference, skinfold thickness and 
gestational weight gain did not show any associations. 
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Table 8.5 (a) - (b) Maternal anthropometry and glucose results according to thresholds of GLP-1 parameters1 
a) Total AUC split by median 
         Total AUC below median Total AUC above median p-value Adj p-value2 Adj p-value3 
  Glucose0min § 4.68 ± 0.611 4.51 ± 0.78 NS NS NS 
  Glucose120min § 7.43 ± 1.98 6.12 ± 2.17 0.015 0.037 NS 
  BMI (kg/m2) § 32.9 ± 7.33 33.5 ± 8.14 NS NS NS 
  Waist circumference (cm) 106.2 ± 16.23 105.9 ± 16.86 NS NS NS 
  Triceps skinfold thickness (mm) 26.9 ± 7.25 29.6 ± 6.97 NS NS NS 
  Subscapular skinfold thickness (mm) 29.8 ± 9.84 29.7 ± 8.66 NS NS NS 
  Gestational weight gain (kg) 4.7 ± 4.27 5.1 ± 3.22 NS NS NS 
   
b) GLP30min split by median 
       GLP30min below median GLP30min above median p-value Adj p-value2 Adj p-value3 
Glucose0min § 4.65 ± 0.51 4.50 ± 0.79 NS NS NS 
Glucose120min § 7.25 ± 1.55 6.32 ± 2.34 0.041 NS NS 
BMI (kg/m2) § 34.5 ± 8.38 32.7 ± 8.39 NS NS NS 
Waist circumference (cm) 109.1 ± 16.31 104.5 ± 18.35 NS NS NS 
Triceps skinfold thickness (mm) 27.3 ± 7.63 29.7 ± 6.69 NS NS NS 
Subscapular skinfold thickness (mm) 30.2 ± 9.51 29.1 ± 8.70 NS NS NS 
Gestational weight gain (kg) 4.1 ± 4.29 5.8 ± 3.40 NS NS NS 
Table of maternal anthropometry (recorded in early pregnancy) and glucose results (from GTT) in participants according to thresholds of (a) total AUC of GLP-1 and (b) 
GLP30min. Data are mean (±SD), comparison of means by Student's t-test or ANOVA after adjustment for covariates. 
1: sample size is n=57 from the total cohort who had complete GTT and GLP-1 results measured 
2: Model adjusted for BMI, age, ethnicity and smoking 
3: As for model 2 plus gestational weight gain 
§: log-transformed for statistical comparison, AUC: area under the curve, NS: non-significant, BMI: body mass index, GTT: glucose tolerance test 
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8.4. Discussion 
Main findings 
The analysis of GLP-1 profile in GDM and hyperglycaemia of pregnancy reveal 3 key 
findings:- 1) Overall GLP-1 response as measured by total AUC reduced by 13% in 
GDM compared to NGT pregnancies; 2) There seems to be an early impairment or 
‘delay’ in GLP-1 secretion during the GTT in GDM (as shown by 20% lower 
GLP30min levels) and 3) Lower GLP-1 concentrations at baseline or 30 minutes after a 
consuming glucose load independently predict higher glucose levels at 2 hours. 
 
Comparison with other studies in GDM  
3 of the 6 studies which investigated GLP-1 response or the incretin effect during 
GDM pregnancy reported mean and/or total AUC for GLP-1 (see summary table in 
Chapter 7, Table 7.1) (Bonde et al. 2013; Cypryk et al. 2007; Lencioni et al. 2011). Of 
these, Bonde et al found a non-significant decrease of 25% in the 3rd trimester of 
pregnancy compared to NGT. This result is in keeping with that found by our study 
but the magnitude of difference we found was lower at 13%. Possible reasons for this 
variance are that 1) a smaller sample size (the study was powered to detect a 
difference in GLP-1 response in GDM women between pregnancy and post-partum), 
2) different glucose load used and 3) longer duration of sampling (4 hours vs. 2 hours 
in our study). It has been shown previously that mixed meal load is a stronger 
stimulus for incretin release (but not GLP-1) than an isolated glucose load possibly 
because of its higher fat and protein content (Vollmer et al. 2008). 
 
The studies by Lencioni et al and Cypryk et al found no difference in the total 
response of GLP-1 of GDM women during a 3-hour 100g and 75g GTT respectively 
(Cypryk et al. 2007; Lencioni et al. 2011). In the Lencioni et al study, mean GLP-1 
values were lower only at 180 minutes in GDM compared to NGT (37.1 vs. 27.6 
pmol/l, p<0.05). However it should be noted that the authors only sampled GLP-1 at 
0, 60, 120 and 180 minutes of the GTT thereby any potential lowering of GLP-1 at 30 
minutes, which was observed in our cohort, would have been missed. This study 
reported lower first phase insulin secretion and the related insulin sensitivity-secretion 
index in GDM women (discussed in detail in the following section) but this should be 
interpreted with caution because the authors of the original formula have stated that 
the optimal sampling time to estimate first phase insulin secretion should include 
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insulin data at 30 minutes (Stumvoll et al. 2001). Therefore it may not be possible to 
draw any conclusions from this study about the relationship between the early GLP-1 
impairment, which was observed in our study and impaired insulin secretion.  
 
Lencioni and colleagues also did not find any correlation between GLP-1 AUC and 
maternal factors such as age or BMI, which was in keeping with our results. Previous 
studies which have found a positive relationship between GLP-1 concentrations and 
BMI in non-pregnant adults have measured GLP-1 levels across a range of BMIs (E. 
Muscelli et al. 2008a; M.-B. Toft-Nielsen et al. 2001a). Therefore the result cannot 
necessarily be extrapolated to our cohort of pregnant women since the majority of 
them were obese due to the selective screening criteria used for GTT although the 
GDM women were heavier (mean BMI 37.6 vs. 29.1 kg/m2 in GDM and NGT 
women respectively). In our study, there was no correlation between BMI or other 
surrogate markers of obesity (e.g. waist circumference, skinfold thickness) and any of 
the GLP-1 indices.  
 
Fasting GLP-1 levels in GDM pregnancies continues to be controversial. While 
Bonde et al found this to be nearly 30% lower in glucose intolerant women, our study 
found a non-significant 13% lowering. However, Cypryk and colleagues and Reyes-
Lopez and colleagues both noted significantly higher fasting GLP-1 in GDM women 
(Cypryk et al. 2007; Reyes-Lopez et al. 2014). Type 2 diabetic patients have lower 
fasting GLP-1 levels, which was in turn associated with higher baseline insulin 
concentrations and HbA1c, regardless of the duration of diabetes (Legakis et al. 
2003). Interestingly, higher fasting GLP-1 levels may be metabolically protective in 
glucose tolerant adults where it is positively associated with resting energy 
expenditure and substrate oxidation (Pannacciulli et al. 2006). Taken together, these 
findings suggest that fasting GLP-1 concentrations are expected to be decreased in 
GDM pregnancies and the finding by Cypryk et al and Reyes-Lopez et al may be 
outliers.  
 
Kosinski et al did not measure GLP-1 levels in their study of 10 GDM women and 8 
NGT controls but did detailed studies (4-hour GTT and isoglycaemic intravenous 
glucose infusion) to measure the incretin effect and gastrointestinal-induced glucose 
disposal (GIGD) (Kosinski et al. 2013). They showed that the incretin effect as 
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measured by AUC for insulin and C-peptide were not reduced in GDM compared to 
NGT mothers. However GIGD, which is a measure of the amount of glucose 
preferentially cleared by the oral route (largely by activating incretin hormones) (J. J. 
Holst et al. 2016) were reduced to levels similar to diabetic patients in GDM (37±3 
vs. 48±3%, p=0.04).  
 
The 5th study by Gonzalez et al only measured a random GLP-1 concentration during 
delivery in 15 GDM women (Gonzalez et al. 2011) so their findings cannot be 
directly compared with those of my study and others in pregnancy which looked at the 
response of GLP-1 to an oral glucose or mixed meal load. Additionally, this was the 
only study to measure GLP-1 by an electrochemiluminescent assay (ELISA), which 
detects only the active GLP-1 forms (namely 7-36 and 7-37). Therefore, timely 
addition of DPP-4 inhibitors is crucial to prevent degradation of active GLP-1. A 
comparative study has shown relatively weak correlation between the ELISA 
technique and the RIA method used in our study (r=0.39, p<0.05) (Heijboer et al. 
2011).  
 
Consequences of impaired early phase insulin secretion in non-pregnant adults 
A novel finding of my study is a particular time point of lower GLP-1 response (i.e. 
GLP30min) seems to be linked to adverse outcomes, namely decreased levels in GDM 
vs. NGT after adjustment for confounders and additionally as an negative predictor of 
post-challenge glucose as a continuous variable. The latter observation was found in a 
range of glucose120min values below the threshold of GDM diagnosis. I will now 
discuss the implications of impaired early phase GLP-1 secretion and its potential 
relevance to impaired insulin secretion in impaired glucose tolerance (IGT) and 
GDM.  
 
First-phase insulin secretion is typically defined as the acute insulin response after an 
intravenous glucose load but because that can be cumbersome to perform, various 
calculations such as the Stumvoll formulae have been developed and validated to 
estimate it after an oral glucose load. The Stumvoll calculation takes into 
consideration fasting glucose and insulin at 0 and 30 minutes to estimate the early 
insulin response (Stumvoll et al. 2000). Impairment in the first phase of insulin 
secretion has been shown to be one of the earliest detectable abnormalities in adults 
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who are predisposed to develop T2DM (Gerich 2002; Weyer et al. 1999) and 
independently predicts conversion from NGT to T2DM (Y. Sun et al. 2016). The 
decrease in first-phase insulin secretion may be due to a reduction in beta-cell mass 
due to ageing or genetic factors (Szoke et al. 2008; Vaag et al. 1995). However, in 
adults with IGT, it has been shown to be compromised to a greater degree than the 
second phase insulin secretion during a hyperglycaemic clamp experiment (Szoke et 
al. 2008), suggesting that it be involved in the primary pathogenesis of insulin 
resistance  
 
The insulinogenic index, defined as the incremental change in insulin concentrations 
at 30 minutes of a GTT divided by the change in glucose at 30 minutes in the same 
time period is an surrogate of the early insulin response and beta-cell function 
(Wareham et al. 1995). In a large study of over 5000 Japanese adults, the 
insulinogenic index of people with isolated IGT was significantly lower than those 
with isolated impaired fasting glucose (IFG) and it was the strongest independent 
predictor of glucose120min in patients with IGT (β-coefficient -0.29, p<0.0001) while 
glucose0min was predicted by the insulin sensitivity index (Aoyama-Sasabe et al. 
2016).  In a separate study, plasma insulin levels at 30 minutes following an oral 
glucose load was negatively correlated with glucose concentrations at 2-hours 
supporting the relationship with IGT (r=-0.75, p<0.001) (Mitrakou et al. 1992).  
 
Animal studies have shown that the first phase insulin secretion has a greater effect on 
reducing gluconeogenesis from the liver than peripheral disposition in skeletal 
muscles, providing further insight into how its impairment may contribute to IGT or 
T2D (Del Prato and Tiengo 2001; Steiner et al. 1986).  
 
It has been proposed that diabetes or pre-diabetes caused by predominant IGT is a 
different pathophysiological entity from predominant IFG. The former has been 
shown in epidemiological studies to have greater association with future 
cardiovascular-related deaths (Decode Study Group 2001; Tominaga et al. 1999). 
Tissue level studies confirm these findings since acute hyperglycaemia can lead to 
development of diabetic complications mediated by a hypercoagulable state, 
impairment of endothelial function and oxidative stress (Del Prato and Tiengo 2001).  
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Insulin indices in GDM 
Whilst there have been several studies investigating the precise insulin secretion and 
resistance abnormalities in T2D or IGT (as discussed above), the evidence in GDM is 
more sparse. There is conflicting data on whether GDM is predominantly a problem 
of insulin resistance or impaired pancreatic beta-cell function whereby insulin 
secretion cannot be increased in response to rise in glucose. Studies that have 
supported the former abnormality have found higher fasting insulin levels, HOMA-IR 
and weaker correlation between fasting glucose and C-peptide in GDM (Ismail et al. 
2013; Weijers et al. 2002). In fact, Ismail at al showed that higher HOMA-IR scores 
were even predictive of neonatal hypoglycaemia and Caesarean section rates in GDM, 
raising the possibility that it could be the main pathophysiological factor in mediating 
complications.  However other studies have shown that fasting insulin levels are 
lower in GDM compared to NGT women (suggesting preserved insulin sensitivity) 
and concluded that the predominant problem is defective β –cell function (R. L. 
Mamabolo et al. 2007). 
 
Specifically the insulinogenic index, which is a surrogate marker of early phase 
insulin secretion (as discussed above) was reduced by 35-60% in GDM women in 
mid- or late-pregnancy compared to NGT (R. L. Mamabolo et al. 2007; Y. H. Wang 
et al. 2013). However in the study by Mamabolo et al, when the insulinogenic index 
was adjusted for changes in insulin sensitivity, the result became non-significant 
suggesting that the 2 abnormalities are not mutually exclusive entities. In a different 
study, impairment in the early phase insulin secretion correlated negatively with 
higher amplitude of glucose excursion and higher overall insulin secretion, so it may 
also be a marker of the development of insulin resistance in pregnancy (Su et al. 
2013). Impairment of insulin secretion found in women diagnosed with GDM or 
milder glucose intolerance was associated with a decrease in post-partum β-cell 
function (as measured by insulin secretion-sensitivity index) at 3-12 months after 
pregnancy but increased in previous NGT women, suggesting long-term metabolic 
effects (Retnakaran et al. 2010b). 
 
The reality is that GDM is most likely a combination of both impairment in insulin 
secretion and resistance with increase in HOMA-IR and reduction in insulin 
sensitivity index, first and second phase insulin secretion and HOMAβ- cell function 
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(S. J. Yang et al. 2013). Interestingly, even in a subgroup of women with milder 
gestational IGT (i.e. below the threshold for diagnosis of GDM) all the above indices, 
except for HOMA-IR but including the insulin sensitivity index and insulin-secretion 
sensitivity index, were significantly different compared to NGT lending support for 
the findings of my study that the metabolic insults to these women occur across a 
continuum of glucose values. It has also been shown that a decrease in insulin 
sensitivity occurs physiologically in all pregnant women but when insulin secretion 
does not increase sufficiently to compensate for this, hyperglycaemia or GDM occurs 
(Damm et al. 1996). 
 
Although ours was a case-control study where the controls were selected from the 
lowest quartile for glucose120min levels, fasting glucose levels were also higher in 
GDM compared to NGT women [4.95 vs. 4.18 mmol/l, p<0.01], supporting earlier 
findings that insulin resistance plays a role in the pathogenesis of the condition. We 
have not analysed the insulin concentrations (collected at the same 5 time-points as 
GLP-1) in our study yet, which will add value to the findings as it will allow 
calculation of surrogates of insulin resistance as well (e.g. HOMA-IR, insulin 
sensitivity index, etc.).  
 
Potential role of GLP-1 in mediating defective early phase insulin secretion 
Given the evidence supporting the link between early impairment in insulin response 
and overall β –cell function and tendency to glucose intolerance, it is plausible that 
factors which affect early insulin secretion, such as reduced GLP-1 response in the 
initial period of the GTT, will increase tendency to IGT too. 
 
There have been no previous studies which have shown an impairment of GLP-1 
response at a specific time-point of a GTT and development of GDM. However, in a 
series of women with previous GDM and NGT controls who underwent a 75g GTT at 
4-5 years after the index pregnancy, the former group had lower initial insulin and 
GLP-1 responses (measured as 0 – 30 minute AUC for both) despite normalisation of 
glucose values, which can be postulated to be involved in their higher risk of 
progression to T2D (Forbes et al. 2005). This finding was not replicated in another 
cohort of women studied following GDM pregnancy (Meier et al. 2005). 
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The inverse relationship between GLP30min concentrations (or early GLP-1 response 
between 0 and 30 minutes) and insulin secretion abnormalities or impaired glucose 
tolerance in non-pregnant adults has been better characterised. Early impairment in 
insulin secretion during GTT has been shown in adults with IGT, which were 
associated with or may be caused by decreased GLP-1 levels at 30 minutes (Rask et 
al. 2004). More recently, the large ADDITION-PRO study found equivocal results in 
that T2D women had a 1.2-fold decrease in early GLP-1 response compared to 
isolated IFG but no difference was found in IGT women or all male participants 
(Faerch et al. 2015). This study also found that a doubling of the relative GLP-1 
response between 0 and 30 minutes was associated with a 23% rise in the 
insulinogenic index but only 4% rise in the insulin sensitivity index suggesting that it 
influences β-cell function more than amelioration of insulin resistance. However, this 
observation is not universal because a multi-national study found overall decreased 
GLP-1 levels during intravenous GTT in all patients with abnormal glucose tolerance, 
with no relation to differential insulin secretion (Laakso et al. 2008).  
 
The effect of GLP-1 in augmentation of first phase insulin secretion has been 
confirmed by hyperglycaemic clamp studies whereby infusion of duodenal nutrition 
augmented first phase insulin secretion more than second, which was then attenuated 
by infusion of a GLP-1 receptor antagonist, exendine-(9-39) (Woerle et al. 2012).  
 
Significant insight into the mechanism by which GLP-1 influences insulin secretion is 
additionally provided by studying diabetic patients who have undergone bariatric 
surgery. One series of 30 patients found that diabetes remission after roux-en-y 
bypass was related to enhanced insulin secretion and exaggerated post-prandial GLP-
1 response in the early phase, thereby suggesting an association between the two 
(Martinussen et al. 2015).  
 
Therefore, although the relationship between lower GLP-1 levels at 30 minutes GTT 
and impaired early phase insulin secretion after a GTT has not yet been shown in my 
study (due to unavailability of insulin levels), it may be present, based on the findings 
from IGT or T2D adults, thereby providing a novel mechanism to explain the 
pathogenesis of GDM. 
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Strengths and weaknesses 
This is the largest study, to our knowledge, investigating GLP-1 levels in GDM 
pregnancy using a glucose challenge that is routinely available clinically (i.e. the 75g 
oral GTT). The study has significant advantages in that at the time of GLP-1 
sampling, neither the pregnant women now the research team knew her GDM status, 
thereby minimising selection bias. Additionally, GLP-1 levels were sampled every 30 
minutes over 2 hours which enabled us to obtain a detailed profile of GLP-1 changes 
during the GTT and observe finer differences at the various time points. 
 
However, there are some important limitations which cannot be ignored. Firstly, the 
matching of cases and controls was done according to the highest and lowest quartiles 
for glucose120min values, thereby potentially exaggerating differences in GLP-1 levels 
or response. However, since the thresholds for diagnosing GDM are variable across 
different countries and one of our aims was to detect differences in GLP-1 response 
across a continuum of glucose values, this was thought to be the best method. 
Additionally, we adjusted for potential confounders of post-prandial hyperglycaemia 
in our analysis, such as BMI, age, ethnicity, and even fasting glucose and gestational 
weight gain where appropriate, which would remove some of the inherent differences 
between women with highest and lowest glucose120min values. Secondly, although the 
required sample size was 20 women with GDM based on the power calculation for 
total GLP-1 response, we only considered 19 for this analysis and excluded 3 who had 
isolated fasting glycaemia. This may partly account for the reason why the magnitude 
of difference seen in total GLP-1 response was weaker than expected. Thirdly, to 
prove or disprove the hypothesis that a lower early GLP-1 response may account for 
early impairment in insulin secretion, insulin levels for the duration of GTT and 
glucose levels at 30, 60 and 90 minutes are required (which have been collected but 
not analysed yet). Finally, although we accounted for several confounders that can 
influence risk of GDM or GLP-1 levels, there are other variables (eg. parity, 
socioeconomic status) which were not adjusted for in the regression analysis. This 
information has been collected as a part of the PRiDE study and will be analysed and 
included in any further data generated from this pilot study.  
 
 
 
  148 
8.5. Conclusion 
In summary, we have shown that total GLP-1 response is reduced by 13% in GDM 
women compared to NGT following a GTT and, for the first time in a pregnancy 
cohort, that GLP-1 levels at 30 minutes are reduced by 20% in GDM and that they 
independently predict higher glucose values at 120 minutes.  If the association with 
lower early phase insulin secretion is proven with further analysis, our study will 
provide novel evidence that impairment of GLP-1 secretion may be responsible for 
the decrease in early phase insulin response found in glucose intolerance of 
pregnancy. 
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of hyperglycaemia-induced oxidative stress in 
endothelial cells: methodology of a basic science 
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9.1. Introduction 
Longitudinal studies have shown that women with a history of gestational diabetes 
mellitus (GDM) are 7.4 times higher risk of developing type 2 diabetes (T2D) 
(Bellamy et al. 2009). Although the risk increases with longer follow-up times, the 
pooled risk ratio was still 4.7 at less than 5 years from the index pregnancy. 
Additionally, these women are at are also at increased risk of metabolic syndrome and 
cardiovascular complications in the future, which accounts for most of the excess 
morbidity and mortality in diabetes (Retnakaran et al. 2010a; Schalkwijk and 
Stehouwer 2005). A recent 10-year follow up recent study in women with a history of 
GDM found increased hazard ratios of macro vascular complications (e.g. coronary 
artery disease) which were mediated by development of T2D but microvascular 
complications  (e.g. photocoagulation for retinopathy, renal dialysis and foot 
infections) were independent of T2D status (Retnakaran and Shah 2017). It is well 
known that the abovementioned complications are mediated by endothelial 
dysfunction in the vasculature in response to hyperglycaemia. Indeed, endothelial 
dysfunction, as measured by flow mediated dilatation (FMD) of a peripheral artery, 
has been shown to be decreased in women with previous hyperglycaemia of 
pregnancy despite return to normoglycaemia (Anastasiou et al. 1998; Davenport et al. 
2012). 
 
Therefore, pregnancy provides a crucial opportunity to identify these high risk women 
and offer safe and effective therapeutic interventions to reduce future morbidity. In 
the previous chapter, I have shown that reduced glucagon like peptide-1 (GLP-1) 
response mediates post-glucose challenge hyperglycaemia in GDM pregnancies so it 
is plausible that GLP-1 analogues may have a protective role to play in reducing 
hyperglycaemia and associated complications. It is also possible that a sub-group of 
women who are identified to have impaired GLP-1 response to be given GLP-1 
analogue post pregnancy to reduce their risk of developing recurrent GDM or 
subsequent future risk of T2D. 
 
Most of the studies investigating the action of GLP-1 receptor agonists (GLP-1 RAs) 
on endothelial cells have attributed its benefits to enhanced endothelial nitric oxide 
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synthase (eNOS) production and consequent nitric oxide (NO)-mediated 
vasodilatation and anti-inflammatory effects (Ban et al. 2008; Dong et al. 2013). 
However, other mechanisms such as inhibition of endothelin-1 (a potent 
vasoconstrictor) (Dai et al. 2013) and advance glycation-end product (AGE) 
formation (Ishibashi et al. 2010) may also be present. It is not known which exact 
downstream pathways this class of drugs modulates in the context of hyperglycaemia-
induced oxidative stress, but may involve the protein kinase B second messenger (also 
known as Akt), which is a potent activator of eNOS in the endothelial cell (Uruno et 
al. 2005).  
 
The hypothesis of this set of experiments is that liraglutide will alleviate 
hyperglycaemia induced oxidative stress in endothelial cells via the Akt/eNOS and 
other related signaling pathways. 
 
The primary aim of my pilot study was to describe a protocol for the cell culture of 
endothelial cells under high glucose (HG) conditions and determine optimal time 
point, concentration and duration of treatment with liraglutide to alleviate markers of 
oxidative stress.  The overall objective of related experiments would be to determine 
if the drug protects against hyperglycaemia-induced endothelial cell damage by 
mediating by the Akt/eNOS signaling pathways or if other pathways (e.g. (AMPK) 
were predominantly involved. Prior to investigating this, I wanted to determine the 
time point of maximal Akt suppression after exposure to high glucose (HG) 
conditions and what the optimal concentration and duration of liraglutide treatment 
was as this has not yet been established in other studies.  
 
9.2. Materials and Methods 
9.2.1. Justification of study design 
I used a cell culture model of human umbilical vein endothelial cells (HUVECs) 
which were exposed to HG (25mM) for variable lengths of time followed by 
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treatment with liraglutide. The proteins of interest were extracted at the end of cell 
culture experiments and their expression analysed by Western blotting. This was 
thought to be the best method to address my study questions since I was primarily 
interested in looking at the effect of oxidative stress generated in endothelial cells due 
to HG conditions, which will mimic the pathophysiology of cardiovascular 
complications in diabetic patients. Additionally I was interested in studying the 
mechanisms by which liraglutide has protective effect in these patients so a basic 
science model to examine its influence on the proteins of interest was felt to be the 
most appropriate.  
 
9.2.2. Cell culture 
9.2.2.1. HUVEC cell culture: General principles 
HUVECs were isolated from umbilical cords of patients from University Hospital of 
Coventry and Warwickshire after written informed consent. For all my experiments, I 
used previously extracted HUVECs that were cryopreserved in liquid nitrogen at 
passage 4-6. The cells were maintained in freezing media containing 10% 
dimethylsulfoxide (DMSO) (Fisher-Scientific), supplemented with 40% fetal bovine 
serum (FBS) (Biosera, Ringmer, UK) and 50% growth media.  
 
Normal growth media for the cells contained 500ml MCDB 131 cell culture media 
(Gibco Life Technologies, UK) supplemented with 5ml glutamine, 5ml 
penicillin/streptomycin (Invitrogen, Paisley, UK), 20% or 10% (50mls) fetal bovine 
serum, 10mg (1ml) endothelial cell growth supplement from bovine neural tissue 
(Sigma-Aldrich, UK) and 8000 units (0.9ml) heparin (Sigma-Aldrich, UK). This was 
in keeping with other studies, which used similar protocols for the culture of 
HUVECs (Bruno Schisano et al. 2012).  
 
All the cells were initially incubated in a 75ml flask containing 15ml growth media at 
37oC in a humidified atmosphere of 5% CO2 and 95% air. They were grown to 80-
90% confluence before being subcultured into plates for further experiments. This 
was done by first washing with 15ml phosphate-buffered saline at room temperature 
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and 2.5mls of trypsin was added to ensure detachment. The cells were then 
centrifuged at 2000rpm for 15 minutes and the supernatant removed before the cells 
were resuspended in growth media.  
 
A haemocytometer was used to count the cells and an average cell count of 1.2 x 106 
cells/ml media was obtained across all the experiments. From this, the cells were 
seeded at a density of 50,000 cells/well in gelatine-coated 6-well plates to achieve an 
initial confluence of 20-30%. At this seeding density, the cells usually reached 
confluence within 5 to 7 days when the experimental conditions were started.  
 
 
Growth media was changed every 48 hours until the day before any treatments were 
due to be done, in which case the cells were exposed to serum starved media (normal 
growth media containing 3% FBS) overnight prior to changing to a normal glucose or 
high glucose media (see below). 
 
When the cells were ready to be harvested at the various time-points or at end of the 
experiment, triplicates of protein and RNA were obtained from each plate. The cells 
were first washed 3 times with phosphate buffered saline (PBS). 1x radio-
immunoprecipitation assay (RIPA, Sigma-Aldrich, UK) solution was made up by 
diluting 10x RIPA with distilled water. A cocktail of protease inhibitors was prepared, 
which contained 2 tablets of Roche Complete Mini, sodium fluoride 8mg and sodium 
orthovanadate 20mg added to 2ml of 1x RIPA. 100μl of the cocktail was mixed with 
5ml of 1x RIPA and 250μl of this solution was added to each well at 4oC prior to 
scraping each well for 30 seconds. For RNA extraction, a Bioline kit (#BIO-65026) 
was used and 350μl of this was added to each well with the rest of the procedure the 
same as that described for protein extraction. The cell lysates were then frozen at -
20oC until the time of future experiments. 
 
9.2.2.2. Gelatin-coating of flask 
In order to optimize adherence of the cells to the flask, I first did an experiment of 
coating the flasks with gelatin. 10mls 0.2% gelatin was added to a 75cm2 flask, 
  154 
removed after 10 minutes and the flask allowed to dry for at least 30 minutes in an 
incubator. One cryovial of HUVECs was then added to the gelatin-coated flask 
containing 15mls growth media with a control set of cells in a flask without gelatin-
coating. The cells in both sets were 20-30% confluent at the beginning. After 4 days 
of incubation, the cells in the gelatin coated flask were 50% confluent while those in 
the control flask had attached poorly. Therefore it was decided to continue all future 
experiments with gelatin coating of flasks and 6-well plates. The procedure for 
gelatin-coating the latter was similar to that described above, with the exception that 
2ml gelatin was added to each well of the plate. 
 
9.2.2.3. Initial HUVEC culture (no treatment) 
The aim of my first set of experiments was to optimize the cell culture conditions and 
practice the extraction of protein and RNA for future experiments. Two cryovials of 
HUVECs from liquid nitrogen were cultured in 2 75cm2 flasks and after the 2nd 
passage, split into 4 x 6-well plates. Once the cells reached around 90% confluence, 
they were harvested and protein and RNA extracted according to the protocol 
described in Section 9.2.2.1.  
 
9.2.2.4. Chronic (10 day) high glucose treatment (with insulin 
stimulation) 
One of the key research questions I had was whether exposure of endothelial cells to 
chronic HG would lead to inhibition of the phospho-Akt pathway due to the 
development of insulin resistance and if this inhibition could be alleviated by 
liraglutide. Therefore, this experiment was done to determine the time-point in which 
maximal phospho-Akt suppression or other markers of endothelial dysfunction occurs 
and to confirm if any inhibition was due to the development of insulin resistance.  
 
To prepare the HG media, 20mM of 45% glucose (Sigma-Aldrich, UK) was added to 
500ml of the earlier prepared normal glucose (NG) growth media (since MCDB 131 
media already contains 5.5mM glucose). Therefore the final concentration of HG 
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media was 25mM glucose. 
 
In keeping with other studies done on HUVECs, which used L-glucose for osmotic 
balance in the NG conditions (Busik et al. 2008), I cultured 2 additional plates with 
this condition at Day 2 of the experiment (termed normal glucose/L-glucose, NG/LG). 
Therefore there were a total of 5 time-points (between Days 2 and 10 of treatment) 
and for each time-point of the experiment, an additional plate exposed to each 
experimental condition had 100nmol/L of insulin added for 10 minutes prior to 
harvesting (termed NG+I, HG+I and NG/LG+I respectively).  
 
To ensure optimal uptake of insulin by the cells, it was necessary to starve them of 
serum prior to insulin treatment. This was achieved by reducing the serum 
concentration of media by from 20% to 10% overnight on the day before the insulin 
treatment. On the day of the insulin treatment, the media was changed to NG, HG or 
NG/LG plus 1% bovine serum albumin for 3 hours before the insulin treatment was 
given and cells harvested.  
 
9.2.3. Liraglutide treatment experiments  
9.2.3.1. Chronic (6 day) HG treatment  
The aim of this experiment was to determine if liraglutide would alleviate 
hyperglycaemia-induced oxidative stress in HUVECs and the following cell culture 
conditions were used to determine the optimal time-point, concentration and duration 
of treatment of Liraglutide.  
 
HUVECs were cultures as described in Section 9.2.2.1 and transferred to 6-well plates 
at a seeding density of 50, 000 cells per well when over 80% confluence was reached. 
On the day prior to insulin or liraglutide treatment, the cells were kept in a serum 
starved HG medium (containing 3% FBS).  
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Liraglutide was obtained as from Novo Nordisk as a complement. A stock of 6mg/ml 
in a 3ml vial was received on dry ice and from this 3 concentrations (1nM, 10nM and 
100nM) were prepared and frozen until further use. On the day of the experiment, 
liraglutide was added to serum-starved media and the cells in the HG media treated 
with each of these concentrations of liraglutide for 3 or 6 hours prior to harvesting on 
Days 2, 4 and 6. The control groups consisted of NG, NG+LG and HG plates (without 
liraglutide treatment).  
 
9.2.3.2. Acute (12, 24 and 48 hours) HG treatment 
Since previous studies done on HUVECs treated with liraglutide or other GLP-1 
analogues did so after a shorter duration of HG exposure due to accelerated cell 
apoptosis (Batchuluun et al. 2014), I hypothesised that the maximal benefit of 
Liraglutide may be seen after acute exposure to hyperglycaemia.  
 
The aim of this experiment was to confirm if maximal downregulation of phospho-
Akt and phospho-AMPK expression in endothelial cells occurred at less than 48 hours 
of exposure to hyperglycaemia and whether treatment with liraglutide alleviated this. 
Cells were exposed to HG conditions for 12, 24 and 48 hours. Similar to the earlier 
experiment, they were treated with Liraglutide at concentrations of 1, 10 or 100nM 
for 3 or 6 hours. However, to avoid any bias from unequal duration of exposure to HG 
(due to the shorter duration of treatment overall), additional control plates of NG and 
HG were harvested at 3 and 6 hours in line with the duration of liraglutide treatment. 
The cell culture and harvesting protocol was identical to previous experiments. 
 
9.2.4. Protein quantification    
In order to quantify the RIPA extracted proteins for further experiments, 1μg/μL 
Bovine Serum Albumin (BSA, Sigma, UK) was added to 1ml Bradford Protein Assay 
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kit (Biorad) in serial dilutions from 0 to 7μL. This was used to determine the standard 
curve of absorbance against protein concentration. A volume of 5μL of the protein 
samples was added to the Bradford reagent and both the standards and samples were 
measured at a wavelength of 595nm using a spectrophotometer (Tecan, UK).  
 
9.2.5. Western blot 
The composition of the materials used for the Western blot experiments (e.g. running 
and transfer buffers, Tris-buffered saline, I-block and sodium dodecyl sulphate (SDS) 
gels are provided in Appendix 4.1). 
 
Protein lysates were prepared by adding the 15ug of protein to 10ul of loading dye 
and distilled water to make the total volume up to 40 or 50ul. They were heated at 
95oC for 10 minutes and then cooled on ice before being centrifuged at 10000 rpm for 
15 seconds to ensure even suspension. 
 
The samples were loaded onto 10% polyacrylamide gels (Geneflow Ltd, Fradley, UK) 
and separated by SDS-PAGE at 100V for 2 hours. They were then transferred to SDS-
PAGE membranes, blocked with I-Block for 1 hour and incubated with primary 
antibodies (+0.2% I-block) overnight. The next day, the membranes were washed 6 
times for 5 minutes each with Tris-buffered saline under gentle agitation. Following 
this anti-rabbit secondary antibody was added at a concentration of 1:50 000 (+0.2% 
I-Block), followed by 6 washes with Tris-buffered saline. The ECL/ECL+ 
chemiluminescent detection system (GE Healthcare, Amersham Biosciences, UK) 
was added before the membranes were subject to X-ray imaging for visualisation. 
Densitometry was done to quantify the intensity of the bands (GeneTool Software, 
Syngene, UK). 
 
The primary antibodies and their concentrations are as follows: phospho-Akt (Ser473) 
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(1:500, Cell Signaling), phospho-AMPK (1:500, Cell Signaling), phospho-eNOS 
(Ser1177) (1:250, Cell Signaling), Bcl-2 associated X protein (BAX) (1:1000, Cell 
Signaling), phospho-forkhead box class O 1a (phospho-FOXO 1a) (1:500, Cell 
Signaling) and β-Actin (1:1000, Cell Signaling).  
In all the Western blot experiments, equal protein loading was confirmed by 
normalisation was with β–Actin (1:1000, Cell Signaling). Stripping buffer was 
prepared dissolving 0.76g Tris base, 2g SDS and 700ul in 100ml β-mercaptoethanol. 
The pH was adjusted to 6.8 and the solution warmed to 50oC in an incubator before 
the rehydrated membranes were added to it. The membranes were placed in the 
stripping buffer for 5 to 10 minutes under gentle agitation then washed 8 times before 
being blocked with 0.2% I-block. The remainder of the steps were identical to that of 
the in Western blot (Section 9.2.5).  
 
9.2.6. Statistical analysis 
All statistical analysis was performed using SPSS version 22 (IBM Corp Released 
2013). The results are expressed as mean ± SD of 3 experiments, unless otherwise 
stated. Paired student’s t-test was used to compare means of control and treated 
samples. The significance value was set as P < 0.05 for all experiments.  
 
9.2.7. Ethics approval 
The HUVECs used for the experiments were isolated from umbilical cords provided 
by pregnant women at University Hospitals Coventry and Warwickshire NHS Trust at 
the time of delivery. Written informed consent was obtained from all women and after 
local ethics committee approval.  
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9.3. Results 
9.3.1. Cell culture and Western blot technique optimisation experiments 
For the initial experiments, I cultured the HUVECs in NG conditions without any 
treatment. Figure 9.1 shows the cells at Day 2 after reviving (around 20% 
confluence). The cells grew in a monolayer with a typical cobblestone appearance and 
the individual cells were spindle-shaped.  
 
 
The first few western blots which I did were on the untreated samples from the above 
experiment to optimise the protocol and antibody concentrations. Before incubating 
with the primary antibody, each membrane was typically cut at the 95kDa mark so 
that so that at least 2 proteins of interest could be studied, phospho-eNOS (molecular 
weight, MW 140 kDa) and phospho-Akt or phospho-AMPK (MW 60 and 64 kDa 
respectively). Figure 9.2 is a photograph of 2 membranes immersed in Ponceau 
solution, to visualize the proteins and aid accurate cutting the membranes.   
Figure 9.1 Microscope image HUVEC cells at A) 10x (left hand image) and B) 40x 
magnification (right hand image). In this experiment, the cells were cultured under 
normoglycaemic (5.5mM) conditions with MCDB-131 growth medium.  
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Despite using 2 different stripping buffers and reprobing protocols on several Western 
blot experiments, I was unable to obtain convincing results for the total isoforms of 
the various phosho-proteins studied. The bands, which were of the same molecular 
weight as the phospho-proteins, were not visualised after reprobing. Therefore, equal 
protein loading was studied by reprobing for beta-actin (molecular weight 42 kDa) 
and the results for protein expression in the following sections are presented after 
normalisation with actin.  
 
9.3.2. 10 day HG experiment with insulin 
Phospho-Akt (Ser473) 
There was a trend of decrease in Akt (Ser473) phosphorylation with HG conditions 
compared to NG at Days 2 and 4 but it did not reach statistical significance (Figure 
9.3). At Day 6, phospho-Akt expression decreased by 15% with HG compared to NG 
control at the same time point (p<0.05). However, the same trend was not observed at 
Days 8 and 10. On visualisation of the cells under microscopy at the time of cell 
culture, increased cell death noted at these time-points as well.  
Figure 9.2 Photograph of  2 SDS-PAGE membranes from a western blot immersed 
in Ponceau stain. The proteins were separated according to their molecular weight and 
visualised  against the markers in lanes 1 and 10. They were then cut at predetermined 
molecular weights  and added to the appropriate primary antibody.   
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Phospho-eNOS (Ser1177) 
There was slight decrease in phospho-eNOS (Ser1177) expression found at Days 2 
and 6 with exposure to HG conditions (Figure 9.4). However none of the results were 
significant enough to draw any meaningful conclusions.   
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Figure 9.3  Time-course of phospho-AKT (Ser473) expression after exposure to high glucose (HG). 
Human umbilical endothelial cells were cultured in 6-well plates. Upon confluence, they were exposed to 
HG conditions (25 mM) for 2, 3, 4, 6, 8 and 10 days (abbreviated as D2/3/4/6/8/10 respectively). Control 
plates were in normal glucose (NG) or NG + L-glucose (NG/LG, 20mM) for osmotic balance. Phospho-
AKT (Ser473) expression was determined by Western blot. The graph is that of fold-change of the protein, 
against NG for that respective day, after normalising with β-actin. Three independent experiments were 
performed and data are mean ± SEM of these. Representative blot provided in the figures. *: p<0.05 
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Insulin stimulated experiment 
Two independent experiments done on 6 separate days of treatment (Days 3, 4, 6, 8 
and 10) did not show any increase in phospho-Akt expression following insulin 
treatment compared to the respective HG conditions without insulin (data not shown). 
Therefore it was concluded that phospho-Akt activation in response insulin acting on 
insulin-receptor substrate (IRS) does not play a major role in endothelial cells 
(compared to other tissues such as skeletal muscle and adipose tissue and no further 
experiments with insulin stimulation were done (Artwohl et al. 2007)). 
 
9.3.3. Liraglutide treatment after 48 hours exposure to HG  
From the first set of liraglutide experiments, I decided to test the samples treated at 48 
hours (Day 2) because there is evidence that endothelial cells undergo apoptosis at 
exposure to hyperglycaemia for more than 48 hours (Hou et al. 2015). Therefore it 
will not be clear if any observed elevation in markers of cell damage or oxidative 
stress are due to hyperglycaemia or apoptosis.  
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Figure 9.4  Time-course of phospho-eNOS (Ser1177) expression after exposure to high glucose (HG). 
Experimental details and abbreviations are as provided in Figure legend 9.3. The graph is that of fold-change of 
the protein, against NG for that respective day, after normalising with B-actin. Three independent experiments 
were performed and data are mean ± SEM of these. Representative blot provided in the figures. 
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Western blots from 3 independent experiments showed no significant change in 
phospho-Akt (Ser473) expression after 48 hours of treatment with 25mM glucose 
before or after adding liraglutide 1, 10 or 100nM (Figure 9.5).  
 
Phospho-AMPK 
Three independent experiments confirmed that phospho-AMPK was downregulated 
after exposure to 48 hours of hyperglycaemia (Figure 9.6). Although there was not 
much change in suppression of phospho-AMPK after 3 hours of treatment of 
liraglutide, it became upregulated at 6 hours which was significant with 1nM 
liraglutide (fold-change compared to HG 1.68, p<0.05). There was also alleviation of 
phospho-AMPK with 10nM liraglutide at 6 hours but this did not reach statistical 
significance. 
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Figure 9.5 Expression of phospho-AKT (Ser473) in endothelial cells exposed to high glucose (HG) for 48 hours 
followed by Liraglutide treatment. Human umbilical endothelial cells were cultured in 6-well plates. Upon confluence, 
they were exposed to HG conditions (25 mM) for 48 hours and treated with Liraglutide 1nM, 10nM or 100nM for 3 
hours (abbreviated as Li1 3hr/Li10 3hr/Li1003hr) or 6 hours (Li 1 6hr/Li10 6hr/Li100 6hr). Control plates were in normal 
glucose (NG) or NG + L-glucose (NG/LG, 20mM) for osmotic balance. Phospho-AKT expression was determined by 
Western blot. The graph is that of fold-change of the protein, against NG, after normalising with β-actin. Three 
independent experiments were performed and data are mean ± SEM of these. Representative blot provided in the figure. 
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Phospho-eNOS (Ser1177) 
As expected, phospho-eNOS (Ser1177) expression was downregulated after exposure 
to HG. The alleviation of eNOS (Ser1177) suppression by liraglutide mirrored that of 
phospho-AMPK, with maximal upregulation with 1nM of drug at 6 hours although 
the difference did not reach statistical significance (Figure 9.7). 
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Figure 9.6 Expression of phospho-AMPK in endothelial cells exposed to high glucose (HG) for 48 hours followed by 
Liraglutide treatment. Experimental details and abbreviations are as provided in Figure legend 9.5. The graph is that of fold-
change of the protein, against NG, after normalising with β-actin Three independent experiments were performed and data are 
mean ± SEM of these. Representative blot provided in the figure. *: p<0.05   
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Figure 9.7 Expression of phospho-AMPK in endothelial cells exposed to high glucose (HG) for 48 hours followed by 
Liraglutide treatment. Experimental details and abbreviations are as provided in Figure legend 9.5. The graph is that of fold-
change of the protein, against NG, after normalising with β-actin Two independent experiments were performed and data are 
mean ± SEM of these. Representative blot provided in the figure   
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BAX is a pro-apoptotic protein which has been shown to induce caspase-3, a key 
enzyme involved in cellular apoptosis (Finucane et al. 1999). Bcl-2 and BAX form a 
heterodimer complex and decreased Bcl-2/BAX ratio, which may be caused by low 
Akt expression, leads to apoptosis (Hou et al. 2015; Oltvai et al. 1993). 
Therefore, I examined BAX expression under the experimental conditions in my 
study. BAX expression was upregulated with 25mM glucose exposure but treatment 
with 100mM of liraglutide for 6 hours reduced this marginally by 1.06-fold (p<0.05) 
(Figure 9.8). 
 
Phospho-FOXO1a 
To confirm that suppression of Akt phosphorylation was not the major signaling 
mechanism causing cell damage after 48 hours of hyperglycaemia exposure or that 
Liraglutide did not exert any beneficial effect through this, I repeated the experiment 
with phospho-FOXO1, a direct substrate of phospho-Akt. Similar to the pattern 
observed with phospho-Akt, there was no change observed in phospho-FOXO1 
expression with HG or subsequent liraglutide treatment (Figure 9.9) 
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Figure 9.8 Expression of BAX in endothelial cells exposed to high glucose (HG) for 48 hours followed by 
Liraglutide treatment. Experimental details and abbreviations are as provided in Figure legend 9.5. The graph is that 
of fold-change of the protein, against NG, after normalising with β-actin Three independent experiments were 
performed and data are mean ± SEM of these. Representative blot provided in the figure. *: p<0.05   
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9.3.4. Liraglutide treatment after 12 hours exposure to HG 
Since other studies have shown cell damage with HG treatment for 12 hours and the 
inhibition of oxidative stress by liraglutide may be seen as early as 1 hour after 
treatment (Batchuluun et al. 2014), it was decided to repeat the cell culture 
experiments with 12, 24 and 48 hours of exposure to hyperglycaemia. I analysed the 
results after 12 hours of exposure to HG.  
Phospho-Akt(Ser473) 
Three independent experiments showed a marginal but significant alleviation of 
phospho-Akt suppression with 10nM liraglutide treatment for 3 hours (fold-change 
1.06, p<0.05) (Figure 9.10).  
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Figure 9.9 Western blot of expression of phospho-FOXO1 after exposure to high glucose (HG) and subsequent Liraglutide 
treatment. Experimental details and abbreviations are as provided in Figure legend 9.5. Results were only obtained from a single 
experiment due to technical problems with the antibody and detection of the protein.   
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Figure 9.10 Expression of phospho-AKT (Ser473) in endothelial cells exposed to high glucose (HG) for 12 hours 
followed by Liraglutide treatment. Experimental details and abbreviations are as provided in Figure legend 9.5. The 
graph is that of fold-change of the protein, against NG, after normalising with β-actin. Three independent experiments 
were performed and data are mean ± SEM of these. Representative blot provided in the figure. *: p<0.05 
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Phospho-AMPK 
The effect of Liraglutide on phospho-AMPK was similar to that seen with phospho-
Akt with the exception that a significant difference was observed with 1nM 
Liraglutide treatment for 3 hours instead of 10nM (fold-change 1.07, p<0.05) (Figure 
9.11). There was no benefit noted with 6 hours of liraglutide treatment when the 
duration of hyperglycaemia exposure was only 12 hours.  
 
Phospho-eNOS 
No difference in eNOS (Ser1177) phosphorylation was observed with liraglutide 
treatment at any dose or duration of treatment in these experiments (Figure 9.12). 
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Figure 9.11 Expression of phospho-AMPK in endothelial cells exposed to high glucose (HG) for 12 hours followed 
by Liraglutide treatment. Experimental details and abbreviations are as provided in Figure legend 9.5. The graph is that 
of fold-change of the protein, against NG, after normalising with β-actin. Three independent experiments were performed 
and data are mean ± SEM of these. Representative blot provided in the figure.. *: p<0.05 
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9.4. Discussion 
The primary objective of this study was to develop a protocol for liraglutide treatment 
of endothelial cells exposed to HG conditions with the overall aim of studying the 
protective pathways it influences in the alleviation of oxidative stress. This was 
demonstrated by cell culture experiments using different time points of HG treatment, 
concentrations and durations of treatment of the drug followed by Western blots to 
look at the expression of proteins of interest. Based on preliminary data prior to 
normalising the expression of phospho-proteins with the total isoforms, 3 findings 
from my results are: (1) oxidative stress mediated cellular apoptosis in endothelial 
cells exposed to 48 hours of HG is likely mediated by the phospho-AMPK pathway 
and phospho-Akt signaling does not appear to play a major role; (2) treatment with 
liraglutide for 6 hours can alleviate some of this damage by upregulating phospho-
AMPK; (3) with more acute (12 hours) hyperglycaemia, inhibition of both phospho-
Akt and phospho-AMPK pathways may be present and a shorter duration of 
liraglutide treatment (for 3 hours) upregulates both these proteins. There is no clear 
dose-dependent relationship for the effect of liraglutide, instead the duration of 
treatment seems to be proportional to the duration of exposure to hyperglycaemia.  
 
Signaling pathways activated by oxidative stress in hyperglycaemic conditions 
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Figure 9.12 Expression of phospho-eNOS (Ser1177) in endothelial cells exposed to high glucose (HG) for 12 hours 
followed by Liraglutide treatment. Experimental details and abbreviations are as provided in Figure legend 9.5. The 
graph is that of fold-change of the protein, against NG, after normalising with β-actin. Three independent experiments 
were performed and data are mean ± SEM of these. Representative blot provided in the figure. 
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When I begun these experiments, my hypothesis was that liraglutide exerted its 
benefit on endothelial damage by reducing oxidative stress and the primary aim was 
to elucidate the mechanisms behind this. However, the first set of experiments were 
not conclusive of a definite suppression of Akt phosphorylation in HG conditions, 
with the exception of the Day 6 time-point (Figure 9.3). Possible reasons for this lack 
of effect are that the duration of HG exposure was too long causing senescence and 
apoptosis (a previous experiments has shown reduced cell viability with even 15mM 
of glucose after 24 or 48 hours (Hou et al. 2015)). An alternate explanation is that 
there is no significant effect on the phosphoinositol-3 kinase (PI3K)/Akt pathway by 
hyperglycaemia in endothelial cells. Glucose uptake and metabolism in response to 
insulin, which are important effects of Akt activation in muscle cells and adipocytes, 
are not shown to be activated by high glucose and insulin in micro- and macro-
vascular endothelial cells (Artwohl et al. 2007) so it is possible that Akt activation by 
insulin receptor substrate is not a major player in this cell type.  
 
Hyperglycaemia can activate oxidative stress and endothelial dysfunction by several 
pathways (reviewed in Kolluru and colleagues, Figure 9.13)(Kolluru et al. 2012). 
Briefly, these include uncoupling of eNOS and defective Akt/eNOS phosphorylation, 
which may be as a consequence of insulin resistance (McVeigh et al. 1992; 
Pannirselvam et al. 2002), activation of the diacylglyeryl (DAG)/protein kinase C 
(PKC)/NADH oxidase and nuclear factor-kappa B (NF-κB) pathways and formation 
of AGE. Therefore I sought to determine which of these pathways were alleviated by 
liraglutide treatment in my experiments.  
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Anti-oxidant effects of Liraglutide 
Although it is well recognized that liraglutide functions as an antioxidant, there are 
various theories on how this occurs. They include promotion of vasodilatation due to 
upregulation of eNOS levels, reduction in endothelin-1 or preventing cellular damage 
by other means (Dai et al. 2013; Ding and Zhang 2012). Indeed, the protective effect 
of GLP-1 on endothelial cells have been shown to occur by NO-dependent and 
independent means (Ban et al. 2008; Nystrom et al. 2004). GLP-1 also alleviates 
oxidative damage by suppressing AGE receptor expression and consequent reduction 
in AGE-mediated vascular-cell adhesion molecule-1 (VCAM-1) (Ishibashi et al. 
2010).  
 
It is important to note that although all these processes of endothelial damage can 
occur with hyperglycaemia, the abovementioned experiments by other groups were 
conducted under normoglycaemic conditions. Therefore it is possible that exposure to 
HG and consequent cell damage may activate additional pathways, which liraglutide 
has an effect on.  
 
Figure 9.13 Signaling mechanisms leading to endothelial dysfunction in diabetes mellitus. pARP: poly (ADP-ribose) 
polymerase; AGE: advance glycation end products; DAG: diacylglycerol; NF-κB: nuclear factor kappa- B; PKC: protein 
kinase C; iNOS: inducible nitric oxide synthase; NADH: nicotinamide adenine dinucleotide; NO: nitric oxide; RAGE: 
receptor for advanced glycation endproducts; O2 • : super- oxide anion; ONOO− : peroxynitrite; PI3K: 
phosphatidylinositol 3-kinases; AKT: protein kinase B; eNOS: endothelial nitric oxide synthase; GTPCH: GTP 
cyclohydrolase; BH4: tetrahydrobiopterin; BH2: dihydrobiopterin. (From Kolluru et al. 2012) 
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Effect of Liraglutide on the AMPK pathway 
My study showed that with moderate (i.e. 48-hour) hyperglycaemia exposure, 
liraglutide exerts its benefit predominantly on the AMPK pathway, which leads to 
inhibition of cellular apoptosis (reflected by downregulation of BAX expression) 
(Figures 9.6 and 9.8). The effect on AMPK phosphorylation occurred maximally after 
6 hours of treatment with 1nM liraglutide. Downregulation of BAX, albeit with a 
much lower magnitude of effect, also occurred with liraglutide treatment for 6 hours 
suggesting that the anti-apoptotic benefits may be due to AMPK signaling. Liraglutide 
had no effect on phospho-Akt or phospho-eNOS expression at the 48-hour time point 
in my experiments. The AMPK pathway was upregulated by liraglutide after 12 hours 
of HG exposure but this time, only 3 hours of 1nM of treatment was sufficient to lead 
to an increase in AMPK phosphorylation (Figure 9.11).  
 
There is good evidence for the role of the AMPK pathway in mediating the anti-
inflammatory effects of liraglutide in the endothelium. A key study was by 
Batchuluun and colleagues who used a model of human aortic endothelial cells 
exposed to 25mM glucose and demonstrated reactive oxygen species (ROS) 
production with dihydroethidium staining and fluorescent microscopy (Batchuluun et 
al. 2014). The cells were then treated with 10uM metformin and 30nM liraglutide 
either alone or in combination and the effects they had on the DAG-PKC-NADPH 
oxidase proteins assessed by plasmid transfection of PKC-β without a DAG-binding 
site, PKC translocation experiments, NADPH oxidase activity assays and Western 
blotting. The results showed that PKC translocation was stimulated by DAG (a direct 
by-product of glucose metabolism) preceding the detection of ROS, establishing a 
causal relationship. PKCβ translocation and DAG levels, as measured by mass 
spectrometry, were reduced by metformin, liraglutide and combination of the 2 drugs. 
Since glucose incorporation into DAG has been previously shown to be inhibited by 
AMPK (Ido et al. 2002), the authors did further experiments with AICAR, an AMPK 
activator which confirmed that the effects of the drugs on PKC inhibition were 
mediated by AMPK and additionally had an effect on NADPH oxidase reduction. 
Similar to our results, they could not find further increase in AMPK phosphorylation 
with liraglutide 30nM compared to 3uM suggesting no dose-dependent relationship.  
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Animal studies (on diabetic rat myocytes) also support that theory that liraglutide 
exerts its anti-oxidative effects by modulating the AMPK-PKC-NADPH oxidase, via 
a mechanism independent of plasma glucose, insulin or body weight (Balteau et al. 
2014; Inoue et al. 2015). The mechanism by which liraglutide stimulates AMPK is 
believed to be adenosine triphosphate (ATP)-dependent (since HG increases ATP 
production, which is an inhibitor of AMPK) (Carling et al. 2011) or ATP-independent 
(by increasing intracellular cyclic AMP (cAMP) levels) (Luo et al. 2013). cAMP and 
its downstream protein, protein kinase A (PKA), are key second messengers activated 
by the GLP-1 receptor, which directly inhibit NADPH oxidase and reduce oxidative 
stress in the renal vasculature (Hendarto et al. 2012).  However AMPK was not 
specifically measured in this study so it was not possible to conclude if the anti-
oxidant effect of liraglutide was due to cAMP increasing AMPK activity downstream, 
although that it is a plausible mechanism. Further proof of principle of the association 
between liraglutide and AMPK was provided by Krasner et al, who showed that the 
drug increased intracellular Ca2+ concentrations, which in turn activated calmodulin-
dependent protein kinase kinase-β (CaMKKβ), a direct stimulator of AMPK 
phosphorylation (Krasner et al. 2014).  
 
Aside from reversing DAG-PKC-NADPH oxidase signaling, liraglutide may also 
influence other downstream targets of AMPK to exert its anti-oxidant or anti-
inflammatory effects, including suppression of NF-κB and increasing NO production 
(Cacicedo et al. 2004).  
 
More recently, a GLP-1 receptor/cAMP/PKA/liver kinase B1 (LKB1)/AMPK/eNOS 
cascade has been suggested for NO production by GLP-1 (Liu et al. 2012), but further 
experiments are needed to determine if this has any cross-talk with PI3K/Akt pathway 
for eNOS phosphorylation. 
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Effect of Liraglutide on the Akt signaling pathway  
It is believed that activation of the GLP-1 receptors trigger at least 2 second 
messenger systems: 1) the cAMP-PKA pathway (which causes AMPK activation, as 
described above) and 2) indirect activation of epidermal growth factor activation 
leading to PI3K/Akt signaling (Buteau et al. 1999; Drucker 2006).  
 
Native GLP-1 and GLP-1 agonists are effective in increasing the activity and 
phosphorylation of eNOS, which may be due to or independent of the GLP-1 receptor 
(Ding and Zhang 2012). This effect may be mediated by PKA, a major downstream 
protein of GLP-1 receptor stimulation action, that can directly phosphorylate eNOS at 
Ser1177 (Dong et al. 2013). The NO thus produced can protect endothelial cells by 
stimulating vasodilatation, scavenging ROS products and inhibiting leukocyte 
adhesion (Krasner et al. 2014; Ou et al. 2012).  
 
Aside from a non-significant increase with 1nM liraglutide after 6 hour of treatment 
in the 48-hour time-point (which mirrored the effects seen with phospho-AMPK), I 
was not able to show any consistent suppression of eNOS phosphorylation after HG 
exposure or alleviation by liraglutide in my experiments. Possible reasons for this are 
technical issues with the antibody used or that these experimental conditions were not 
appropriate to show any changes in eNOS. Unfortunately, the study which was similar 
in design to ours which examined the effect of liraglutide in HG conditions did not 
evaluate phospho-eNOS expression or NO production (Batchuluun et al. 2014). Also, 
further experiments could be done to demonstrate decreased NO bioavailability aside 
from phospho-eNOS (Ser1177) protein expression, such as measurement of eNOS 
activity and eNOS mRNA levels.  
 
Since a major upstream activator of eNOS activity is phospho-Akt (Dimmeler et al. 
1999; Uruno et al. 2005), studying this protein can provide further insight into 
whether this signaling pathway is ameliorated by liraglutide in HG-mediated ROS. 
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Similar to the issue with phospho-eNOS, there have been no other studies which have 
examined phospho-Akt expression or regulation in experimental conditions similar to 
ours so no direct comparison is possible. However, it has been shown that exendin-4 
(another GLP-1 analogue) leads to endothelial cell proliferation through upregulating 
phospho-Akt and phospho-eNOS expression (Erdogdu et al. 2010) and PKA was an 
important second messenger in this. Therefore the hypothesis is that another 
mechanism by which GLP-1 activates eNOS is through reversal of PKA/Akt 
inhibition. This may be particularly relevant in hyperglycaemic conditions since Akt 
phosphorylation has been shown to be downregulated by ROS activation, mediated by 
an increase in PTEN (Hou et al. 2015).  
 
Therefore our study is potentially the first, to our knowledge, that suggests that 
liraglutide may exert its effect via the PI3K/Akt pathway under hyperglycaemic 
conditions, although the magnitude of effect is weak and may only be occur with 
acute exposure to HG.  
 
Although Dong et al demonstrated PKA-mediated eNOS phosphorylation and 
increase NO levels with GLP-1 infusion, they did not observe any changes in Akt 
phosphorylation in skeletal muscle suggesting that this pathway may not be 
universally activated by GLP-1 (Dong et al. 2013). When evaluating oxidative-stress 
induced cell senescence in HUVECs, Oeseburg and colleagues concluded that the 
protective effect of GLP-1 was dependent on cAMP/PKA rather than PI3K/Akt 
(Oeseburg et al. 2010).  
 
Optimal dose and duration of treatment of Liraglutide 
There is no standard dose or duration of treatment of liraglutide for experiments on 
endothelial cells since different studies have had different methodologies and aims. In 
the Batchuluun et al study, the cells were only treated with 1 hour each of HG 
medium and liraglutide likely because they were doing several dynamic assays of 
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ROS detection, PKC translocation and so on; notably the cells were pre-treated with 
the drugs prior to HG exposure.  
 
One hundred (100) nM liraglutide, which exceeds the therapeutic range obtained in 
patients taking the 1.8mcg/day preparation of liraglutide, was the maximum dose used 
in our study (Jacobsen et al. 2016). However, we also experimented with smaller 
doses of 1nM and 10 nM because: 1) there is no evidence regarding potential toxicity 
of very high doses of liraglutide and 2) anti-inflammatory and anti-oxidant effects of 
the drug have been found at concentrations of 30nM in cell models (Batchuluun et al. 
2014; Shiraki et al. 2012).  
 
In my study, one of the key questions initially was whether the ROS production 
increased with chronic exposure to HG which liraglutide may alleviate so a 6 to 10 
day time course experiment was designed. However it transpired that cell apoptosis 
possibly due to senescence became apparent at durations beyond 4 days of HG, so we 
decided to focus on the 48hour time point and additionally studied a 12-hour time 
point as well. In accordance, the duration of liraglutide was also varied between 3 and 
6 hours. Although not conclusive, it appears that longer exposure to HG requires a 
longer duration of liraglutide to observe a benefit possibly reflecting more oxidative 
stress-mediated damage that needs to be overcome. 
 
Translational / Therapeutic options 
In clinical settings, liraglutide treatment has been shown to improve endothelial 
function in patients with T2D, lending more support to the observations found at the 
tissue level. Various biochemical and physiological markers of endothelial 
dysfunction have been identified in clinical use and the effect of GLP-1 RAs on them 
studied. For example, liraglutide has been shown to reduce levels of urinary diacron-
reactive oxidation metabolites (d-ROMs) in diabetic patients (Okada et al. 2014). 
Brachial artery FMD, measured by ultrasonography, represents endothelial NO 
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bioavailability and is widely accepted as an early marker of atherosclerosis (Corretti 
et al. 2002). However the effect GLP-1 RAs or liraglutide have on FMD is variable, 
possibly due to population differences (control of DM, pre-existing atherosclerosis, 
concomitant drugs) and the GLP-1 treatment used (Nomoto et al. 2015; Nystrom et al. 
2004). 
 
If further laboratory studies confirm the anti-oxidant / anti-inflammatory role of 
liraglutide on endothelial cell damage as suggested by my study and others, the next 
step would be clinical trials to identify a subgroup of diabetic patients who may 
benefit from GLP-1 RA treatment to reduce cardiovascular complications. For 
instance, 2 clinical studies on diabetic patients has shown that the endothelium 
becomes less sensitive to the protective effects of a GLP-1 infusion when 
hyperglycaemia is more pronounced (as measured by markers of oxidative stress and 
FMD) (Ceriello et al. 2011) and that the effect of exenatide on postprandial 
endothelial function was mediated by lowering of triglyceride levels (Koska et al. 
2010).  
 
Strengths and weaknesses 
In this pilot study, I have shown through several cell culture and Western blot 
experiments a possible methodology for studying the mechanism by which liraglutide 
can alleviate oxidative stress in endothelial cells when exposed to HG conditions. 
Aside from Batchuluun et al, there have been no other studies, to our knowledge, 
which have studied the role of liraglutide in a hyperglycaemic milieu similar to what 
diabetic individuals would experience. Particularly, I was interested in examining the 
relative contributions of both the phospho-AKT and phospho-AMPK pathways, 
which have been separately shown to be important in alleviating oxidative stress. 
However this is a pilot study, which has a few important limitations. Firstly, in the 
absence of total-AKT and total-AMPK protein expression, the results from the 
phospho-isoforms must be interpreted with caution. This is possibly due to the 
protocol I used for reprobing, which meant that bands for the total isoforms did not 
show up clearly on repeat Western blots despite multiple attempts. These experiments 
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need to be replicated after optimisation of the stripping buffer and reprobing protocol. 
Additionally, further experiments need to be done to study gene expression of the 
relevant proteins (eg. by polymerase chain reaction) to confirm the findings of the 
Western blots. The generation and alleviation of oxidative stress under the various 
conditions used in the experiments can also demonstrated by dynamic fluorescence 
assays as proof of principle.  
 
9.5. Conclusion 
In the basic science part of my thesis, I have presented a methodology of studying the 
how liraglutide may alleviate oxidative stress in endothelial cells using cell culture 
and Western blot experiments. Putting the preliminary findings of these experiments 
and evidence from other studies together, my impression from this pilot study is that 
liraglutide inhibits ROS formation predominantly by the increasing AMPK 
phosphorylation, which results in decreased DAG synthesis and PKC activity, after 
acute and moderate-term exposure to HG. The downstream signaling pathways 
following the formation of ROS and endothelial cell damage are believed to include 
Bcl-2/BAX mediated cell apoptosis, which GLP-1 RAs may alleviate. The phospho-
Akt pathway may also be activated by this drug, particularly with more acute 
exposure to HG and shorter duration of drug treatment. Therefore it is possible that 
liraglutide acting via AMPK may exert antioxidant/anti-inflammatory effects on 
endothelial cells with or without the PI3K/AKT/eNOS signaling pathway. If this 
observation is confirmed by further experiments, it could mean that newly diagnosed 
diabetic patients with acute hyperglycaemia-mediated endothelial dysfunction may 
benefit most from the cardiovascular protection of liraglutide. 
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Overall discussion and conclusion 
  
Chapter 10 
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10.1. Introduction 
Gestational diabetes mellitus (GDM) is a multifactorial heterogeneous condition 
which can have long-term consequences for the mother and her affected fetus(es). I 
have thus far described in my study how 2 potential biomarkers, namely vitamin B12 
(B12) and glucagon-like peptide-1 (GLP-1), may be independently associated with 
this condition and also showed, at a tissue level, possible mechanisms by which GLP-
1 agonist treatment may be beneficial in alleviating cell damage caused by 
hyperglycaemia.  
 
The next logical step would be to examine if there are any treatment options (such as 
supplementation or fortification of B12 and GLP-1 agonist treatment respectively) 
that can be used in ‘at-risk’ pregnant women to reduce their metabolic risks. However 
prior to that, there are still a few issues which need careful consideration: the 
biomarkers I have studies are only associated with GDM, not causative, and one way 
to confirm these associations would be to evaluate other related factors with regards 
to GDM risk. Secondly, if impairments in B12 and GLP-1 are indeed linked to 
glucose intolerance in pregnancy, they should by definition resolve post-partum 
although it is unknown if there are any long-term ‘metabolic memory effects’. Related 
to this, it is possible that the affected women may become pregnant again. This would 
put her and her future offspring at the same (if not higher) risk of GDM thereby 
making the inter-partum period an ideal time to intervene. Thirdly, there need to be 
more studies with regards to feasibility and safety of interventions such as B12 
supplementation or GLP-1 potentiating treatment in pregnancy or post-partum. I will 
discuss these issues in turn, along with available evidence, in the following sections.  
 
10.2. Risk of Type 2 diabetes and metabolic disease following GDM 
pregnancy 
Gestational diabetes mellitus (GDM) resolves after delivery due to improvement of 
the insulin resistance induced by pregnancy and reduction in levels of diabetogenic 
hormones such as human placental lactogen, growth hormone and progesterone (C. 
Kim 2014). Women with GDM are advised to have post-natal follow-up which varies 
in different countries and areas based on local practice, but by and large includes a 
fasting plasma glucose, annual HbA1c and rarely a 75g glucose tolerance test 
(National Institute for Health and Care Excellence 2015a). Longitudinal studies have 
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shown that women with a history of a GDM pregnancy have a 40% chance of 
developing it in a subsequent pregnancy, compared to around 4% risk in the 
background population (Ehrlich et al. 2011; Getahun et al. 2008). These women also 
have a higher risk of T2D as early as 9 months after the index pregnancy and a meta-
analysis found a 7-fold increase risk over a follow-up time of 2 - 25 years (Bellamy et 
al. 2009; Feig et al. 2008). In addition, I discussed in Chapter 9 how these women are 
also at increased risk of cardiovascular events, macro- and micro-vascular disease, 
mediated in part by endothelial dysfunction (Carr et al. 2006; C. Kim 2014; 
Retnakaran and Shah 2017). 
 
Strategies which are advocated to reduce a woman’s intrapartum and future risk of 
diabetes include weight loss, particularly for women who were overweight or obese in 
the index pregnancy, intensive lifestyle modification (as shown in the Diabetes 
Prevention Program) and breastfeeding (Ehrlich et al. 2011; O'Reilly et al. 2011; 
Ratner et al. 2008; Ziegler et al. 2012). 
 
I would argue that in addition to these generalised measures, it is important to 
consider novel factors (e.g. B12 insufficiency or impaired early GLP-1 response to 
glucose load) that may have put her at risk of GDM in the index pregnancy and 
therefore future GDM in a following pregnancy or T2D. If any association is indeed 
proven between the factors I have studied and metabolic health outcomes, accurate 
risk stratification of the affected women should involve re-evaluation of these risk 
factors post-pregnancy and correction, where appropriate.  I will discuss possible 
strategies of doing this in the following sections.  
 
10.3. Confirming association and establishing causation between vitamin B12 
and GDM / related metabolic outcomes 
In Chapter 5, I have shown that low maternal B12 insufficiency is linked to higher 
odds of obesity, GDM and additionally may have an independent effect on fetal 
macrosomia. The possible mechanisms associated with this risk have been discussed 
and are believed to include adipocyte dysfunction, abnormal lipid metabolism and 
hypomethylation of cholesterol biosynthesis pathways. 
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However, the one-carbon metabolism cycle at a cellular level is complex with several 
interdependent pathways and if B12 is indeed causative for any metabolic insults to 
pregnant women or their offspring, derangements in other related biomarkers are to be 
expected too. It should be stressed that to confirm any association and establish 
potential causality between B12 or other related biomarkers with GDM, they should 
be measured pre-conceptionally or in early pregnancy and such studies are lacking at 
present but are ongoing (e.g. PRiDE study in University of Warwick).  
 
In our study, we found no significant relationship between maternal folate levels and 
obesity or GDM (Chapter 5) but surprisingly, folate showed a positive relationship 
with the risk of fetal macrosomia (i.e. highest risk in women with folate in the highest 
quartile, OR 4.99, adjusted p=0.02). Taken in the context of an inverse relationship 
between maternal B12 and risk of macrosomia of the same magnitude (OR 5.3 for 
macrosomia in the lowest quartile of B12, p=0.05), we can speculate that the 
combination of low B12 and high folate may contribute to excessive fetal growth, 
potentially due to exposure to a hyperglycaemic intrauterine environment. 
Interestingly, in the Pune Maternal Nutrition Study, children born to mothers with 
B12/folate imbalance in the 3rd trimester of pregnancy were observed to be more 
centrally adipose and insulin resistance at age 6, although this is a very different 
population with different inherent risks (C. S. Yajnik et al. 2008).  
 
There is no convincing evidence of an inverse relationship between folate and risk of 
GDM or obesity, although it does predict lower fetal birthweight (BW) (Bergen et al. 
2012; Relton et al. 2005). 
 
Homocysteine has not been independently linked to maternal obesity or GDM but in a 
meta-analysis of over 21000 individuals, was associated with a small but significant 
risk of small for gestational age (SGA) births (OR 1.25 95% CI  1.09, 1.44, 1SD 
increase in Hcy associated with 31g increase in BW) (Hogeveen et al. 2012). Yajnik et 
al proved a causal relationship between hyperhomocysteinaemia and low BW using 
instrumental variable analysis of a polymorphism in the methylene tetrahydrofolate 
reductase (MTHFR) gene (C. S. Yajnik et al. 2014). Hyperhomocysteinaemia among 
pregnant women has been attributed to both B12 and folate insufficiencies depending 
  182 
on the population studied and their micronutrient status (Bondevik et al. 2001; Selhub 
et al. 2007a; C. S. Yajnik et al. 2014).  
 
An exploratory metabolomics study, with 29 GDM women and 25 controls has 
identified that urinary choline and associated plasma betaine excretion was higher in 
the former (Diaz et al. 2011). Choline metabolism has been shown to be altered in 
hyperhomocysteinaemia since the Hcy to methionine conversion is coupled with 
betaine metabolism and choline is a direct precursor of betaine. Aside from choline, 
there are several other markers relevant to the B12-folate-Hcy-methionine cycle, such 
as AdoMet, AdoHcy, vitamin B6 and cysteine, which remain to be studied with 
regards their associations to metabolic disease in pregnancy. These can be 
investigated via a metabolomics approach or other exploratory studies to begin with 
before being tested in clinical samples. 
 
 
10.4. Supplementation (or fortification) of vitamin B12 
From Chapter 4 and 5 of my study, is apparent that B12 insufficiency during 
pregnancy is prevalent in several populations across the world and may potentially be 
associated with adverse consequences for mother and baby (e.g. GDM, high BMI, 
extremities of birthweight). However to strengthen these observations and prove 
causality, it would be necessary to show, via a randomised control trial, that B12 
supplementation to mothers preconceptionally or during pregnancy can reverse these 
outcomes. Prior to that, it is necessary to conduct small feasibility trials to determine 
the optimal route, dose or duration of B12 which should be given to pregnant women 
with B12 insufficiency. There also needs to be careful consideration about the 
primary outcome which is being studied as that will influence the design and conduct 
of the trial. Possibilities include 1) normalisation of serum B12 levels, Hcy or MMA 
levels, 2) prevention of GDM or other associated metabolic outcomes and 3) 
prevention of extremities of fetal birthweight or prematurity 
 
There have no trials so far where offspring BW has been reported a primary outcome 
in pregnant women supplemented with oral B12 alone versus placebo. An placebo-
controlled trial of B12 supplementation for pregnant women from 14 weeks of 
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pregnancy found higher maternal and infant plasma B12, folate and lower Hcy and 
MMA concentrations in the treated group but no significant reduction in the rate of 
fetal growth retardation (secondary outcome) (Duggan et al. 2014).  A meta-analysis 
of multiple micronutrient supplementation trials (which typically contains 1 RDA of 
B12), done in 12 low-income countries in Asia, Africa and Central/South America, 
showed that supplementation was associated with modest increase in BW (effect size 
+22g, p=0.002), reduced low birthweight (LBW), SGA and increased large-for-
gestational age babies, all of which were significant (Fall et al. 2009). Surprisingly, 
the effect was larger as maternal BMI increased with no or even a negative effect in 
mothers with BMI <20kg/m2.  
 
The more recently conducted Mumbai Maternal Nutrition Project, showed no overall 
increase in neonatal BW in the supplemented group but subgroup analysis on mothers 
who had the supplements for more than 3 months before conception (per protocol 
analysis), found that there was a positive effect on BW, particularly as maternal BMI 
increased (overall effect size +48g (p=0.046); maternal BMI >21: +113g) (Potdar et 
al. 2014). This suggests that optimisation of maternal B12 in the periconceptional 
period may be more beneficial than during pregnancy itself. The available data 
support the hypothesis that even in populations which show an apparent association 
between low B12 levels and LBW offspring, the most ‘at-risk’ (i.e. underweight) 
women are unlikely to benefit from micronutrient supplementation alone as their 
nourishment and macronutrient status needs to be optimised first.  
 
Another reason for the disparity observed between populations who benefit from 
supplementation and those who do not, may be the baseline micronutrient status of the 
women. For example, in the trial which showed 64g increase in BW, the Nepalese 
women had relatively a higher rate of folate deficiency (11%) and lower rate of B12 
deficiency (27%) (Christian et al. 2003; Stewart et al. 2011). In comparison, in the 
Mumbai trial there were no micronutrient levels reported but the corresponding folate 
and B12 and folate insufficiency rates in pregnant women were from India are around 
<5% and 40-60% respectively (Krishnaveni et al. 2014; C. S. Yajnik et al. 2008), 
suggesting that the combination of low B12 and high folate may be more deleterious 
in the pregnant women and their offspring, which may not be so easily reversed with 
micronutrient supplementation. 
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It can be concluded from the above evidence and my findings from Chapter 4 and 5 
that B12 supplementation with the aim for increasing BW or reducing LBW / SGA 
are probably not necessary and are unlikely to be effective in the context of the UK 
population due to low inherent risk. However low B12 status is still an important 
problem in our population (26% of high-risk pregnant women in our population and 
12% of women of child-bearing age nationally have levels <150pmol/l, which in the 
latter group was associated with hyperhomocysteinaemia). Therefore is there a role 
for B12 supplementation to reduce GDM outcomes in pregnant women with certain 
risk factors (e.g. obesity, vegetarianism) or should national policies be reviewed with 
regards to increasing the recommended nutrient intake (RNI) for B12, targeting 
women of child-bearing age? Paucity of randomised control trials (RCT) on B12 
supplementation in pregnancy or pre-conception makes it difficult to answer this 
question but more robust evidence and feasibility studies are needed first. Some of 
these issues that need to be determined are the optimal route and dose of B12 
supplementation.  
 
Route 
The 2 forms of B12 commonly used in treatment are cyanocobalamin (oral route) or 
hydroxocobalamin (intramuscular route). As alluded to in Chapter 7, B12 in animal 
products is predominantly protein-bound while in fortified foods or vitamin 
supplements it is in the free form. B12 in food exists as hydroxocobalamin while in 
vitamin supplements it is cyanocobalamin, which was believed to be more easily 
digested in the gastrointestinal tract than hydroxocobalamin anecdotally. However a 
recent animal study has shown comparable absorption rates (Kornerup et al. 2016).  
 
It is currently not standard practice in the UK, to give oral B12 supplements to 
pregnant women at risk of, or diagnosed, with B12 insufficiency. If a woman is found 
to have low B12 levels either in the pre-conceptional or antenatal period which is 
thought to be due to dietary deficiency, the practice in our NHS Trust is to give a 3 
loading doses of 1mg vitamin B12 intramuscular injection and repeat the B12 levels. 
If the insufficiency is a chronic problem, general practitioners will usually prescribe 
3-monthly B12 injections as maintenance. Such practice is broadly in keeping with 
the NICE clinical knowledge summary with the added recommendation of giving 50 – 
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150mcg oral cyanocobalamin daily for younger people or non-vegans (National 
Institute for Health and Care Excellence 2015b)  
 
Dose and risks of over supplementation 
Although the RNI for B12 intake in adults in the UK is 1.5mcg/day, commercial oral 
formulations contain anywhere between 2.5 – 100mcg (e.g. Pregnacare® contains 
6mcg, Boots® Pregnancy Support tablets contain 2.5mcg, Holland and Barrett® B12 
Tablets contain 100mcg). One rationale for taking higher doses is that bioavailability 
of B12 decreases to about 5-10% with higher concentrations, similar to dietary intake. 
 
High B12 intakes and blood levels are generally considered safe but no studies have 
specifically examined the adverse effects over a prolonged period, especially during 
the periconceptional stage. While most of the excess amounts of water- soluble 
vitamins are excreted in urine, urinary excretion of B12 does not increase when large 
doses of B12 are supplemented (Fukuwatari et al. 2009). It is believed that excess 
amounts are stored in the liver and the effect of this especially during pregnancy is 
unknown. B12 crosses the placenta, probably through active transport as cord blood 
levels are higher than maternal level (Chapter 4). 
 
Therefore whilst B12 supplementation may an appropriate and effective treatment in 
pregnant women diagnosed with insufficiency, there is still insufficient evidence with 
regards to implanting this on a population level. An alternative is to consider co-
fortification of B12 together with folate which is timely given the on-going 
discussions which are taking place in the UK. Some of the challenges with B12 
fortification (in contrast to folate) are reduced bioavailability when attached to certain 
foods, saturation of intrinsic-factor process at high intakes and the effect of co-
existing malabsorptive conditions (Carmel 2008).  
 
In conclusion, there is still insufficient evidence to recommend routine B12 
supplementation in pregnant women or fortification on a population level. However 
based on my findings from Chapter 6, more consideration could be given to 
increasing the RNI of B12 intake to al least match European recommendations of 
4.5mcg/day particularly in women of reproductive age. This, accompanied by more 
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public health messages to raise the awareness about the importance of adequate B12 
status for women planning pregnancy, may mean that they enter pregnancy with 
higher B12 reserves.  
 
10.5. Biomarkers related to GLP-1 
From my results in Chapter 8 and surrounding discussion, it is likely that there is 
association between GLP-1 levels (particularly in the early phase after an oral load), 
impaired insulin secretion and GDM. However the situation with the other incretin 
hormones is less conclusive.  
 
Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin 
hormone secreted by the K-cells of the distal small intestine in response to oral load 
and in addition to potentiation of insulin secretion, has systemic effects which are 
quite diametrically opposite GLP-1. It has been shown to have 
diabetogenic/adipogenic properties which could mediate the link between high fat 
diets and metabolic outcomes such as obesity, insulin resistance and T2D (Chia et al. 
2009; Irwin and Flatt 2009) There does not seem to be a consistent change in GIP 
levels in GDM with some studies one study showing no change (Cypryk et al. 2007) 
and one showing increase in fasting GIP concentrations only compared to controls 
(Bonde et al. 2013).  
 
Interestingly, it has been suggested that obese individuals, such as those with GDM or 
a history of it, have a greater insulinotropic in response to GIP administration under 
experimental conditions, which may be a compensatory mechanism to their insulin 
resistance (Meier et al. 2005). This is at variance with the reduced insulinotropic 
response to GIP observed in type 2 diabetics and their first-degree relatives, which 
was thought to represent a genetic defect in GIP action in predisposed individuals 
(Meier et al. 2001; Nauck et al. 1993). Therefore further studies are needed to 
determine any association between GIP secretion or action and glucose intolerance in 
pregnancy.  
 
Anyhow, latest evidence from non-pregnant adults is that that GIP and GLP-1 
responses are independent of each other and are regulated by different factors 
(Vollmer et al. 2008).  Some predictors of reduced GLP-1 response during a GTT in 
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non-pregnant adults, which warrant further study in GDM, are fasting glucagonaemia, 
impaired glucagon suppression during GTT and lower fasting free fatty acid 
concentrations. GLP-1 action, but not GIP, has been found to contribute to pancreatic 
B-cell growth and increased intrapancreatic insulin content in pregnant mice 
providing further proof of principle that the former hormone is required for increased 
insulin production to compensate for the insulin resistance of pregnancy (Moffett et 
al. 2014). 
 
10.6. GLP-1 levels and incretin response following GDM pregnancy 
There is good evidence that any impairment in GLP-1 response during a GDM 
pregnancy improves post-natally if normal glucose tolerance is established but does 
not normalise entirely. Two of the 5 studies which measured GLP-1 levels during 
pregnancy did follow up studies with a repeat glucose challenge post-partum 
(summarised in Table 7.1) (Bonde et al. 2013; Lencioni et al. 2011). Bonde and 
colleagues found that the total GLP-1 response in GDM women increased by over 
50% compared to their pregnancy levels (8.4 vs. 5.5 nM x min, p=0.005) (Bonde et al. 
2013). These women appear to have persistent abnormalities in their GLP-1 levels 
compared to their counterparts who did not have GDM, with reduction in fasting 
GLP-1 levels and total GLP-1 response. In fact, Lencioni et al found that when the 
GLP-1 levels were corrected for prevailing glycaemia, the GLP-1/glycaemia ratio 
showed an almost flat line indicating that previous GDM women continue to mount 
an inadequate incretin response. However other cross-sectional studies do not support 
an impairment of GLP-1 secretion in women with a history of GDM (Meier et al. 
2005). 
 
It has been shown that impairment of GLP-1 response may be an early insult in the 
pathogenesis of T2D as shown in experiments on previously healthy individuals who 
had insulin resistance induced by steroid therapy (discussed in Chapter 7). Beta-cell 
secretory capacity was normal in these individuals as observed by the insulin 
secretion in response to an intravenous glucose load but that in response to an oral 
load was specifically reduced implicating defective incretion hormone 
secretion/action.  
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Similar to the impaired GLP-1 response observed in previously healthy individuals 
who had insulin resistance induced by steroid therapy (discussed in Chapter 7), my 
study has shown that the women who are predisposed to develop diabetes in later life 
may show early abnormalities in their incretin response (including GLP-1 levels) and 
this manifests in pregnancy as GDM when their beta-cell capacity cannot increase 
sufficiently to cope with physiological insulin resistance. It will be insightful to have 
long-term follow up studies on such women with previous GDM and impaired GLP-1 
levels to look specifically at factors such as whether their time to development of T2D 
was shorter or if they presented with more complications when compared to previous 
GDM women without impaired GLP-1 levels. If so, it could be possible to identify a 
subgroup of women with previous GDM for more targeted follow up and perhaps 
early intervention to prevent future T2D.  
 
10.7. GLP-1 axis potentiating drugs in pregnancy and post-partum 
GLP-1 receptor agonists (GLP-1 RA) are currently not recommended during 
pregnancy because animal studies have shown that Liraglutide is associated with early 
embryonic deaths and reduced fetal growth in mid-gestation (Novo Nordisk Limited 
2016). 
 
However, the post-partum period may be an ideal time to intervene in women who 
have had a GDM pregnancy given their high risk of progression to T2D. Drugs that 
modulate the entero-insular axis will be even more favourable if defects in GLP-1 
secretion are confirmed to be account for decreased first-phase insulin secretion or 
impaired incretin response in GDM or early T2D. Indeed, exenatide (another GLP-1 
RA) has been associated with increase in first and second phase insulin secretion 
although an intravenous glucose load was used for this experiment (Fehse et al. 2005). 
 
Two RCTs are currently being carried out of liraglutide vs. placebo and 
liraglutide/metformin vs. placebo/metformin in women with a diagnosis of GDM 
during pregnancy within the last 1-10 years (Elkind-Hirsch 2016; Foghsgaard et al. 
2013).  The estimated total sample size is 100 and 150 respectively and the open label 
observation phase is expected to be complete in 2019/2020 with results available 
shortly after. It will be interesting to note if, in addition to the primary outcomes of 
glucose tolerance and insulin sensitivity markers, the investigators report any changes 
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in markers of vascular complications in these patients which would tie in with the 
anti-oxidant effects of Liraglutide observed in Chapter 9. 
 
There is no data on the safety of any other drugs which could potentiate incretin 
hormones (e.g. DPP-4 inhibitors) during pregnancy and their use is not recommended. 
However metformin, which is widely used in the management of GDM, has been 
shown in lean and obese non-pregnant women with polycystic ovarian syndrome to 
increase GLP-1 secretion after a GTT (Svendsen et al. 2009). The positive effect 
metformin has on GLP-1 levels is a direct one (i.e. not only related to weight loss or 
improvement of insulin resistance) and is believed to be due to enhancing GLP-1 
biosynthesis and secretion as well as inhibiting the degradation enzyme dipeptidyl-4 
(B. D. Green et al. 2006; Lindsay et al. 2005).  
 
While long-term use of these medications in women of reproductive age are not 
desirable, they may be useful as an adjunct approach in certain individuals if efficacy 
and safety are proven in RCTs.  
 
10.8. ‘Individualised’ management of GDM 
It can be seen from the earlier results and discussions that while the burden of GDM is 
increasing rapidly, it continues to remain an incompletely understood condition with a 
heterogeneous pathophysiology. This can, in turn, have differential adverse effects on 
both the affected woman and her offspring. Therefore novel biomarkers may help to 
better diagnose and characterise these women with the ultimate aim of tailoring their 
management in pregnancy and in the prevention of future metabolic disease.  
 
For instance through Chapters 4 to 5, I have shown that in addition to GDM, low B12 
is independently associated with higher BMI and extremities of fetal birthweight and 
mechanistic studies suggest that the process of adipocyte dysfunction and insulin 
resistance may mediate this link. My study of GLP-1 levels in Chapter 7 has found 
that lower GLP-1 levels early in a glucose tolerance test are independently related 
post-glucose challenge hyperglycaemia and there is good evidence that this could be 
due to impaired beta-cell function, which itself may progress post-pregnancy.  
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Other non-pharmacological strategies which have been tried, but not definitely shown 
to be beneficial in the management of GDM are low-glycaemic index or carbohydrate 
diets (Hernandez et al. 2016; Markovic et al. 2016) and encouraging breaks in 
sedentary behaviour to reduce post-prandial glucose (Henson et al. 2013). 
 
Therefore the emerging theme is that there can be multiple mechanisms explaining the 
metabolic insults which give rise to glucose intolerance in pregnancy (e.g. 
predominant insulin resistance or insulin secretion or combination of factors) and 
different biomarkers can provide further insight into these. Current practice dictates 
that all women with GDM are managed along similar lines (blood glucose 
monitoring, oral hypoglycaemic agents or insulin and fetal growth monitoring as 
outlined according to NICE guidelines) (National Institute for Health and Care 
Excellence 2015a). However, I argue that a “one size fits all” approach cannot be 
applied to all women with GDM and more careful consideration needs to be given to 
her individual risk factors, aided by identified and yet-to-be identified biomarkers, 
which can enable a more focussed and targeted management to be provided both 
during pregnancy and afterwards.  
 
 
10.9. Fetal programming of metabolic disease 
 
The other problem with current management strategies for GDM is that diagnosis and 
treatment typically begins in the early 3rd trimester providing a window of only 10 to 
12 weeks for intervention prior to delivery. Exposure of the fetus to hyperglycaemia 
prior to adequate control of GDM as well as the effects of in utero exposure to other 
insults which have predisposed the pregnant woman to GDM, may result in long-term 
consequences for the offspring extending to adulthood.  Longitudinal cohort studies 
have shown that offspring of diabetic mothers (GDM or type 1 diabetes), mediated in 
part by their own body mass indices, are prone to obesity, insulin resistance and other 
abnormalities from childhood thereby perpetuating the trans-generational effect of 
metabolic disease (Boney et al. 2005; Clausen et al. 2008; Clausen et al. 2009). 
 
In the course of my research, I have found that low maternal B12 levels is associated 
with small for gestational age babies in women from high-risk populations (Chapter 
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1) and in our population, was linked to over 5-times higher risk of fetal macrosomia in 
a subgroup of non-diabetic women. Fetal birthweight might only be one of the 
mechanisms by which B12 can influence offspring metabolic health and birthweight 
itself may be a surrogate marker for other epigenetic, nutritional or metabolic 
processes linked to micronutrient insufficiency. More longitudinal cohort and 
mechanistic studies are urgently needed to explore any possible between B12 and 
other 1-carbon metabolite status in pregnancy and long-term maternal and child 
health.  
 
Although I did not examine any fetal outcomes with regards to impaired GLP-1 
concentrations or response in my study, this is something which can be studied in the 
cohort of patients I recruited who have had detailed anthropometric measurements at 
birth as part of the PRiDE study. One study has shown that lower fasting GLP-1 
levels were correlated with higher fetal abdominal circumference and birthweight in 
non-overweight/obese, non-diabetic pregnant women (Valsamakis et al. 2010). 
Interestingly the GLP-1 impairment was also linked negatively to parameters of 
insulin resistance, which may of course mediate the higher fetal anthropometry.  
 
The transgenerational perpetuation of diabetes may also involve the GLP-1/insulin 
axis as observed in long-term follow-up studies. Non-diabetic normal BMI offspring 
of diabetic mothers (both T1D and GDM) demonstrate impaired fasting GLP-1 levels, 
total GLP-1 response and glucagon suppression after an oral challenge in childhood 
and early adulthood compared to offspring not exposed to hyperglycaemia in utero 
(Chandler-Laney et al. 2014; Kelstrup et al. 2015). In the absence of incretin hormone 
measurements in the pregnant women during the index pregnancy and correlation 
analyses, it is not possible to determine if these effects are due to genetic impairments 
of incretin hormone secretion/action or if they represent an early tendency to diabetes 
and metabolic disease due to altered in utero programming but the inclusion of 
offspring of T1D women in 1 study supports the latter theory.   
 
The ideal biomarkers should therefore enable early identification of women at risk of 
GDM not only for the benefit of improving their glycaemic control during pregnancy, 
but also to minimise the exposure of their fetuses to metabolic insults which could 
programme them for chronic diseases later on.  
  192 
 
10.10. Conclusion  
In summary, my study supports the hypothesis that GDM is a multifactorial 
heterogeneous condition that is still incompletely understood. The 2 novel biomarkers 
I have studied, namely vitamin B12 and GLP-1, provide useful insight into different 
pathogenic mechanisms which exist in diabetes in pregnancy. Specifically, B12 may 
be related to obesity, GDM and birthweight abnormalities while impaired GLP-1 
secretion (particularly in the early phase following a glucose challenge) may predict 
impaired beta-cell function and postprandial glucose. These observations warrant 
replication in larger prospective studies. If the associations are proven and potential 
causality identified, these biomarkers can be used to risk stratify these women, both 
during the pregnancy and afterwards, to reduce her likelihood of future GDM, T2D 
and related complications. Therefore, adopting a more ‘individualised’ approach to 
manage this escalating problem can positively influence the health of young women 
and their offspring to tackle the global epidemic of diabetes.  
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Appendix 1 – Supplemental Tables (Chapter 4) 
 
1.1 Quality assessment criteria used to grade studies1 
 
Question no Criteria Comment 
1 The study addresses an appropriate and clearly focused question.  
Selection of subjects  
2 The two groups being studied are selected from source populations that are comparable in all respects other 
than the factor under investigation. 
 
3 The study indicates how many of the people asked to take part did so, in each of the groups being studied.  
4 The likelihood that some eligible subjects might have the outcome at the time of enrolment is assessed and 
taken into account in the analysis. 
 
5 What percentage of individuals or clusters recruited into each arm of the study dropped out before the study 
was completed. 
Not assessed for some 
cross-sectional studies 
6 Comparison is made between full participants and those lost to follow up, by exposure status. Not assessed for some 
cross-sectional studies 
Assessment 
7 The outcomes are clearly defined.  
8 The assessment of outcome is made blind to exposure status.  
9 Where blinding was not possible, there   is some recognition that knowledge of exposure status could have 
influenced the assessment of outcome. 
 
10 The measure of assessment of exposure is reliable.  
11 The measure of assessment of exposure is valid.  
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12 Exposure level or prognostic factor is assessed more than once.  
Confounding 
13 The main potential confounders are identified and taken into account in the design and analysis.  
Statistical analysis 
14 Confidence intervals are provided  
1Adapted from Scottish Intercollegiate Guidelines Network (SIGN) 
 
  195 
 
1.2 Quality assessment of studies included in the ‘Prevalence of B12 insufficiency’ sub-
review 
 
Study Reference Overall study quality grade 
Whiteside, 1968  - 
Roberts, 1973  + 
Jiang, 2005  ++ 
Murphy, 2007  ++ 
Garcia-Casal, 2005  + 
Ray, 2008  + 
Kosus, 2012  ++ 
Dwarkanath, 2013  ++ 
Heppe, 2013  ++ 
Samuel, 2013  ++ 
Shamim, 2013  ++ 
Shields, 2011  + 
Lowenstein, 1960  - 
Jacob, 1976  + 
Yajnik, 2008  ++ 
Katre, 2010  + 
Marzan, 1971  + 
Areekul, 1976  + 
Knight, 1991  + 
Bruinse, 1995  + 
Ackurt, 1995  ++ 
Pagan, 2002  + 
Park, 2004  ++ 
Li, 2008  ++ 
Takimoto, 2007  ++ 
Goedhart, 2011  ++ 
House, 2000  - 
Milman, 2006  ++ 
Wu, 2013  ++ 
Hinderaker, 2002  ++ 
Zachau-Christiansen, 1962  - 
Yusufji, 1973  + 
Baker, 1975  + 
Osifo, 1976  - 
Bjorke-Monsen, 2001  ++ 
Pathak, 2007  + 
Krishnaveni, 2009  ++ 
Cole, 1974  + 
Colman, 1975  - 
Frery, 1992  ++ 
Giugliani, 1984  + 
Ho, 1987  + 
Black, 1994  + 
Ma, 2004  + 
Hall, 2007  ++ 
Gibson, 2008  + 
Schulpis, 2004  + 
Koc, 2006  + 
Barbosa, 2008  ++ 
Hussein, 2009  + 
Vanderjagt, 2009  + 
Halicioglu, 2012  + 
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Balci, 2014  + 
Guerra-Shinoara, 2004  + 
Abdelrahim, 2009  ++ 
Cook, 1971  ++ 
Jacquemyn, 2014  + 
Table showing the methodological quality assessment of studies included in the 
‘Prevalence of B12 insufficiency’ sub-review based on the checklist for cohort studies 
adapted from SIGN. The studies are listed in order in which they are presented in 
Table 1. 
++: ‘All or most of the criteria fulfilled’ (i.e. ≥ 67% of criteria fulfilled), +: ‘Some of 
the criteria fulfilled’ (i.e. 34-66% of criteria fulfilled),  
-:‘Few or none of the criteria fulfilled’ (≤ 33% of criteria fulfilled) 
 
1.3 Quality assessment of studies included in the ‘B12 insufficiency and birthweight’ 
sub-review 
 
Study Reference Overall study quality grade 
Muthayya, 2006  ++ 
Dwarkanath, 2013  ++ 
Furness, 2013  ++ 
Hogeveen, 2010  ++ 
Sukla, 2013  + 
Ubeda, 2011  + 
McGarry, 1972  - 
Krishnaveni, 2014  ++ 
Baker, 1977  - 
Navarro, 1984  - 
Abbas, 1994  + 
Lindblad, 2005  ++ 
Yajnik, 2005  ++ 
Mamabolo, 2006  + 
Abraham, 2013  + 
Gomes, 2010  + 
Hay, 2010  + 
Relton, 2005  + 
Takimoto, 2007  ++ 
Pagan, 2002  + 
Faintuch, 2009  - 
Frery, 1992  ++ 
Guerra-Shinoara, 2004  + 
Table showing the methodological quality assessment of studies included in the ‘B12 
and birthweight’ sub-review based on the checklist for cohort studies adapted from 
SIGN. The studies are listed in order in which they are presented in Tables 4.3-4.5. 
++: ‘All or most of the criteria fulfilled’ (i.e. ≥ 67% of criteria fulfilled), +: ‘Some of 
the criteria fulfilled’ (i.e. 34-66% of criteria fulfilled),  
-:‘Few or none of the criteria fulfilled’ (≤ 33% of criteria fulfilled) 
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Appendix 2 – Supplementary Table (Chapter 5) 
 
A2.1 Table of characteristics of no-GDM women who did and did not undergo 
GTT 
Variables GTT No GTT 
Number (%) 90 (44.8) 111 (55.2) 
Age (yrs) 30.2 ± 5.9 29.1 ± 5.8 
BMI (kg/m2) § 29.7 ± 8.5 24.3 ± 4.5 ***a 
Obesity (%) 43.3 4.5 *** 
Current smokers (%)  21.1 18.9 
Parity 1.0 ± 1.1 1.1 + 1.2 
Ethnicity (%)     
European 87.8 87.4 
South Asian 8.9 7.2 
Afro-Caribbean 1.1 1.8 
Other 1.1 0.9 
Gestation of B12 bloods (weeks) 26.5 ± 5.7 25.9 ± 5.8 
Vitamin B12 (pmol/l) § 180.4 (146.7, 221.6) 218.4 (163.1, 259.8) * 
Vitamin B12 deficiency (<150pmol/l) (%) 25.6 18.9 
Serum folate (nmol/L) § 22.0 (14.5, 34.9) 19.7 (14.3, 34.0) 
Serum folate deficiency (<7nmol/l) (%) 1.1 0.9 
Continuous variables are mean ± SD (or median (IQR)), categorical 
variables are percentages 
a: p-value as compared to undergone-GTT group, *p<0.05, ***p<0.001 
§: Log-transformed for statistical comparison 
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Appendix 3 – Study documents for PRiDE-GLP1 clinical study (Chapter 8) 
 
A3.1 Participant Information Sheet 
 
 
 
 
Participant Information Sheet 
Study Title: Role of GLP-1 Levels in gestational diabetes mellitus (PRiDE-GLP1 Sub-
study)  
You are being invited to take part in a clinical study to look at whether a hormone known as 
Glucagon-Like Peptide 1 (GLP-1) is altered in mothers who are diagnosed with diabetes in 
pregnancy. This is a small addition to the PRiDE study, which you are already a part of. 
However, before you decide whether or not you want to take part in this sub-study, you 
should understand what it involves. Please take time to read this information sheet and 
discuss it with family and friends if you wish. 
What is the purpose of the study? 
GLP-1 is a hormone released by the gut in response to food. It helps our pancreas to produce 
more insulin which in turn helps to the lower blood sugar levels after a meal. Studies have 
shown that GLP-1 levels are reduced by up to 50% in adults with Type 2 Diabetes (T2D) and 
drugs which mimic the action of GLP-1 are routinely used to treat diabetes. It has also been 
shown that in people at higher risk of T2D, those who have defective GLP-1 secretion are 
more likely to develop full-blown T2D. Gestational diabetes mellitus (GDM) is considered to 
be a T2D-like state brought on by pregnancy. Though it resolves in most mothers after 
delivery, mothers with history of GDM have 7-8 times higher risk of T2D later on in life. There 
is little evidence on whether GLP-1 levels are faulty in GDM.  This study is therefore designed 
to look at whether GLP-1 levels are indeed faulty in mothers who develop GDM. If it is, it 
provides a novel opportunity for improving the way GDM mothers are treated both during 
pregnancy and after delivery to reduce their likelihood of developing T2D in the future.  
Why have I been chosen? 
You have been chosen because you are currently in the PRiDE Study and are due to have 
your glucose tolerance test (GTT) soon. 
Do I have to take part? 
Participation in this sub-study is entirely voluntary. If you decide not to participate, you can 
still carry on in the main PRiDE Study and the standard of your antenatal care will not be 
affected in any way.  
What will happen to me if I take part? 
We will ask you to sign a consent form to confirm your willingness to participate. This sub-
study only involves additional blood tests during your GTT.  
To accurately determine how GLP-1 levels change in response to consuming glucose, it is 
necessary to check the GLP-1 levels every 30 mins during your 2-hour GTT. A cannula will 
be inserted into a vein in your forearm at the start of your GTT and blood will be drawn at 0, 
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30, 60, 90, 120 min. Normal GTT bloods are drawn only at 0 and 120 min. While the regular 
GTT involves 2 separate needles, the additional samples for this sub-study only involves the 
initial insertion of the cannula. Around 10 mls of extra blood will be taken for this sub-study at 
each time point.   
If you are diagnosed to have GDM, you will be offered a GTT around 6 weeks after delivery 
as part of your regular clinical care. For this GLP-1 sub-study, we would require the 3 
additional blood samples as described above to test the GLP-1 levels during this GTT too. 
What are the possible advantages and disadvantages of taking part? 
The results of this study will help to determine if reduced GLP-1 levels is a factor contributing 
to GDM and diabetes risk in mothers after their pregnancy. If so, it can pave way for future 
novel treatment of mothers with GDM either during or after their pregnancy. This may be 
relevant for you directly if you are planning any future pregnancies too. There are no specific 
disadvantages apart from insertion of a small cannula in your forearm for 2 hours and the 
additional blood samples described above. However, this will only involve 1 needle insertion 
as opposed to the 2 for your normal GTT.  
What will happen if I change my mind about taking part? 
You are free to withdraw from the study at any time, without giving a reason if you do not wish 
to. All the blood samples you have provided us with until that point can be destroyed if you do 
not want them to be used. The remainder of your and your baby’s care will continue as 
normal. 
Will my taking part in this study be kept confidential? 
Your participation in the study will be kept entirely confidential. Any personally identifiable 
information will be stored in a password-protected database or secure area that only the 
research staff and study regulatory authorities will have access to. You will be allocated a 
unique study number and any samples we take from you will only be identified by this number 
when processed or stored in the lab. 
Who has funded and reviewed this study? 
The study is being funded by West Midlands (South) Comprehensive Local Research 
Network after thorough review. The NHS Research Ethics Committee has approved the 
study. Your local NHS Trust and antenatal department have also approved it.  
What if there is a problem? 
Your rights to the regular NHS complaints procedure are not affected in anyway by taking part 
in this study. If you are concerned about any aspect of the study or unhappy with how you 
were treated by the research staff at any point, please contact Ms Nicola Owen, University of 
Warwick Research Support Services (Tel: 024 7652 2785, email: 
Nicola.Owen@warwick.ac.uk). You can contact Dr P Saravanan or his research team on 
02476153592 if you would like more information about the study. If you would like to speak to 
someone independent about taking part in this study please contact the Patient Advice and 
Liaison Service on 02476865550.  
What will happen to the results of this study? 
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You will be informed of the summary of the results, after all the data analyses are complete. 
The scientific results will be published in medical journals and presented in conferences.  
------------------------------------------------------------------------------------------------------- 
A3.2 Consent form 
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A3.3 Diprotin A preparation and blood sampling protocol 
 
PRiDE-GLP1 sub-study sample collection protocol 
 
Calculations - Need Diprotin A 35ul/ml of plasma (round up to 40ul/tube) – final concentration 
0.1mM/ml plasma - Solubility: 1mg/ml - For 10 participants, need (5x10) = 50 tubes with total of (50 x 40ul) = 2000ul or 2ml 
 
To make-up - 2ml Mili-Q water - Weigh out 2mg Diprotin A powder - Add powder to small Falcon, then water to make up 2 ml - Dissolve well - Aliquot into 10 Eppendorfs of 200uL each (or equivalent for total amount) - Store at -20oC until use 
 
Protocol 
Before blood collection - Require plasma sample x1 (EDTA tube, purple-top) and serum sample x1 (Plain tube, 
yellow-top) at each time point during GTT (i.e. 0, 30, 60, 90 and 120 mins) - Remove DPP-4 inhibitor (Diprotin A) from freezer to thaw on the bench. Vortex for 
10 seconds before use. - Add 40ul Diprotin A to EDTA tube before blood is taken and store tube at 4oC until 
use 
 
After blood collection - Draw additional 5 mls of blood for GLP-1 sub-study every 30 mins during GTT (i.e. 
0, 30, 60, 90 and 120 mins) - Divide into 1 EDTA and 1 Plain tube which have been prepared earlier (2.5mls in 
each) - Invert tubes 8-10 times to allow thorough mixing but do not vortex - Spin tubes at 20oC, 2000 rpm for 15mins - Aliquot plasma and serum into 2 vials each (at least 500ul in each vial) - Label with Study ID, time point (GLP 0/30/60/90/120 corresponding with time of 
sampling during GTT) and date 
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A3.4 PRiDE-GLP1 sub-study ethics approval 
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Appendix 4 – Materials for laboratory experiment (Chapter 9) 
 
A4.1 Solutions for Western blot 
4.1.1 Running buffer 
900ml distilled water (dH2O) 
100ml tris-glycine 10x 
1g sodium dodecyl sulphate (SDS) (final concentration 0.1%) 
 
4.1.2 Transfer buffer 
700ml dH2O 
200ml methanol 
100ml tris-glycine 10x 
 
4.1.3 Phosphate buffer saline – Tween (PBS-T) 
900ml dH2O 
100ml PBS 10x 
1ml Tween 
 
4.1.4 I-block 
200m PBS-T 
400mg I-block (final concentration 0.2%) 
Stirred on gentle heat until well dissolved 
 
4.1.5 10% Resolving gel (per 2 plates) 
7.8ml dH2O 
6.6ml acrylamide 
5.2ml resolving buffer 
200ul APS 
20ul TEMED 
 
4.1.6 4% Stacking gel (per 2 plates) 
6.1ml dH2O 
1.3ml acrylamide 
2.5ml stacking buffer 
50ul APS 
10ul TEMED 
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